{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Final"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "original_directory = \"Originals/\"\n",
    "original_files = os.listdir(original_directory)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "directory_2019 = \"2019/\"\n",
    "directory_2020 = \"2020/\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in original_files:\n",
    "    data = pd.read_excel( os.path.join(original_directory, i) )\n",
    "    data[\"Release Date\"] = pd.to_datetime(data[\"Release Date\"])\n",
    "    \n",
    "    data2020 = data[(data['Release Date'] >= '2020-01-1') & (data['Release Date'] <= '2020-12-31')]\n",
    "    data2019 = data[(data['Release Date'] >= '2019-01-1') & (data['Release Date'] <= '2019-12-31')]\n",
    "    \n",
    "    data2020.to_excel(os.path.join(directory_2020, i.split()[0] + \"_ene-sep2020.xlsx\"), index=False)\n",
    "    data2019.to_excel(os.path.join(directory_2019, i.split()[0] + \"_ene-dic2019.xlsx\"), index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Insulina"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"INSULINA\".startswith(\"INSU\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in original_files:\n",
    "    if i.startswith(\"INSULINA\"):\n",
    "        data = pd.read_excel( os.path.join(original_directory, i) )\n",
    "        data[\"Release Date\"] = pd.to_datetime(data[\"Release Date\"])\n",
    "\n",
    "        data2020 = data[(data['Release Date'] >= '2020-01-1') & (data['Release Date'] <= '2020-12-31')]\n",
    "        data2019 = data[(data['Release Date'] >= '2019-01-1') & (data['Release Date'] <= '2019-12-31')]\n",
    "\n",
    "        data2020.to_excel(os.path.join(directory_2020, i.split()[0] + i.split()[1] + \"_ene-sep2020.xlsx\"), index=False)\n",
    "        data2019.to_excel(os.path.join(directory_2019, i.split()[0] + i.split()[1] + \"_ene-dic2019.xlsx\"), index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Jugar"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import pandas as pd\n",
    "pd.set_option('display.max_rows', 500)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "atazanavir = pd.read_excel(\"Originals/ATAZANAVIR 07 SEPT 2020.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Report Id</th>\n",
       "      <th>Safety Report Name</th>\n",
       "      <th>Record Type</th>\n",
       "      <th>Release Date</th>\n",
       "      <th>Drugs</th>\n",
       "      <th>Adverse Events</th>\n",
       "      <th>Mechanism of Action</th>\n",
       "      <th>Number of Cases</th>\n",
       "      <th>Serious</th>\n",
       "      <th>First Report</th>\n",
       "      <th>...</th>\n",
       "      <th>Reporter Country</th>\n",
       "      <th>Source Country</th>\n",
       "      <th>Country of publication</th>\n",
       "      <th>Drug Class</th>\n",
       "      <th>Age Group</th>\n",
       "      <th>Route Of Administration</th>\n",
       "      <th>Treatment</th>\n",
       "      <th>Special Situation</th>\n",
       "      <th>References</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>803500083</td>\n",
       "      <td>Atazanavir/ritonavir - Atazanavir crystal-indu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-09-02</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Chronic granulomatous disease drug-induced, In...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Varghese V, Rodriguez R, Self S, Velez JCQ....</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>803499015</td>\n",
       "      <td>Antiretrovirals - Anaemia and viral rebound: 2...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-08-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Anaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Anti-infectives , Antiretrovirals , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>803499019</td>\n",
       "      <td>Antiretrovirals - Virologic failure: 6 case re...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-08-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Anti-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>803488559</td>\n",
       "      <td>Antiretrovirals - Drug resistance, virologic r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-10</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>Dizziness drug-induced, Drowsiness drug-induce...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Singapore</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Alkynes , Antipsoriatics , Antiretrovirals , B...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ho S, Wong JG, Ng OT, Lee CC, Leo YS, Lye D...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>803485910</td>\n",
       "      <td>Antiretrovirals - Weight gain: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-01</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>Weight gain drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Israel</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Antivirals , Carbam...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Israel S, Elinav H, Elazary R, Porat D, Gib...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>803478784</td>\n",
       "      <td>Atazanavir/cobicistat/darunavir - Various toxi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-01</td>\n",
       "      <td>Atazanavir adverse reactions, Cobicistat adver...</td>\n",
       "      <td>Anxiety drug-induced, Appetite disorders drug-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Carbamates , Furans , Morpho...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tyler S, Sivaraj V, Kulasegaram R. Central ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>803474501</td>\n",
       "      <td>Atazanavir/emtricitabine/raltegravir - Hypertr...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-05-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Hypertriglyceridaemia drug-induced, Pancreatit...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Deoxyribonucleosides , Napht...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Joury A, Alshehri M, Mahendra A, Anteet M, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>803473063</td>\n",
       "      <td>Antiretrovirals - Exposure during pregnancy: 3...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-05-06</td>\n",
       "      <td>Atazanavir adverse reactions, Cobicistat adver...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Badell ML, Sheth AN, Momplaisir F, Rahangda...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>803470701</td>\n",
       "      <td>Antiretrovirals - Paradoxical or unmasking of ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Melzani A, De Reynal De Saint Michel R, Nta...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>803469994</td>\n",
       "      <td>Antivirals/immunosuppressants interaction - Dr...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>Abacavir drug interactions (Serious), Atazanav...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, H...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Turkey</td>\n",
       "      <td>Adenine nucleotides , Amides , Anti-inflammato...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Senechal I, Chateauvert N, Gervais P, Voisi...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>803468110</td>\n",
       "      <td>Atazanavir/ritonavir - Indirect bilirubin leve...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-09</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir/riton...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Mandimika C, Ogbuagu O. Successful sofosbuv...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>803455694</td>\n",
       "      <td>Atazanavir/ritonavir/tenofovir disoproxil fuma...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-02-14</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ritona...</td>\n",
       "      <td>Fanconi syndrome drug-induced, Rhabdomyolysis ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Amides , Antiretrovirals , Antivirals , Carbam...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Favarel-Garrigues M, Hentzien M, Berger J-L...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>803455935</td>\n",
       "      <td>Atazanavir - Urolithiasis: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-02-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Urolithiasis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Brunel V, Massy N, Malval B. Atazanavir uro...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>803453169</td>\n",
       "      <td>Antiretroviral - Non alcoholic fatty liver dis...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Hepatic fibrosis drug-induced, Non-alcoholic f...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Thailand</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>Adolescents, Children</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sudjaritruk T, Bunupuradah T, Aurpibul L, K...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>803449989</td>\n",
       "      <td>Antivirals/lidocaine interaction - Various tox...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-24</td>\n",
       "      <td>Abacavir drug interactions (Serious), Atazanav...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, D...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acetanilides , Amides , Antiretrovirals , Carb...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kramer ME, Holtan EE, Ives AL, Wall RT. Per...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>803449175</td>\n",
       "      <td>Atazanavir/tacrolimus interaction - Increase i...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-17</td>\n",
       "      <td>Atazanavir drug interactions, Tacrolimus drug ...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiasthmatics , Antipsoriatics , Antiretrovir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tsapepas DS, Webber AB, Aull MJ, Figueiro J...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>803443825</td>\n",
       "      <td>Atazanavir/lopinavir - Virological non-respons...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-12-27</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Taiwan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Amides , Antiretrovirals , Oligopeptides , Pyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Chen GJ, Sun HY, Chang SY, Cheng A, Huang Y...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>803440764</td>\n",
       "      <td>Atazanavir/ledipasvir/sofosbuvir - Headache an...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-12-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ledipa...</td>\n",
       "      <td>Headache drug-induced, Hyperbilirubinaemia dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Antivirals , Azabicyclo comp...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ishida H, Ishihara A, Tanaka S, Iwasaki T, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>803435020</td>\n",
       "      <td>Antiretrovirals - Type 1 diabetes mellitus, hy...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-11-18</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Didano...</td>\n",
       "      <td>Hypertriglyceridaemia drug-induced, Lipodystro...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>Children</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Filho ENS, Young EC, De Almeida Pinto Borge...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>803434892</td>\n",
       "      <td>Antiretrovirals - Development of dolutegravir ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>Gastrointestinal disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Portugal</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Anti-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cardoso M, Baptista T, Diogo I, Aleixo MJ, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>803434874</td>\n",
       "      <td>Atazanavir/lamivudine/tenofovir - Disseminated...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>Atazanavir adverse reactions, Lamivudine adver...</td>\n",
       "      <td>Human papillomavirus infections drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>Adenine nucleotides , Antiretrovirals , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Do Vale DA, Ferracini LMA, Da Silva Rodrigu...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>803429382</td>\n",
       "      <td>Atazanavir/dolutegravir - Virological failure:...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-10-16</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Antir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Castagna A, Rusconi S, Gulminetti R, Bonora...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>803428900</td>\n",
       "      <td>Atazanavir/dolutegravir - Neuropsychiatric sid...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-16</td>\n",
       "      <td>Atazanavir adverse reactions, Dolutegravir adv...</td>\n",
       "      <td>Neurological disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Antir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Castagna A, Rusconi S, Gulminetti R, Bonora...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>803429039</td>\n",
       "      <td>Neural tube defects after exposure to antiretr...</td>\n",
       "      <td>News</td>\n",
       "      <td>2019-10-14</td>\n",
       "      <td>Atazanavir adverse reactions, Bictegravir adve...</td>\n",
       "      <td>Neural tube defects drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. van De Ven NS, Pozniak AL, Levi JA, Clayden...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>803426748</td>\n",
       "      <td>Antiretrovirals - Neural tube defects followin...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-09</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Neural tube defects drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Adenine nucleotides , Amides , Antipsoriatics ...</td>\n",
       "      <td>Neonates</td>\n",
       "      <td>Transplacental</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Money D, Lee T, O'Brien C, Brophy J, Bitnun...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>803421461</td>\n",
       "      <td>Antiretrovirals - Maternal exposure during pre...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-09-13</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>14.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Anti-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vannappagari V, Thorne C. Pregnancy and Neo...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>803414455</td>\n",
       "      <td>Atazanavir/darunavir - Virological failure due...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Daruna...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>14.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Castain L, Perrier M, Charpentier C, Palich...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>803410125</td>\n",
       "      <td>Ritonavir/lopinavir - Renal stone: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-26</td>\n",
       "      <td>Atazanavir adverse reactions, Lopinavir advers...</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Zhao AM, Angoff NR. Renal stone composed of...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>803408652</td>\n",
       "      <td>Multiple drugs - Increased tacrolimus level an...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-19</td>\n",
       "      <td>Abacavir drug interactions, Atazanavir drug in...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Antia...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Jimenez HR, Natali KM, Zahran AAR. Drug int...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>803402189</td>\n",
       "      <td>Antiretrovirals - Antiretrovirals resistance, ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-06-21</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Ataxia drug-induced, Encephalitis drug-induced...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>Adolescents, Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Manesh A, Barnabas R, Mani S, Karthik R, Ab...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>803401023</td>\n",
       "      <td>Antiretrovirals - Virologic failure due to nau...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-06-17</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Nausea drug-induced, Vomiting drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Badowski M, Kassem S, Taylor C, Mckamey L, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>803393639</td>\n",
       "      <td>Antivirals - Rash and pruritus: 8 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-05-14</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Exanthema drug-induced, Pruritus drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Anti-infectives...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Buijs BS, Van Den Berk GE, Boateng CP, Hoep...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>803386130</td>\n",
       "      <td>Antiretrovirals - Development of resistance du...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-04-15</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Uganda</td>\n",
       "      <td>NaN</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ssebambulidde K, Segawa I, Laker E, Lamorde...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>803383691</td>\n",
       "      <td>HIV protease inhibitors/quetiapine interaction...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-04-05</td>\n",
       "      <td>Atazanavir drug interactions, Atazanavir/riton...</td>\n",
       "      <td>Coma drug-induced, Sedation drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Analgesics , Antidepressants , Antips...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sampson MR, Cao KY, Gish PL, Hyon K, Mishra...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>803376059</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution inflam...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-02-20</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Stewart A, Sowden D, Caffery M, Bint M, Bro...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>803372621</td>\n",
       "      <td>Antiretrovirals - Maculopapular pruritic rash:...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-02-01</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Exanthema drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Kenya</td>\n",
       "      <td>NaN</td>\n",
       "      <td>New Zealand</td>\n",
       "      <td>Alkynes , Amides , Antiretrovirals , Carbamate...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Irungu K. Severe skin rash associated with ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>803366731</td>\n",
       "      <td>Multiple drugs - Neutropenia and various toxic...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-12-31</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Amisulpr...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, B...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Adenine nucleotides , Amides , Antidementias ,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Whiskey E, O'Flynn D, Taylor D. Clozapine, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>803360498</td>\n",
       "      <td>Atazanavir - Nephrolithiasis: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-12-04</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Grant MT, Eisner BH, Bechis SK. Ureteral Ob...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>803357736</td>\n",
       "      <td>Atazanavir - Drug resistance secondary to ataz...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-11-16</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Grude M, Chaix ML, Marcelin AG, Flandre P, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>803346689</td>\n",
       "      <td>Antiretrovirals - Eruptive melanocytic nevi as...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-09-21</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, N...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Portugal</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antipsoriatics ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Garrido PM, Borges-Costa J. Eruptive melano...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>803340341</td>\n",
       "      <td>Atazanavir/ritonavir/tenofovir - Chronic granu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-08-10</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ritona...</td>\n",
       "      <td>Genitourinary disorders drug-induced, Glomerul...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Chu GJ, Henderson C, Evans L, Howlin K, Mur...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>803340549</td>\n",
       "      <td>AEs with second-line ART in South African HIV ...</td>\n",
       "      <td>News</td>\n",
       "      <td>2018-08-08</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Anaemia drug-induced, Renal impairment drug-in...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>South Africa</td>\n",
       "      <td>New Zealand</td>\n",
       "      <td>Amides , Antipsoriatics , Antiretrovirals , An...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Onoya D, Hirasen K, van den Berg L, Miot J,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>803337329</td>\n",
       "      <td>Atazanavir/ritonavir/tacrolimus interaction - ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-07-27</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>Amides , Antiasthmatics , Antipsoriatics , Ant...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kuten SA, Patel SJ, Baru A, Gaber AO, Crutc...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>803319080</td>\n",
       "      <td>Emtricitabine/tenofovir does not increase adve...</td>\n",
       "      <td>News</td>\n",
       "      <td>2018-05-03</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir/emtri...</td>\n",
       "      <td>Pregnancy complications drug-induced, Preterm ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Azides , Carbamates...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Rough K, Seage GR 3rd, Williams PL, Hernand...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>803309947</td>\n",
       "      <td>Atazanavir - Multiple toxicities: 2 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-03-29</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Exanthema drug-induced, Hyperbilirubinaemia dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Children</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. European Pregnancy and Paediatric HIV Cohor...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>803303073</td>\n",
       "      <td>Atazanavir - Granulomatous interstitial nephri...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-03-06</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Interstitial nephritis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hara M, Momoki K, Ubukata M, Ohta A, Tonook...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>803301512</td>\n",
       "      <td>Antiretrovirals - Fanconi renal syndrome: 13 c...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-02-27</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Fanconi syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Medland NA, Chow EPF, Walker RG, Chen M, Re...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>803299586</td>\n",
       "      <td>Multiple drugs - Drug induced kidney injury: 2...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-02-16</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Allopuri...</td>\n",
       "      <td>Renal impairment drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>24.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>2 pyridinylmethylsulfinylbenzimidazoles , Adju...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Douros A, Bronder E, Klimpel A, Erley C, Ga...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>803297443</td>\n",
       "      <td>Multiple drugs - Emergence of anti-retroviral ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-01-25</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Alkynes , Amides , Anti-infectives , Antiretro...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Widera M, Dirks M, Bleekmann B, Jablonka R,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>803294958</td>\n",
       "      <td>Antiretrovirals - Various toxicities: 21 case ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-01-15</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Anaplastic large cell lymphoma drug-induced, A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>21.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>Adolescents, Children, Infants, Neonates</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hleyhel M, Goujon S, Delteil C, Vasiljevic ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>803295427</td>\n",
       "      <td>Atazanavir/ritonavir/lopinavir/tenofovir disop...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2018-01-15</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Kidney disorders drug-induced, Proteinuria dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Thailand</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bunupuradah T, Phupitakphol T, Sophonphan J...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>803290156</td>\n",
       "      <td>Effect of antiretroviral regimen on renal comp...</td>\n",
       "      <td>News</td>\n",
       "      <td>2017-12-18</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir/emtri...</td>\n",
       "      <td>Kidney disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Alkynes , Amides , Anti-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. LaFleur J, Bress AP, Esker S, Knippenberg K...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>803282133</td>\n",
       "      <td>Atazanavir - Crystalline nephropathy and acute...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-11-10</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Acute kidney injury drug-induced, Kidney disor...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Santoriello D, Al-Nabulsi M, Reddy A, Salam...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>803277425</td>\n",
       "      <td>Antivirals - Various toxicities: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-10-13</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Anaemia drug-induced, Cholelithiasis drug-indu...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Italy</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vavassori A, Lanza P, Izzo I, Casari S, Odo...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>803275435</td>\n",
       "      <td>Atazanavir - Ureteral stone: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-10-11</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Ureteral calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ziegelmann M, Carrasco A, Knoedler J, Kramb...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>803275144</td>\n",
       "      <td>Atazanavir/darunavir/lopinavir - Development o...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-10-10</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Oligopeptides , Pyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. El Bouzidi K, Collier D, Nastouli E, Copas ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>803274754</td>\n",
       "      <td>Multiple drugs interaction - Febrile neutropen...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-10-09</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Fanconi syndrome drug-induced, Febrile neutrop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Argentina</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Adenine nucleotides , Amides , Antineoplastics...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cordova E, Morganti L, Odzak A, Arcondo F, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>803268679</td>\n",
       "      <td>Atazanavir/ritonavir/Ergotamine/dipyrone/caffe...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-09-04</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Caffei...</td>\n",
       "      <td>Ergotism drug-induced, Ischaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Chile</td>\n",
       "      <td>Amides , Analgesics , Antimigraines , Antiretr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cifuentes M D, Blanco L S, Ramirez F C. [Er...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>803267559</td>\n",
       "      <td>Antiretrovirals - Acute pancreatitis secondary...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-08-31</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Hypertriglyceridaemia drug-induced, Pancreatit...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Portugal</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Cyclop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Pereira M, Guerra I. Clinical case: Acute p...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>803263661</td>\n",
       "      <td>Risk of kidney disease with atazanavir-contain...</td>\n",
       "      <td>News</td>\n",
       "      <td>2017-08-07</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir/cobic...</td>\n",
       "      <td>Renal failure drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Antiretrovirals , Carbamates , Morpholines , O...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Health Canada. Evotaz (atazanavir and cobic...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>803254988</td>\n",
       "      <td>Multiple drugs - Various toxicities: 7 case re...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-07-07</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Anaemia drug-induced, Atopic dermatitis drug-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>India</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Amrutha PC, Rakesh TP, Kidangazhiyathmana A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>803255383</td>\n",
       "      <td>Tacrolimus/antiretrovirals interaction - Acute...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-07-07</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Lamivu...</td>\n",
       "      <td>Acute kidney injury drug-induced, Diarrhoea dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiasthmatics , Antipsoriatics , Ant...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Haroon N, Singh A, Bhat ZY. Tacrolimus toxi...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>803244890</td>\n",
       "      <td>Atazanavir - Cholelithiasis and cholangitis: c...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-05-28</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Cholangitis drug-induced, Cholelithiasis drug-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Howlett P, Simons R, Wilkinson M, Kulasegar...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>803245086</td>\n",
       "      <td>Antiretrovirals - Various toxicities: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-05-28</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>Anxiety drug-induced, Exanthema drug-induced, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Anti-infectives , Antiretrovirals , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. McCarty E, Todd S. Complexities of establis...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>803241275</td>\n",
       "      <td>Atazanavir - Cholelithiasis: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-05-15</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Cholelithiasis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bianchi C, Levesque K, Boucher M, Ferreira ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>803241548</td>\n",
       "      <td>Tenofovir disoproxil fumarate/efavirenz/emtric...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-05-15</td>\n",
       "      <td>Atazanavir overdose, Efavirenz overdose (Serio...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Benzoxazines , Deoxyribonucl...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ostberg L, Hojer J. Acute tenofovir overdos...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>803240626</td>\n",
       "      <td>Multiple drugs - Various toxicities: 10 case r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-05-07</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, F...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>2 ring heterocyclic compounds , Abortifacients...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gupta NK, Nolan A, Omuro A, Reid EG, Wang C...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>803239344</td>\n",
       "      <td>Multiple drugs interaction - Iatrogenic Cushin...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-04-29</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Adrenal insufficiency drug-induced, Cushing sy...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>19.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Analgesics , Androstadienes , Anti-in...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Nasal, Topical</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Elliot ER, Theodoraki A, Jain LR, Marshall ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>803239147</td>\n",
       "      <td>Antiretrovirals - Premature atherosclerosis an...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-04-27</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Atherosclerosis drug-induced, Myocardial infar...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Alkynes , Amides , Antipsoriatics , Antiretrov...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Griffith DC, Aronis KN, Orozco AM, Traill T...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>803237013</td>\n",
       "      <td>Atazanavir/lamivudine/abacavir - Decrease in e...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-04-13</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Cyclopentanes , Cyclopropane...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Llibre JM, Cozzi-Lepri A, Pedersen C, Risto...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>803235795</td>\n",
       "      <td>Antiretrovirals - Opsoclonus myoclonus ataxia ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-04-07</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Lamivu...</td>\n",
       "      <td>Ataxia drug-induced, Immune reconstitution syn...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Pereira NMD, Shah I, Kulkarni S. Opsoclonus...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>803230014</td>\n",
       "      <td>Atazanavir/lurasidone/risperidone interaction ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-03-07</td>\n",
       "      <td>Atazanavir drug interactions, Lurasidone drug ...</td>\n",
       "      <td>Basal ganglia disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antidepressants , Antineoplastics , Antipsycho...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Naccarato M, Hall E, Wai A, Ostrowski M, Ca...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>803229862</td>\n",
       "      <td>Atazanavir - Multiple intra-renal stones: case...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-03-03</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vallet A, Noel N, Bahi R, Teicher E, Querta...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>803224287</td>\n",
       "      <td>Atazanavir/raltegravir - Development of atazan...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2017-02-09</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Antiretrovirals , Naphthyridines , Oligopeptid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Marinaro L, Calcagno A, Ripamonti D, Cender...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>803210999</td>\n",
       "      <td>Atazanavir/ritonavir - First report of acute i...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-12-06</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ritona...</td>\n",
       "      <td>Acute intermittent porphyria drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bharti S, Malhotra P, Hirsch B. Acute inter...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>803207391</td>\n",
       "      <td>Antiretrovirals - Diarrhoea due to disseminate...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-11-15</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Diarrhoea drug-induced, Immune reconstitution ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Austria AM, Lynch SM. Disseminated MAC: Bro...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>803199272</td>\n",
       "      <td>Antiretrovirals - Drug resistance: 6 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-09-12</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Antir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Lazenby GB, Mmeje O, Fisher BM, Weinberg A,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>803195649</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution inflam...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-08-15</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Hepatitis B drug-induced, Immune reconstitutio...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Adenine nucleotides , Antipsoriatics , Antiret...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Lepelletier C, Salmona M, Bercot B, Maylin ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>803194375</td>\n",
       "      <td>Atazanavir - Urolithiasis and pyelonephritis: ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-08-08</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Pyelonephritis drug-induced, Urolithiasis drug...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Noma Y, Tambo M, Kitamura J, Okegawa T, Nut...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>803192184</td>\n",
       "      <td>Antivirals - Erythema elevatum diutinum: case ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-07-19</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Erythema drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>India</td>\n",
       "      <td>Amides , Antipsoriatics , Antiretrovirals , Ca...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Jose SK, Marfatia YS. Erythema elevatum diu...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>803190529</td>\n",
       "      <td>Atazanavir/ritonavir and orlistat - Virologica...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-07-04</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Anorectics , Antiretrovirals , Carbam...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gervasoni C, Cattaneo D, Di Cristo V, Casto...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>803188304</td>\n",
       "      <td>Antivirals - Grade 4 hyperbilirubinaemia: case...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-06-24</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Dasabu...</td>\n",
       "      <td>Hyperbilirubinaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Anilides , Antiretrovirals , Antivirals , Aza ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cattaneo D, Riva A, Clementi E, Milazzo L, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>803185951</td>\n",
       "      <td>Atazanavir/ritonavir - Nephrolithiasis: case r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-05-29</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ritona...</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Stephens JR, Coward RM, Viprakasit DP. Prot...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>803185799</td>\n",
       "      <td>Multiple drug interaction - Acneiform rash: 2 ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-05-27</td>\n",
       "      <td>Abacavir drug interactions, Atazanavir drug in...</td>\n",
       "      <td>Acne drug-induced, Skin eruptions drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Ireland</td>\n",
       "      <td>Alkynes , Amides , Antineoplastics , Antipsori...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Crequit P, Ruppert A-M, Rozensztajn N, Goun...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>803185679</td>\n",
       "      <td>Atazanavir/ivabradine/ritonavir interaction - ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-05-23</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Ivabra...</td>\n",
       "      <td>Bradycardia drug-induced, Heart failure drug-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Spain</td>\n",
       "      <td>Amides , Antiretrovirals , Benzazepines , Brad...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Romero-Leon JM, Galvez-Contreras MC, Diez-G...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>803183305</td>\n",
       "      <td>Atazanavir - Acute pancreatitis: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-05-07</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Pancreatitis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sahni H, Kirti K, Palshetkar R. Right flank...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>803178080</td>\n",
       "      <td>Multiple drugs - Nausea/nephrotoxicity/rhabdom...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-04-06</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir/riton...</td>\n",
       "      <td>Kidney disorders drug-induced, Nausea drug-ind...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>South Korea</td>\n",
       "      <td>NaN</td>\n",
       "      <td>South Korea</td>\n",
       "      <td>Adenine nucleotides , Amides , Antihyperlipida...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Jin S, Kim MH, Park JH, Jung HJ, Lee HJ, Ki...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>803167775</td>\n",
       "      <td>Antiretrovirals - Nodular regenerative hyperpl...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-01-28</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Hyperplasia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Lee MW, Izzy M, Kalia H. Nodular regenerati...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>803165256</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution inflam...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-01-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Efavir...</td>\n",
       "      <td>Burkitt's lymphoma drug-induced, Immune recons...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vishnu P, Dorer RP, Aboulafia DM. Immune Re...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>803163726</td>\n",
       "      <td>Atazanavir/cotrimoxazole/lamivudine/rifabutin/...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-01-05</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Cotrim...</td>\n",
       "      <td>Bone marrow disorders drug-induced, Immune rec...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Poland</td>\n",
       "      <td>Adenine nucleotides , Amides , Antibacterials ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Brahmachari U, Saha S, Guchhait B, Guha SK....</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>803163539</td>\n",
       "      <td>Atazanavir - Hyperbilirubinaemia and digestive...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2016-01-02</td>\n",
       "      <td>Atazanavir adverse reactions, Ritonavir advers...</td>\n",
       "      <td>Digestive system disorders drug-induced, Hyper...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Le MP, Mandelbrot L, Descamps D, Soulie C, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>803159585</td>\n",
       "      <td>Antiretrovirals - Urticarial rash: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-12-17</td>\n",
       "      <td>Atazanavir adverse reactions, Darunavir advers...</td>\n",
       "      <td>Urticaria drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Italy</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Cycloh...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Latini A, Colafigli M, Dona MG, Frasca M, A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>803157354</td>\n",
       "      <td>Antiretrovirals - Hypersensitivity reactions: ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-12-10</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Daruna...</td>\n",
       "      <td>Hypersensitivity drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Italy</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. D'Erme AM, Severino M, Tiradritti L, Tchoi ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>803152402</td>\n",
       "      <td>Antivirals - Increase in atazanavir concentrat...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-11-16</td>\n",
       "      <td>Atazanavir drug interactions, Atazanavir/riton...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, R...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Antivirals , Carbam...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gervasoni C, Cattaneo D, Micheli V, Cristo ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>803151453</td>\n",
       "      <td>Antiretrovirals - Avascular necrosis of the kn...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-11-10</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Osteonecrosis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Puerto Rico</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Puerto Rico</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Declet VR, Salas AS. Knee avascular necrosi...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>803150701</td>\n",
       "      <td>Atazanavir - Kidney stone: 3 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-11-04</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Arumainayagam N, Gresty H, Shamsuddin A, Ga...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>803145535</td>\n",
       "      <td>Abacavir/atazanavir/lamivudine - Cervical lymp...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-10-13</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, L...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antipsoriatics , Antiretrovirals , Cyclopentan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sethupathi M, Yoganathan K. Late onset of c...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>803145789</td>\n",
       "      <td>Atazanavir/ritonavir - Granulomatous interstit...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-10-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Interstitial nephritis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hara M, Suganuma A, Yanagisawa N, Imamura A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>803144389</td>\n",
       "      <td>Atazanavir/raltegravir - Integrase inhibitor r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-10-06</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Jaundice drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Naphthyridines , Oligopeptid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gantner P, Koeppel C, Partisani M, Batard M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>803143153</td>\n",
       "      <td>Multiple drugs - Various toxicities: 6 case re...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-09-30</td>\n",
       "      <td>Abacavir drug interactions (Serious), Atazanav...</td>\n",
       "      <td>Acute kidney injury drug-induced, Elevated ami...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Rwanda</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Anti-ischaemics , Antibacterials , An...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Amendezo E, Kambutse I, Maniraguha Y, Habim...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>803140600</td>\n",
       "      <td>Atazanavir/everolimus/ritonavir interaction - ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-09-14</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Everol...</td>\n",
       "      <td>Oral ulcer drug-induced, Ulcer drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>Amides , Antineoplastics , Antiretrovirals , C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Pasin VP, Pereira AR, de Carvalho KA, de Pa...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>803130437</td>\n",
       "      <td>Atazanavir/nevirapine - Transaminitis and hype...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-07-15</td>\n",
       "      <td>Atazanavir adverse reactions, Nevirapine adver...</td>\n",
       "      <td>Elevated aminotransferase levels drug-induced,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Antiretroviral...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Samuel M, Bradshaw D, Perry M, Chan SY, Dha...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>803126705</td>\n",
       "      <td>Prenatal atazanavir exposure safe for language...</td>\n",
       "      <td>News</td>\n",
       "      <td>2015-06-11</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Developmental disabilities drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Infants</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Himes SK, Huo Y, Siberry GK, Williams PL, R...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>803117040</td>\n",
       "      <td>Atazanavir/ritonavir/vinblastine interaction -...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-03-26</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Ritona...</td>\n",
       "      <td>Febrile neutropenia drug-induced, Neurological...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antineoplastics , Antiretrovirals , C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Uldrick TS, Little RF. How I treat classica...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>803116870</td>\n",
       "      <td>Atazanavir - Acute renal failure secondary to ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-03-23</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Acute kidney injury drug-induced, Urolithiasis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Inagaki I, Adachi M, Ito H, Yasuda M, Tsuru...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>105</th>\n",
       "      <td>803115686</td>\n",
       "      <td>Antiretrovirals - Drug hypersensitivity: 4 cas...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-03-08</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Efavir...</td>\n",
       "      <td>Drug hypersensitivity drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Poland</td>\n",
       "      <td>Alkynes , Antiretrovirals , Azides , Benzoxazi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dutta N, De R, Pain S, Modak D, Guha SK. A ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>803115296</td>\n",
       "      <td>Corticosteroids/HIV protease inhibitors intera...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-02-25</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Adrenal insufficiency drug-induced, Cushing sy...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Anti-infectives , Antiretrovirals , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hyle EP, Wood BR, Backman ES, Noubary F, Hw...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>803113778</td>\n",
       "      <td>HIV PI use in pregnancy reduces birth weight</td>\n",
       "      <td>News</td>\n",
       "      <td>2015-01-27</td>\n",
       "      <td>Atazanavir adverse reactions, Darunavir advers...</td>\n",
       "      <td>Fetal growth retardation drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>New Zealand</td>\n",
       "      <td>New Zealand, USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Papp E, Mohammadi H, Loutfy MR, Yudin MH, M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>803112855</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution inflam...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2015-01-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Graves' disease drug-induced, Immune reconstit...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Portugal</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Poland</td>\n",
       "      <td>Alkynes , Amides , Antiretrovirals , Azides , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Almeida Ferreira M, Carvalho AC, Silva SV, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109</th>\n",
       "      <td>803111542</td>\n",
       "      <td>Atazanavir - Hyperbilirubinaemia following &lt;EM...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-12-10</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Hyperbilirubinaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Neonates</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Atrio JM, Sperling RS, Posada R, Rodriguez ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>803110946</td>\n",
       "      <td>Antiretrovirals - Treatment failure: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-11-25</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>HIV infections drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>India</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dutta N, De R, Mukherjee P, Bhowmik A, Modo...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td>803108902</td>\n",
       "      <td>Amiodarone/atazanavir interaction - Elevated s...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-10-04</td>\n",
       "      <td>Amiodarone drug interactions, Atazanavir drug ...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Benzofurans , Class III anti...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Naccarato M, Yoong D, La Porte C, Fong I. A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>803108356</td>\n",
       "      <td>Atazanavir/ritonavir - Recurrent kidney stones...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-09-18</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Lanzafame M, Bonora S, Lattuada E, Calcagno...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>803107642</td>\n",
       "      <td>Efavirenz/ergotamine/HIV protease inhibitors i...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-09-01</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Daruna...</td>\n",
       "      <td>Ergotism drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>23.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Thailand</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Alkynes , Amides , Antimigraines , Antiretrovi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Avihingsanon A, Ramautarsing RA, Suwanpimol...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>803105878</td>\n",
       "      <td>Antiretrovirals/antivirals - Anaemia and incre...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-07-11</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Adenine nucleotides , Amides , Antineoplastics...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Burger DM, Arends JE, Jacobs BS, Van Elst-L...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>803105550</td>\n",
       "      <td>Antivirals interaction - Acute renal failure a...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-07-03</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Acute kidney injury drug-induced, Liver injury...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. den Eynde EV, Ferrer E, Podzamczer D. Acute...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>116</th>\n",
       "      <td>803104336</td>\n",
       "      <td>Atazanavir/ritonavir - Atrial fibrillation: ca...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-05-29</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ritona...</td>\n",
       "      <td>Atrial fibrillation drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Atazanavir: Atrial fibrillation: case repor...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>117</th>\n",
       "      <td>803103769</td>\n",
       "      <td>Antiretrovirals/sorafenib - Hepatotoxicity, li...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-05-20</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Daruna...</td>\n",
       "      <td>Diarrhoea drug-induced, Fatigue drug-induced, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antineoplastics , Antiretrovirals , B...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Mancuso A, Zavaglia C, Bai F, Puoti M, Bell...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>803102000</td>\n",
       "      <td>Antiretrovirals - Nephrotoxicity: 5 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-04-11</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Daruna...</td>\n",
       "      <td>Kidney disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Foisy MM, Hughes C, Hills-Nieminen C, Singh...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>803100981</td>\n",
       "      <td>Ergotamine/protease inhibitors interaction - E...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-03-24</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Ergotism drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Argentina</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Argentina</td>\n",
       "      <td>Amides , Analgesics , Anti-infectives , Antimi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Finn BC, Vadala S, Meraldi A, Bruetman JE, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>803100312</td>\n",
       "      <td>Antiretrovirals/peginterferon--2a/ribavirin -...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-03-05</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Neutropenia drug-induced, Prurigo drug-induced...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Amides , Antineoplastics , Antiretrovirals , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cenderello G, Pontali E, Cassola G, Torresi...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>121</th>\n",
       "      <td>803099799</td>\n",
       "      <td>Atazanavir - Nephrolithiasis: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-02-21</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Wang LC, Osterberg EC, David SG, Rosoff JS....</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>803097823</td>\n",
       "      <td>Atazanavir/charcoal/ritonavir interaction - HI...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2014-01-03</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Absorbents , Amides , Antiretrovirals , Carbam...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tseng AL, La Porte C, Salit IE. Significant...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>123</th>\n",
       "      <td>803096407</td>\n",
       "      <td>Antiretrovirals/raltegravir/triamcinolone - Cu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-11-28</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Cushing syndrome drug-induced, DRESS syndrome ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Anti-inflammatories , Antiallergics ,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Raltegravir: First report of DRESS syndrome...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>124</th>\n",
       "      <td>803096370</td>\n",
       "      <td>Atazanavir - Unveiling of Gilbert's syndrome: ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-11-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Gilbert's disease drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Shameem R, Sonpal N, Alemu B, Ahmadi L. Gil...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>125</th>\n",
       "      <td>803095944</td>\n",
       "      <td>Antiretrovirals - Lipodystrophy in an elderly ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-11-15</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Lipodystrophy drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ahmed I, Gandrabura T. Visual vignette. End...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>126</th>\n",
       "      <td>803094685</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution inflam...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-10-17</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Autoimmune disorders drug-induced, Ear disorde...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antipsoriatics , Antiretrovirals , Cyclopentan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ferretti F, Gerevini S, Colombo B, Testa M,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>803093186</td>\n",
       "      <td>Atazanavir/emtricitabine/tenofovir disoproxil ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-09-19</td>\n",
       "      <td>Atazanavir drug interactions, Emtricitabine dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Antiretrovirals , Deoxyribonucleosides , Nucle...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kunimoto Y, Yasui H, Touda N, Okazaki M, Na...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>803091953</td>\n",
       "      <td>Antiretrovirals/sildenafil interaction - Priap...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-08-20</td>\n",
       "      <td>Abacavir drug interactions (Serious), Atazanav...</td>\n",
       "      <td>Priapism drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antihypertensives , Antiretrovirals ,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Coralic Z, Lenhoff T, Kanzaria HK, Gerona R...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>803090706</td>\n",
       "      <td>Atazanavir - Unconjugated hyperbilirubinaemia:...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-07-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Hyperbilirubinaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bradbeer C, Ngwenya S, Baker P, George M. A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>803090440</td>\n",
       "      <td>Atazanavir/ritonavir/garlic interaction - HIV ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-07-24</td>\n",
       "      <td>Atazanavir drug interactions, Atazanavir/riton...</td>\n",
       "      <td>HIV infections drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Duncan A, Mills J. An unusual case of HIV v...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>803088363</td>\n",
       "      <td>Atazanavir/emtricitabine/tenofovir disoproxil ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-06-10</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Hepatic necrosis drug-induced, Hyperbilirubina...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Uchino K, Tateishi R, Nakagawa H, Shindoh J...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>803087486</td>\n",
       "      <td>Atazanavir - QT prolongation and first-degree ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-05-21</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Atrioventricular block drug-induced, QT interv...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Thailand</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Thailand</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Santimaleeworagun W, Pattharachayakul S, Ch...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>803086458</td>\n",
       "      <td>Atazanavir - Atrial fibrillation: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-04-30</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Atrial fibrillation drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Phillips M, Saxon C, Lee V. Atazanavir and ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>134</th>\n",
       "      <td>803086378</td>\n",
       "      <td>Atazanavir/ritonavir - Sialolithiasis: case re...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-04-29</td>\n",
       "      <td>Atazanavir overdose (Serious), Atazanavir/rito...</td>\n",
       "      <td>Calculi drug-induced, Salivary gland disorders...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Le MP, Stitou H, Soulie C, Katlama C, Peyta...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>135</th>\n",
       "      <td>803085635</td>\n",
       "      <td>Atazanavir cheaper and better tolerated than d...</td>\n",
       "      <td>News</td>\n",
       "      <td>2013-04-05</td>\n",
       "      <td>Atazanavir adverse reactions, Darunavir advers...</td>\n",
       "      <td>Exanthema drug-induced, Gastrointestinal disor...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Johnston SS, Juday T, Esker S, Espindle D, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>136</th>\n",
       "      <td>803084891</td>\n",
       "      <td>Antiretrovirals - Porphyria cutanea tarda (fir...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-03-21</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Efavir...</td>\n",
       "      <td>Porphyria cutanea tarda drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>Alkynes , Amides , Antiretrovirals , Antiviral...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Filho FB, Santos MVPQ, De Matos Pinto de Ca...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>803083048</td>\n",
       "      <td>Antiretrovirals - Epidural lipomatosis: case r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-02-04</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Lamivu...</td>\n",
       "      <td>Lipomatosis drug-induced, Spinal disorders dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Amides , Antiretrovirals , Azides , Carbamates...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Billings F, Hoyt MR. Epidural lipomatosis c...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>803082257</td>\n",
       "      <td>Atazanavir/emtricitabine/tenofovir disoproxil ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-01-14</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, L...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Yoshida M, Hoshina T, Tamura K, Kawano S, K...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>803082012</td>\n",
       "      <td>Atazanavir/tenofovir disoproxil fumarate - Ren...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2013-01-04</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Tenofo...</td>\n",
       "      <td>Renal impairment drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Phosphonic a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kanzaki G, Tsuboi N, Miyazaki Y, Yokoo T, U...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>803081776</td>\n",
       "      <td>Atazanavir/ritonavir/salmeterol/fluticasone pr...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-12-27</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Cushing syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Amides , Androstadienes , Antiallergics , Anti...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Canalejo Castrillero E, Pacheco MS. Cushing...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>803080640</td>\n",
       "      <td>Antiretrovirals - Peripheral neuropathy: case ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-11-29</td>\n",
       "      <td>Atazanavir adverse reactions, Didanosine adver...</td>\n",
       "      <td>Polyneuropathy drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Munchhoff M, Bogner J. Case report: Painful...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>142</th>\n",
       "      <td>803079560</td>\n",
       "      <td>Antiretrovirals - Pancreatitis: 3 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-11-02</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Didano...</td>\n",
       "      <td>Pancreatitis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Antir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Beh Y, Allan S. HIV, Highly Active Antiretr...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>143</th>\n",
       "      <td>803078484</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution inflam...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-10-05</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Lamivu...</td>\n",
       "      <td>Gouty arthritis drug-induced, Immune reconstit...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Eyer-Silva WA, Salgado MCF, Pinto JFC, Ferr...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>144</th>\n",
       "      <td>803077310</td>\n",
       "      <td>Antiretrovirals - Major depression: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-09-17</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Depression drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antipsoriatics , Antiretrovirals , Az...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kaestner F, Anneken K, Mostert C, Reichelt ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>145</th>\n",
       "      <td>803074679</td>\n",
       "      <td>Atazanavir/tenofovir - Kidney failure in an el...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-07-30</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Tenofo...</td>\n",
       "      <td>Renal failure drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Portugal</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Antiretrovirals , Oligop...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Coelho S, Aparicio SR, Manso R, Soto K. Qui...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>146</th>\n",
       "      <td>803074587</td>\n",
       "      <td>Atazanavir/raltegravir/tenofovir - Fatal immun...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-07-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ralteg...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, K...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Antiretrovirals , Naphth...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Stover KR, Molitorisz S, Swiatlo E, Muzny C...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>147</th>\n",
       "      <td>803072503</td>\n",
       "      <td>Atazanavir/raltegravir/ritonavir - First repor...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-06-20</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ralteg...</td>\n",
       "      <td>Leucocytosis drug-induced, Skin eruptions drug...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Naphth...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Rouanet I, Jantac M, Lechiche C, Hope-Rapp ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>148</th>\n",
       "      <td>803071870</td>\n",
       "      <td>Atazanavir - Suboptimal CNS levels leading to ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-06-06</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Encephalitis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. del Palacio Tamarit M, Quereda C, Gonzalez-...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>149</th>\n",
       "      <td>803071533</td>\n",
       "      <td>Atazanavir/ritonavir - Biliary lithiasis: case...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-06-01</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Biliary tract disorders drug-induced, Calculi ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Courbon E, Laylavoix F, Soulie C, Le beller...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>150</th>\n",
       "      <td>803070827</td>\n",
       "      <td>Atazanavir - Hyperbilirubinaemia, pruritus and...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-05-21</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Hyperbilirubinaemia drug-induced, Hyperlipidae...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cattaneo D, Meraviglia P, Cozzi V, Baldelli...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>151</th>\n",
       "      <td>803069842</td>\n",
       "      <td>FDA advises against boceprevir use with ritona...</td>\n",
       "      <td>News</td>\n",
       "      <td>2012-05-02</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir/riton...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Amides , Anti-infectives , Antiretrovirals , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Boceprevir plus HIV protease inhibitor use ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>152</th>\n",
       "      <td>803068494</td>\n",
       "      <td>Atazanavir/dapsone - Hyperbilirubinaemia due t...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-03-20</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Dapson...</td>\n",
       "      <td>Haemolysis drug-induced, Hyperbilirubinaemia d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Anti-inflammatories , Antiacnes , Antibacteria...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. East J, Blanton LS. Symptomatic hyperbiliru...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>153</th>\n",
       "      <td>803067545</td>\n",
       "      <td>Antiretrovirals - Hypersensitivity: 2 case rep...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-02-27</td>\n",
       "      <td>Atazanavir adverse reactions, Efavirenz advers...</td>\n",
       "      <td>Drug hypersensitivity drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Alkynes , Amides , Antiretrovirals , Azides , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Testi S, Severino M, D''Erme A, Gola M, Ior...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>154</th>\n",
       "      <td>803067246</td>\n",
       "      <td>Atazanavir - Hyperbilirubinaemia triggering ha...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-02-17</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Haemolysis drug-induced, Hyperbilirubinaemia d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Javelle E, Oliver M, Savini H, Aubry C, Bad...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>155</th>\n",
       "      <td>803065651</td>\n",
       "      <td>Various drugs - Aggressiveness: 56 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-01-13</td>\n",
       "      <td>Alpidem adverse reactions, Alprazolam adverse ...</td>\n",
       "      <td>Aggression drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>56.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>2 pyridinylmethylsulfinylbenzimidazoles , 3-ri...</td>\n",
       "      <td>Adolescents, Children, Elderly</td>\n",
       "      <td>Ophthalmic</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Rouve N, Bagheri H, Telmon N, Pathak A, Fra...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>156</th>\n",
       "      <td>803065886</td>\n",
       "      <td>Atazanavir - Urolithiasis: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2012-01-11</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Urolithiasis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Koblic PM, Gold WL, La Porte CJL, Lee TC. M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>157</th>\n",
       "      <td>803064551</td>\n",
       "      <td>Antiretrovirals - Vanishing bile duct syndrome...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-12-15</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Vanishing bile duct syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gnanaraj J, Fiedler P, Virata M. Vanishing ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>158</th>\n",
       "      <td>803064183</td>\n",
       "      <td>Atazanavir/ritonavir/tacrolimus interaction - ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-12-07</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Ritona...</td>\n",
       "      <td>Drowsiness drug-induced, Renal failure drug-in...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiasthmatics , Antipsoriatics , Ant...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cousins D, Topping K, Lee V, Sweeney J, Law...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>159</th>\n",
       "      <td>803062933</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution syndro...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-11-14</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Efavir...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, M...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Taiwan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Alkynes , Antiretrovirals , Azides , Benzoxazi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hung W-L, Lin Y-H, Wang P-Y, Chang M-H. HIV...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>160</th>\n",
       "      <td>803062537</td>\n",
       "      <td>Fenofibrate/antiretrovirals/lisinopril - Eleva...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-11-09</td>\n",
       "      <td>Atazanavir adverse reactions, Emtricitabine ad...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antihyperlipidaemics , Antihypertensi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bruno CB, Schapiro JM, Saberi P. An increas...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>161</th>\n",
       "      <td>803062126</td>\n",
       "      <td>Atazanavir/ritonavir/triamcinolone interaction...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-10-28</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Ritona...</td>\n",
       "      <td>Adrenal insufficiency drug-induced, Cushing sy...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Anti-inflammatories , Antiallergics ,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Levine D, Ananthakrishnan S, Garg A. Iatrog...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>162</th>\n",
       "      <td>803060853</td>\n",
       "      <td>Atazanavir/darunavir/ritonavir - Acute general...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-09-23</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Daruna...</td>\n",
       "      <td>Acute generalised exanthematous pustulosis dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bourkia M, Charles L, Lambotte O, Orostegui...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>801161083</td>\n",
       "      <td>News from IAS</td>\n",
       "      <td>News</td>\n",
       "      <td>2011-08-23</td>\n",
       "      <td>Atazanavir adverse reactions, Darunavir advers...</td>\n",
       "      <td>CNS disorders drug-induced, Congenital abnorma...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>New Zealand</td>\n",
       "      <td>New Zealand, England</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>Neonates</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Drake A, Roxby A, Kiarie J, John-Stewart G,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>164</th>\n",
       "      <td>803058779</td>\n",
       "      <td>Atazanavir - Neonatal jaundice after &lt;EM&gt;in ut...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-08-09</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Neonatal jaundice drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Ireland</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Neonates</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Mandelbrot L, Mazy F, Floch-Tudal C, Meier ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>165</th>\n",
       "      <td>801160701</td>\n",
       "      <td>Acenocoumarol/antiretrovirals interaction - Fi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-07-06</td>\n",
       "      <td>Acenocoumarol drug interactions (Serious), Ata...</td>\n",
       "      <td>Blood coagulation disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Alkynes , Amides , Anti-ischaemics , Anticoagu...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Welzen MEB, Van Den Berk GEL, Hamers RL, Bu...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>166</th>\n",
       "      <td>803055276</td>\n",
       "      <td>Atazanavir/oxycodone interaction - First repor...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-06-03</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Oxycod...</td>\n",
       "      <td>QT interval prolongation drug-induced, Torsade...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Alkaloids , Antiretrovirals , Morphine derivat...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dabiesingh DS, Psevdos G, Sharp VL. Atazana...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>167</th>\n",
       "      <td>803055093</td>\n",
       "      <td>Antiretrovirals/sorafenib interaction - Variou...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-05-31</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Lamivu...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Greece</td>\n",
       "      <td>Amides , Antineoplastics , Antiretrovirals , B...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ozenne V, Gervais A, Peytavin G, Castelnau ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>168</th>\n",
       "      <td>803054324</td>\n",
       "      <td>Atazanavir/tenofovir interaction - Tenofovir d...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-05-10</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Atazan...</td>\n",
       "      <td>Urinary calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Fabbiani M, Bracciale L, Doino M, D'Avino A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169</th>\n",
       "      <td>803052891</td>\n",
       "      <td>Atazanavir/ritonavir/raltegravir - Insomnia: 3...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-04-08</td>\n",
       "      <td>Atazanavir drug interactions, Atazanavir/riton...</td>\n",
       "      <td>Insomnia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Naphth...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Eiden C, Peyriere H, Peytavin G, Reynes J. ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>170</th>\n",
       "      <td>803052749</td>\n",
       "      <td>Atazanavir/raltegravir - Buffalo hump: case re...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-04-07</td>\n",
       "      <td>Atazanavir adverse reactions, Raltegravir adve...</td>\n",
       "      <td>Lipohypertrophy drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Naphthyridines , Oligopeptid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ceccarelli G, D'Ettorre G, Marchetti F, Riz...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>171</th>\n",
       "      <td>803050661</td>\n",
       "      <td>Atazanavir/ritonavir - Interstitial nephritis:...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-03-07</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Interstitial nephritis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Viglietti D, Verine J, De Castro N, Scemla ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>172</th>\n",
       "      <td>803049917</td>\n",
       "      <td>Atazanavir - Lithiasis: 2 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2011-02-23</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Pastori D, Esposito A, Cagliuso M, Conti V,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>173</th>\n",
       "      <td>803047238</td>\n",
       "      <td>Atazanavir arrests carotid intima media thickn...</td>\n",
       "      <td>News</td>\n",
       "      <td>2010-12-20</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Cardiovascular disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. de Saint-Martin L, Bressollette L, Perfezou...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>174</th>\n",
       "      <td>803045819</td>\n",
       "      <td>Antiretrovirals interaction - Tubular dysfunct...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-12-03</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Didano...</td>\n",
       "      <td>Kidney disorders drug-induced, Mitochondrial d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. de Jong E, Haverkort ME, Heine Rt, Jansen R...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>175</th>\n",
       "      <td>803042768</td>\n",
       "      <td>Antiretrovirals - Fatal acute liver failure: 2...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-10-15</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Adefovir...</td>\n",
       "      <td>Liver failure drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>China</td>\n",
       "      <td>Adenine nucleotides , Amides , Analgesics , An...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Anderson AM, Mosunjac MB, Palmore MP, Osbor...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>176</th>\n",
       "      <td>803034402</td>\n",
       "      <td>Adverse events do not affect compliance with H...</td>\n",
       "      <td>News</td>\n",
       "      <td>2010-09-27</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir thera...</td>\n",
       "      <td>Diarrhoea drug-induced, Various toxicities dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Azides , Deoxyribonucleoside...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sonder GJ, Prins JM, Regez RM, Brinkman K, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>177</th>\n",
       "      <td>803027910</td>\n",
       "      <td>Atazanavir/quetiapine/ritonavir interaction - ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-07-21</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Quetia...</td>\n",
       "      <td>Coma drug-induced, Hypotension drug-induced, P...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Belgium</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Amides , Analgesics , Antidepressants , Antips...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hantson P, Di Fazio V, Wallemacq P. Toxicok...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>178</th>\n",
       "      <td>803015257</td>\n",
       "      <td>Antiretrovirals - Unmasking of PML in HIV-posi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-05-13</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Amprenav...</td>\n",
       "      <td>Progressive multifocal leukoencephalopathy dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Alkynes , Amides , Antipsoriatics , Antiretrov...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sidhu N, McCutchan JA. Unmasking of PML by ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>179</th>\n",
       "      <td>803013899</td>\n",
       "      <td>HIV/HCV coinfection ups risk of liver toxicity...</td>\n",
       "      <td>News</td>\n",
       "      <td>2010-05-04</td>\n",
       "      <td>Atazanavir adverse reactions, Darunavir advers...</td>\n",
       "      <td>Liver disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vispo E, Mena A, Maida I, Blanco F, Cordoba...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>180</th>\n",
       "      <td>803013479</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution inflam...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-04-28</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Mass MK. CNS Immune Reconstitution Inflamma...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>803011687</td>\n",
       "      <td>Atazanavir - Choledocholithiasis leading to he...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-04-16</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Jacques AC, Giguere P, Zhang G, Touchie C, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>803008735</td>\n",
       "      <td>Atazanavir/ritonavir interaction - Hyperbiliru...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-03-18</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Ritona...</td>\n",
       "      <td>Hyperbilirubinaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Uglietti A, Novati S, Gulminetti R, Maserat...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>183</th>\n",
       "      <td>803008749</td>\n",
       "      <td>Antiretrovirals and chronic kidney disease</td>\n",
       "      <td>News</td>\n",
       "      <td>2010-03-18</td>\n",
       "      <td>Atazanavir adverse reactions, Indinavir advers...</td>\n",
       "      <td>Kidney disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kirk O, Mocroft A, Reiss P, De Wit S, Sedla...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>184</th>\n",
       "      <td>801156587</td>\n",
       "      <td>Toxicity defines drug switching with cART</td>\n",
       "      <td>News</td>\n",
       "      <td>2010-03-11</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>CNS disorders drug-induced, Drug hypersensitiv...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Elzi L, Marzolini C, Furrer H, Ledergerber ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>185</th>\n",
       "      <td>803006614</td>\n",
       "      <td>Atazanavir - Renal failure in a patient with c...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-02-24</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Renal impairment drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Spain</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cervero M, Navas E, Agud JL, Garcia-Benaya ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>186</th>\n",
       "      <td>803005508</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution syndro...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-01-28</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Efavir...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Alkynes , Amides , Antir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Jagannathan P, Davis E, Jacobson M, Huang L...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>187</th>\n",
       "      <td>803004214</td>\n",
       "      <td>Atazanavir/ritonavir/quetiapine interaction - ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2010-01-08</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Quetia...</td>\n",
       "      <td>Appetite disorders drug-induced, Confusion dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Analgesics , Antidepressants , Antips...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Pollack TM, McCoy C, Stead W. Clinically si...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>188</th>\n",
       "      <td>803003361</td>\n",
       "      <td>Atazanavir/raltegravir - Renal calculi (first ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-12-21</td>\n",
       "      <td>Atazanavir adverse reactions, Raltegravir adve...</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Antiretrovirals , Naphthyridines , Oligopeptid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Huber M, Beatrice J, BRUNNER A, Muller N. A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>189</th>\n",
       "      <td>801154598</td>\n",
       "      <td>Antiretrovirals/fluticasone propionate interac...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-12-02</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Flutic...</td>\n",
       "      <td>Adrenal insufficiency drug-induced, Cushing sy...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Amides , Analgesics , Androstadienes , Anti-in...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Collet-Gaudillat C, Roussin-Bretagne S, Des...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>190</th>\n",
       "      <td>801150900</td>\n",
       "      <td>Antiretrovirals - Parkinson's disease: 3 case ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-09-24</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Parkinson's disease drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tisch S, Brew B. Parkinsonism in HIV-infect...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>191</th>\n",
       "      <td>801150510</td>\n",
       "      <td>Antiretrovirals - Chronic progressive external...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-09-10</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Blepharoptosis drug-induced, Deglutition disor...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Antiretrovirals: Chronic progressive extern...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>192</th>\n",
       "      <td>801151050</td>\n",
       "      <td>Posaconazole affects antiviral pharmacokinetics</td>\n",
       "      <td>News</td>\n",
       "      <td>2009-08-19</td>\n",
       "      <td>Atazanavir pharmacokinetics, Posaconazole phar...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antifungals , Antiretrovirals , Carba...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Krishna G, Moton A, Ma L, Martinho M, Seibe...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>193</th>\n",
       "      <td>801146696</td>\n",
       "      <td>Antiretrovirals - Genital ulcers: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-07-22</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Genital ulcer drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antipsoriatics ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Adler RS, D'Aquilante DA, Kovarik CL. Antir...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>194</th>\n",
       "      <td>801141696</td>\n",
       "      <td>Antiretrovirals - Drug hypersensitivity result...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-05-21</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Aphthous stomatitis drug-induced, Blepharoedem...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Antipsoriatics , Antiretrovirals , Azides , Cy...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Walkty A, Smith D, Lopko B, Kasper K. Sever...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195</th>\n",
       "      <td>801139380</td>\n",
       "      <td>Atazanavir - Renal calculi: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-05-12</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Renal calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Spain</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Valencia ME, Moreno V. Atazanavir-induced n...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>196</th>\n",
       "      <td>801141005</td>\n",
       "      <td>Antiretrovirals - Neurological immune reconsti...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-04-21</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Alkynes , Amides , Antip...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. McCombe JA, Auer RN, Maingat FG, Houston S,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>197</th>\n",
       "      <td>801135589</td>\n",
       "      <td>Antiretrovirals/ergotamine/fluticasone propion...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-02-11</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Ergota...</td>\n",
       "      <td>Cushing syndrome drug-induced, Ergotism drug-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Spain</td>\n",
       "      <td>2 pyridinylmethylsulfinylbenzimidazoles , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Conejo MM, Cuerda VJM, Martinez JA, Rubio R...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>198</th>\n",
       "      <td>801136006</td>\n",
       "      <td>Antiretrovirals/hirsutine interaction - First ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2009-01-28</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Hirsut...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Alkaloids , Amides , Antiretrovirals , Carbama...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Galera RML, Pascuet ER, Mur JIE, Ronsano JB...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>199</th>\n",
       "      <td>801133624</td>\n",
       "      <td>Antiretrovirals - Hepatotoxicity: 17 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-12-08</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Amprenav...</td>\n",
       "      <td>Fatty liver drug-induced, Hepatic fibrosis dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>17.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Akhtar MA, Mathieson K, Arey B, Post J, Pre...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>200</th>\n",
       "      <td>801124677</td>\n",
       "      <td>Antiretrovirals - Fatal immune reconstitution ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-11-12</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Death drug-induced, Immune reconstitution synd...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Rogers JS, Zakaria S, Thom KA, Flammer KM, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>201</th>\n",
       "      <td>801124651</td>\n",
       "      <td>Atazanavir/raltegravir interaction - Elevated ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-11-10</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Ralteg...</td>\n",
       "      <td>Elevated liver enzymes drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Naphthyridines , Oligopeptid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Fleischbein E, O'Brien J, Martelino R, Fens...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>202</th>\n",
       "      <td>801124515</td>\n",
       "      <td>Atazanavir - Urinary calculi leading to acute ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-11-06</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Renal failure drug-induced, Urinary calculi dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Moriyama Y, Minamidate Y, Yasuda M, Ehara H...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>203</th>\n",
       "      <td>801123866</td>\n",
       "      <td>Abacavir/atazanavir - Hypersensitivity reactio...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-09-19</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Drug hypersensitivity drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antipsoriatics , Antiretrovirals , Cyclopentan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Young B, Squires K, Patel P, Dejesus E, Bel...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>204</th>\n",
       "      <td>801020559</td>\n",
       "      <td>Antiretrovirals - HIV-associated lipodystrophy...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-09-04</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Didano...</td>\n",
       "      <td>Anaemia drug-induced, HIV-associated lipodystr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Fuller J. A 39-year-old man with HIV-associ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>205</th>\n",
       "      <td>801122108</td>\n",
       "      <td>Once-daily atazanavir/ritonavir for HIV-associ...</td>\n",
       "      <td>News</td>\n",
       "      <td>2008-08-19</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir thera...</td>\n",
       "      <td>HIV-associated lipodystrophy syndrome drug-ind...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Moyle G, Girard J-M, Andrade J, Salvato P, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>206</th>\n",
       "      <td>801117480</td>\n",
       "      <td>Antiretrovirals - Acne vulgaris and rosacea re...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-08-13</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Acne vulgaris drug-induced, Immune reconstitut...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>England</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Alkynes , Amides , Antipsoriatics , Antiretrov...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Scott C, Staughton RCD, Bunker CJ, Asboe D....</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>207</th>\n",
       "      <td>801111780</td>\n",
       "      <td>Atazanavir/emtricitabine/tenofovir - First rep...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-06-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, T...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Antiretrovirals , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Prendki V, Dumas J-L, Bouges-Michel C, Boch...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>208</th>\n",
       "      <td>801111644</td>\n",
       "      <td>Atazanavir/tenofovir - Acute renal failure: 2 ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-06-18</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Tenofo...</td>\n",
       "      <td>Renal failure drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Spain</td>\n",
       "      <td>Adenine nucleotides , Antiretrovirals , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vallecillo-Sanchez G, Guelar-Grimberg A, Go...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>801110441</td>\n",
       "      <td>Atazanavir/ritonavir/tenofovir - Urinary calcu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-05-14</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ritona...</td>\n",
       "      <td>Urinary calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. D'Ettorre G, Zaffiri L, Ceccarelli G, Masse...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>210</th>\n",
       "      <td>801109834</td>\n",
       "      <td>Antiretrovirals - Hepatotoxicity (first report...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-05-05</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Aplaviro...</td>\n",
       "      <td>Liver disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Nichols WG, Steel HM, Bonny T, Adkison K, C...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>211</th>\n",
       "      <td>801104260</td>\n",
       "      <td>Methadone interaction - Interaction with ataza...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-02-29</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Fluraz...</td>\n",
       "      <td>Torsades de pointes drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Ireland</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Ireland</td>\n",
       "      <td>Amides , Antiretrovirals , Benzodiazepinones ,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Falconer M, Molloy D, Ingerhaug J, Barry M....</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>212</th>\n",
       "      <td>801100890</td>\n",
       "      <td>Tacrolimus interaction - Interaction with conc...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2008-02-14</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Tacrol...</td>\n",
       "      <td>Renal impairment drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiasthmatics , Antipsoriatics , Antiretrovir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Moreno A, Barcena R, Quereda C, Casado JL, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>213</th>\n",
       "      <td>801058885</td>\n",
       "      <td>Renal function decline with tenofovir + ritona...</td>\n",
       "      <td>News</td>\n",
       "      <td>2008-01-31</td>\n",
       "      <td>Amprenavir adverse reactions, Atazanavir adver...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, R...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Goicoechea M, Liu S, Best B, Sun S, Jain S,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>214</th>\n",
       "      <td>801097500</td>\n",
       "      <td>Atazanavir - Crystal nephropathy: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-11-09</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Kidney disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Izzedine H, Ben M'rad M, Bardier A, Daudon ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>215</th>\n",
       "      <td>801097209</td>\n",
       "      <td>Atazanavir - First report of menorrhagia: case...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-11-08</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Menorrhagia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Greece</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Paparizos VA, Kourkounti S, Leuow K, Kyriak...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>216</th>\n",
       "      <td>801058688</td>\n",
       "      <td>Antiretrovirals - Human T lymphotropic virus t...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-10-17</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, N...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Toro C, Blanco F, Garcia-Gasco P, Sheldon J...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>217</th>\n",
       "      <td>801058648</td>\n",
       "      <td>Atazanavir - Urinary calculi: 11 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-10-02</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Urinary calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Couzigou C, Daudon M, Meynard JL, Borsa-Leb...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>218</th>\n",
       "      <td>801091646</td>\n",
       "      <td>Atazanavir - Hyperbilirubinaemia in a patient ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-09-27</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Hyperbilirubinaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kummer O, Mossdorf E, Battegay M, Elzi L, B...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>801093103</td>\n",
       "      <td>Atazanavir/tenofovir disoproxil fumarate - Acu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-09-20</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Tenofo...</td>\n",
       "      <td>Interstitial nephritis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Phosphonic a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Schmid S, Opravil M, Moddel M, Huber M, Pfa...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>801091090</td>\n",
       "      <td>Antiretrovirals - Immune reconstitution syndro...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-07-25</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Xhani D, Hage CA, Knox KS. A 30-year-old ma...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>221</th>\n",
       "      <td>801071770</td>\n",
       "      <td>Atazanavir/ritonavir - Alopecia (first report ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-06-14</td>\n",
       "      <td>Atazanavir adverse reactions, Ritonavir advers...</td>\n",
       "      <td>Alopecia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Torres HA, Barnett BJ, Arduino RC. Alopecia...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>801071372</td>\n",
       "      <td>Atazanavir - Renal calculi: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-06-07</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Kidney disorders drug-induced, Renal calculi d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Anderson PL, Lichtenstein KA, Gerig NE, Kis...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>801058124</td>\n",
       "      <td>Atazanavir - First report of torsade de pointe...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2007-02-23</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Torsades de pointes drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ly T, Ruiz ME. Prolonged QT interval and to...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>224</th>\n",
       "      <td>801026802</td>\n",
       "      <td>Atazanavir - Urinary calculi: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-11-17</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Urinary calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. PACANOWSKI J, Poirier J-M, Petit I, Meynard...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>225</th>\n",
       "      <td>801035373</td>\n",
       "      <td>Atazanavir - Urinary calculi: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-11-16</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Urinary calculi drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Chang HR, Pella PM. Atazanavir urolithiasis...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>226</th>\n",
       "      <td>801013749</td>\n",
       "      <td>Atazanavir and indinavir uptake reduced by aci...</td>\n",
       "      <td>News</td>\n",
       "      <td>2006-11-10</td>\n",
       "      <td>Atazanavir drug interactions, Atazanavir pharm...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>USA</td>\n",
       "      <td>2 pyridinylmethylsulfinylbenzimidazoles , Anti...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Fulco PP, Vora UB, Bearman GML. Acid suppre...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>801044632</td>\n",
       "      <td>Antiretrovirals - Lymphoid pneumonitis associa...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-09-19</td>\n",
       "      <td>Abacavir adverse reactions, Atazanavir adverse...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, P...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antipsoriatics , Antiretrovirals , Ca...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ingiliz P, Appenrodt B, Gruenhage F, Vogel ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>228</th>\n",
       "      <td>801066893</td>\n",
       "      <td>Atazanavir interaction - Interaction with conc...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-06-19</td>\n",
       "      <td>Atazanavir drug interactions, Ritonavir drug i...</td>\n",
       "      <td>Lipodystrophy drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dellamonica P. Can boosted atazanavir induc...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>229</th>\n",
       "      <td>801064647</td>\n",
       "      <td>Atazanavir - First report of skin eruptions: 3...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-05-31</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Skin eruptions drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ouagari Z, Tubiana R, Mohand HA, Dominguez ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>230</th>\n",
       "      <td>801038189</td>\n",
       "      <td>Atazanavir interaction - Interaction with conc...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-04-11</td>\n",
       "      <td>Atazanavir drug interactions, Esomeprazole dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>2 pyridinylmethylsulfinylbenzimidazoles , Anti...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kiser JJ, Lichtenstein KA, Anderson PL, Fle...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>231</th>\n",
       "      <td>801037182</td>\n",
       "      <td>Buprenorphine - First report of an interaction...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-03-28</td>\n",
       "      <td>Atazanavir drug interactions, Buprenorphine dr...</td>\n",
       "      <td>Somnolence drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Cyclop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bruce RD, Altice FL. Three case reports of ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>232</th>\n",
       "      <td>801017516</td>\n",
       "      <td>Tenofovir interaction - Interaction with conco...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-03-23</td>\n",
       "      <td>Atazanavir drug interactions (Serious), Didano...</td>\n",
       "      <td>Renal failure drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Adenine nucleotides , Amides , Antiretrovirals...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Zimmermann AE, Pizzoferrato T, Bedford J, M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>233</th>\n",
       "      <td>801031367</td>\n",
       "      <td>Atazanavir - Hyperphosphatasemia of infancy an...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2006-01-31</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Metabolic disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>England</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Trower K, Wilmot R, Barlow G, Thaker H. A c...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>234</th>\n",
       "      <td>801026038</td>\n",
       "      <td>Antiretrovirals - Cardiomyopathy (first report...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2005-12-22</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Lamivu...</td>\n",
       "      <td>Cardiomyopathies drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Azides , Deoxyribonucleoside...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Breuckmann F, Neumann T, Kondratieva J, Wie...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>235</th>\n",
       "      <td>801018519</td>\n",
       "      <td>PPIs, H&lt;SUB&gt;2&lt;/SUB&gt;-receptor antagonists inter...</td>\n",
       "      <td>News</td>\n",
       "      <td>2005-08-16</td>\n",
       "      <td>Atazanavir drug interactions</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Khanlou H, FARTHING C. Co-administration of...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>236</th>\n",
       "      <td>800999108</td>\n",
       "      <td>Coadministration of omeprazole reduces atazana...</td>\n",
       "      <td>News</td>\n",
       "      <td>2005-01-12</td>\n",
       "      <td>Atazanavir drug interactions, Atazanavir pharm...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>New Zealand</td>\n",
       "      <td>New Zealand</td>\n",
       "      <td>2 pyridinylmethylsulfinylbenzimidazoles , Amid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bristol-Myers Squibb Company. REYATAZ (Rm) ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>237</th>\n",
       "      <td>800979180</td>\n",
       "      <td>Atazanavir - First report of hepatitis: case r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2004-09-06</td>\n",
       "      <td>Atazanavir adverse reactions</td>\n",
       "      <td>Hepatitis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Eholie SP, Lacombe K, Serfaty L, Wendum D, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>238</th>\n",
       "      <td>809028534</td>\n",
       "      <td>CPMP EU-wide reviews for COX-2 inhibitors and ...</td>\n",
       "      <td>News</td>\n",
       "      <td>2003-11-28</td>\n",
       "      <td>Atazanavir therapeutic use, Colesevelam therap...</td>\n",
       "      <td>Hypersensitivity drug-induced, Hypospadias dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Alkynes , Amines , Antiallergics , Antihypergl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Meeting of the Committee for Proprietary Me...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>239</th>\n",
       "      <td>800863910</td>\n",
       "      <td>Tenofovir: reduced atazanavir concentrations</td>\n",
       "      <td>News</td>\n",
       "      <td>2003-09-24</td>\n",
       "      <td>Atazanavir drug interactions, Atazanavir pharm...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. US Food and Drug Administration. Re: import...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>800841000</td>\n",
       "      <td>Atazanavir attains anti-HIV effects without al...</td>\n",
       "      <td>News</td>\n",
       "      <td>2001-12-06</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir thera...</td>\n",
       "      <td>Hyperlipidaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>New Zealand</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Antiretrovirals , Deoxyribonucleosides , Dideo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Pantaleo G, Sanne I, Cahn P, Percival L, Ph...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>241 rows  23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Report Id                                 Safety Report Name  \\\n",
       "0    803500083  Atazanavir/ritonavir - Atazanavir crystal-indu...   \n",
       "1    803499015  Antiretrovirals - Anaemia and viral rebound: 2...   \n",
       "2    803499019  Antiretrovirals - Virologic failure: 6 case re...   \n",
       "3    803488559  Antiretrovirals - Drug resistance, virologic r...   \n",
       "4    803485910         Antiretrovirals - Weight gain: case report   \n",
       "5    803478784  Atazanavir/cobicistat/darunavir - Various toxi...   \n",
       "6    803474501  Atazanavir/emtricitabine/raltegravir - Hypertr...   \n",
       "7    803473063  Antiretrovirals - Exposure during pregnancy: 3...   \n",
       "8    803470701  Antiretrovirals - Paradoxical or unmasking of ...   \n",
       "9    803469994  Antivirals/immunosuppressants interaction - Dr...   \n",
       "10   803468110  Atazanavir/ritonavir - Indirect bilirubin leve...   \n",
       "11   803455694  Atazanavir/ritonavir/tenofovir disoproxil fuma...   \n",
       "12   803455935             Atazanavir - Urolithiasis: case report   \n",
       "13   803453169  Antiretroviral - Non alcoholic fatty liver dis...   \n",
       "14   803449989  Antivirals/lidocaine interaction - Various tox...   \n",
       "15   803449175  Atazanavir/tacrolimus interaction - Increase i...   \n",
       "16   803443825  Atazanavir/lopinavir - Virological non-respons...   \n",
       "17   803440764  Atazanavir/ledipasvir/sofosbuvir - Headache an...   \n",
       "18   803435020  Antiretrovirals - Type 1 diabetes mellitus, hy...   \n",
       "19   803434892  Antiretrovirals - Development of dolutegravir ...   \n",
       "20   803434874  Atazanavir/lamivudine/tenofovir - Disseminated...   \n",
       "21   803429382  Atazanavir/dolutegravir - Virological failure:...   \n",
       "22   803428900  Atazanavir/dolutegravir - Neuropsychiatric sid...   \n",
       "23   803429039  Neural tube defects after exposure to antiretr...   \n",
       "24   803426748  Antiretrovirals - Neural tube defects followin...   \n",
       "25   803421461  Antiretrovirals - Maternal exposure during pre...   \n",
       "26   803414455  Atazanavir/darunavir - Virological failure due...   \n",
       "27   803410125     Ritonavir/lopinavir - Renal stone: case report   \n",
       "28   803408652  Multiple drugs - Increased tacrolimus level an...   \n",
       "29   803402189  Antiretrovirals - Antiretrovirals resistance, ...   \n",
       "30   803401023  Antiretrovirals - Virologic failure due to nau...   \n",
       "31   803393639     Antivirals - Rash and pruritus: 8 case reports   \n",
       "32   803386130  Antiretrovirals - Development of resistance du...   \n",
       "33   803383691  HIV protease inhibitors/quetiapine interaction...   \n",
       "34   803376059  Antiretrovirals - Immune reconstitution inflam...   \n",
       "35   803372621  Antiretrovirals - Maculopapular pruritic rash:...   \n",
       "36   803366731  Multiple drugs - Neutropenia and various toxic...   \n",
       "37   803360498          Atazanavir - Nephrolithiasis: case report   \n",
       "38   803357736  Atazanavir - Drug resistance secondary to ataz...   \n",
       "39   803346689  Antiretrovirals - Eruptive melanocytic nevi as...   \n",
       "40   803340341  Atazanavir/ritonavir/tenofovir - Chronic granu...   \n",
       "41   803340549  AEs with second-line ART in South African HIV ...   \n",
       "42   803337329  Atazanavir/ritonavir/tacrolimus interaction - ...   \n",
       "43   803319080  Emtricitabine/tenofovir does not increase adve...   \n",
       "44   803309947   Atazanavir - Multiple toxicities: 2 case reports   \n",
       "45   803303073  Atazanavir - Granulomatous interstitial nephri...   \n",
       "46   803301512  Antiretrovirals - Fanconi renal syndrome: 13 c...   \n",
       "47   803299586  Multiple drugs - Drug induced kidney injury: 2...   \n",
       "48   803297443  Multiple drugs - Emergence of anti-retroviral ...   \n",
       "49   803294958  Antiretrovirals - Various toxicities: 21 case ...   \n",
       "50   803295427  Atazanavir/ritonavir/lopinavir/tenofovir disop...   \n",
       "51   803290156  Effect of antiretroviral regimen on renal comp...   \n",
       "52   803282133  Atazanavir - Crystalline nephropathy and acute...   \n",
       "53   803277425       Antivirals - Various toxicities: case report   \n",
       "54   803275435           Atazanavir - Ureteral stone: case report   \n",
       "55   803275144  Atazanavir/darunavir/lopinavir - Development o...   \n",
       "56   803274754  Multiple drugs interaction - Febrile neutropen...   \n",
       "57   803268679  Atazanavir/ritonavir/Ergotamine/dipyrone/caffe...   \n",
       "58   803267559  Antiretrovirals - Acute pancreatitis secondary...   \n",
       "59   803263661  Risk of kidney disease with atazanavir-contain...   \n",
       "60   803254988  Multiple drugs - Various toxicities: 7 case re...   \n",
       "61   803255383  Tacrolimus/antiretrovirals interaction - Acute...   \n",
       "62   803244890  Atazanavir - Cholelithiasis and cholangitis: c...   \n",
       "63   803245086  Antiretrovirals - Various toxicities: case report   \n",
       "64   803241275           Atazanavir - Cholelithiasis: case report   \n",
       "65   803241548  Tenofovir disoproxil fumarate/efavirenz/emtric...   \n",
       "66   803240626  Multiple drugs - Various toxicities: 10 case r...   \n",
       "67   803239344  Multiple drugs interaction - Iatrogenic Cushin...   \n",
       "68   803239147  Antiretrovirals - Premature atherosclerosis an...   \n",
       "69   803237013  Atazanavir/lamivudine/abacavir - Decrease in e...   \n",
       "70   803235795  Antiretrovirals - Opsoclonus myoclonus ataxia ...   \n",
       "71   803230014  Atazanavir/lurasidone/risperidone interaction ...   \n",
       "72   803229862  Atazanavir - Multiple intra-renal stones: case...   \n",
       "73   803224287  Atazanavir/raltegravir - Development of atazan...   \n",
       "74   803210999  Atazanavir/ritonavir - First report of acute i...   \n",
       "75   803207391  Antiretrovirals - Diarrhoea due to disseminate...   \n",
       "76   803199272  Antiretrovirals - Drug resistance: 6 case reports   \n",
       "77   803195649  Antiretrovirals - Immune reconstitution inflam...   \n",
       "78   803194375  Atazanavir - Urolithiasis and pyelonephritis: ...   \n",
       "79   803192184  Antivirals - Erythema elevatum diutinum: case ...   \n",
       "80   803190529  Atazanavir/ritonavir and orlistat - Virologica...   \n",
       "81   803188304  Antivirals - Grade 4 hyperbilirubinaemia: case...   \n",
       "82   803185951  Atazanavir/ritonavir - Nephrolithiasis: case r...   \n",
       "83   803185799  Multiple drug interaction - Acneiform rash: 2 ...   \n",
       "84   803185679  Atazanavir/ivabradine/ritonavir interaction - ...   \n",
       "85   803183305       Atazanavir - Acute pancreatitis: case report   \n",
       "86   803178080  Multiple drugs - Nausea/nephrotoxicity/rhabdom...   \n",
       "87   803167775  Antiretrovirals - Nodular regenerative hyperpl...   \n",
       "88   803165256  Antiretrovirals - Immune reconstitution inflam...   \n",
       "89   803163726  Atazanavir/cotrimoxazole/lamivudine/rifabutin/...   \n",
       "90   803163539  Atazanavir - Hyperbilirubinaemia and digestive...   \n",
       "91   803159585     Antiretrovirals - Urticarial rash: case report   \n",
       "92   803157354  Antiretrovirals - Hypersensitivity reactions: ...   \n",
       "93   803152402  Antivirals - Increase in atazanavir concentrat...   \n",
       "94   803151453  Antiretrovirals - Avascular necrosis of the kn...   \n",
       "95   803150701          Atazanavir - Kidney stone: 3 case reports   \n",
       "96   803145535  Abacavir/atazanavir/lamivudine - Cervical lymp...   \n",
       "97   803145789  Atazanavir/ritonavir - Granulomatous interstit...   \n",
       "98   803144389  Atazanavir/raltegravir - Integrase inhibitor r...   \n",
       "99   803143153  Multiple drugs - Various toxicities: 6 case re...   \n",
       "100  803140600  Atazanavir/everolimus/ritonavir interaction - ...   \n",
       "101  803130437  Atazanavir/nevirapine - Transaminitis and hype...   \n",
       "102  803126705  Prenatal atazanavir exposure safe for language...   \n",
       "103  803117040  Atazanavir/ritonavir/vinblastine interaction -...   \n",
       "104  803116870  Atazanavir - Acute renal failure secondary to ...   \n",
       "105  803115686  Antiretrovirals - Drug hypersensitivity: 4 cas...   \n",
       "106  803115296  Corticosteroids/HIV protease inhibitors intera...   \n",
       "107  803113778       HIV PI use in pregnancy reduces birth weight   \n",
       "108  803112855  Antiretrovirals - Immune reconstitution inflam...   \n",
       "109  803111542  Atazanavir - Hyperbilirubinaemia following <EM...   \n",
       "110  803110946   Antiretrovirals - Treatment failure: case report   \n",
       "111  803108902  Amiodarone/atazanavir interaction - Elevated s...   \n",
       "112  803108356  Atazanavir/ritonavir - Recurrent kidney stones...   \n",
       "113  803107642  Efavirenz/ergotamine/HIV protease inhibitors i...   \n",
       "114  803105878  Antiretrovirals/antivirals - Anaemia and incre...   \n",
       "115  803105550  Antivirals interaction - Acute renal failure a...   \n",
       "116  803104336  Atazanavir/ritonavir - Atrial fibrillation: ca...   \n",
       "117  803103769  Antiretrovirals/sorafenib - Hepatotoxicity, li...   \n",
       "118  803102000   Antiretrovirals - Nephrotoxicity: 5 case reports   \n",
       "119  803100981  Ergotamine/protease inhibitors interaction - E...   \n",
       "120  803100312  Antiretrovirals/peginterferon--2a/ribavirin -...   \n",
       "121  803099799          Atazanavir - Nephrolithiasis: case report   \n",
       "122  803097823  Atazanavir/charcoal/ritonavir interaction - HI...   \n",
       "123  803096407  Antiretrovirals/raltegravir/triamcinolone - Cu...   \n",
       "124  803096370  Atazanavir - Unveiling of Gilbert's syndrome: ...   \n",
       "125  803095944  Antiretrovirals - Lipodystrophy in an elderly ...   \n",
       "126  803094685  Antiretrovirals - Immune reconstitution inflam...   \n",
       "127  803093186  Atazanavir/emtricitabine/tenofovir disoproxil ...   \n",
       "128  803091953  Antiretrovirals/sildenafil interaction - Priap...   \n",
       "129  803090706  Atazanavir - Unconjugated hyperbilirubinaemia:...   \n",
       "130  803090440  Atazanavir/ritonavir/garlic interaction - HIV ...   \n",
       "131  803088363  Atazanavir/emtricitabine/tenofovir disoproxil ...   \n",
       "132  803087486  Atazanavir - QT prolongation and first-degree ...   \n",
       "133  803086458      Atazanavir - Atrial fibrillation: case report   \n",
       "134  803086378  Atazanavir/ritonavir - Sialolithiasis: case re...   \n",
       "135  803085635  Atazanavir cheaper and better tolerated than d...   \n",
       "136  803084891  Antiretrovirals - Porphyria cutanea tarda (fir...   \n",
       "137  803083048  Antiretrovirals - Epidural lipomatosis: case r...   \n",
       "138  803082257  Atazanavir/emtricitabine/tenofovir disoproxil ...   \n",
       "139  803082012  Atazanavir/tenofovir disoproxil fumarate - Ren...   \n",
       "140  803081776  Atazanavir/ritonavir/salmeterol/fluticasone pr...   \n",
       "141  803080640  Antiretrovirals - Peripheral neuropathy: case ...   \n",
       "142  803079560     Antiretrovirals - Pancreatitis: 3 case reports   \n",
       "143  803078484  Antiretrovirals - Immune reconstitution inflam...   \n",
       "144  803077310    Antiretrovirals - Major depression: case report   \n",
       "145  803074679  Atazanavir/tenofovir - Kidney failure in an el...   \n",
       "146  803074587  Atazanavir/raltegravir/tenofovir - Fatal immun...   \n",
       "147  803072503  Atazanavir/raltegravir/ritonavir - First repor...   \n",
       "148  803071870  Atazanavir - Suboptimal CNS levels leading to ...   \n",
       "149  803071533  Atazanavir/ritonavir - Biliary lithiasis: case...   \n",
       "150  803070827  Atazanavir - Hyperbilirubinaemia, pruritus and...   \n",
       "151  803069842  FDA advises against boceprevir use with ritona...   \n",
       "152  803068494  Atazanavir/dapsone - Hyperbilirubinaemia due t...   \n",
       "153  803067545  Antiretrovirals - Hypersensitivity: 2 case rep...   \n",
       "154  803067246  Atazanavir - Hyperbilirubinaemia triggering ha...   \n",
       "155  803065651    Various drugs - Aggressiveness: 56 case reports   \n",
       "156  803065886             Atazanavir - Urolithiasis: case report   \n",
       "157  803064551  Antiretrovirals - Vanishing bile duct syndrome...   \n",
       "158  803064183  Atazanavir/ritonavir/tacrolimus interaction - ...   \n",
       "159  803062933  Antiretrovirals - Immune reconstitution syndro...   \n",
       "160  803062537  Fenofibrate/antiretrovirals/lisinopril - Eleva...   \n",
       "161  803062126  Atazanavir/ritonavir/triamcinolone interaction...   \n",
       "162  803060853  Atazanavir/darunavir/ritonavir - Acute general...   \n",
       "163  801161083                                      News from IAS   \n",
       "164  803058779  Atazanavir - Neonatal jaundice after <EM>in ut...   \n",
       "165  801160701  Acenocoumarol/antiretrovirals interaction - Fi...   \n",
       "166  803055276  Atazanavir/oxycodone interaction - First repor...   \n",
       "167  803055093  Antiretrovirals/sorafenib interaction - Variou...   \n",
       "168  803054324  Atazanavir/tenofovir interaction - Tenofovir d...   \n",
       "169  803052891  Atazanavir/ritonavir/raltegravir - Insomnia: 3...   \n",
       "170  803052749  Atazanavir/raltegravir - Buffalo hump: case re...   \n",
       "171  803050661  Atazanavir/ritonavir - Interstitial nephritis:...   \n",
       "172  803049917             Atazanavir - Lithiasis: 2 case reports   \n",
       "173  803047238  Atazanavir arrests carotid intima media thickn...   \n",
       "174  803045819  Antiretrovirals interaction - Tubular dysfunct...   \n",
       "175  803042768  Antiretrovirals - Fatal acute liver failure: 2...   \n",
       "176  803034402  Adverse events do not affect compliance with H...   \n",
       "177  803027910  Atazanavir/quetiapine/ritonavir interaction - ...   \n",
       "178  803015257  Antiretrovirals - Unmasking of PML in HIV-posi...   \n",
       "179  803013899  HIV/HCV coinfection ups risk of liver toxicity...   \n",
       "180  803013479  Antiretrovirals - Immune reconstitution inflam...   \n",
       "181  803011687  Atazanavir - Choledocholithiasis leading to he...   \n",
       "182  803008735  Atazanavir/ritonavir interaction - Hyperbiliru...   \n",
       "183  803008749         Antiretrovirals and chronic kidney disease   \n",
       "184  801156587          Toxicity defines drug switching with cART   \n",
       "185  803006614  Atazanavir - Renal failure in a patient with c...   \n",
       "186  803005508  Antiretrovirals - Immune reconstitution syndro...   \n",
       "187  803004214  Atazanavir/ritonavir/quetiapine interaction - ...   \n",
       "188  803003361  Atazanavir/raltegravir - Renal calculi (first ...   \n",
       "189  801154598  Antiretrovirals/fluticasone propionate interac...   \n",
       "190  801150900  Antiretrovirals - Parkinson's disease: 3 case ...   \n",
       "191  801150510  Antiretrovirals - Chronic progressive external...   \n",
       "192  801151050    Posaconazole affects antiviral pharmacokinetics   \n",
       "193  801146696      Antiretrovirals - Genital ulcers: case report   \n",
       "194  801141696  Antiretrovirals - Drug hypersensitivity result...   \n",
       "195  801139380            Atazanavir - Renal calculi: case report   \n",
       "196  801141005  Antiretrovirals - Neurological immune reconsti...   \n",
       "197  801135589  Antiretrovirals/ergotamine/fluticasone propion...   \n",
       "198  801136006  Antiretrovirals/hirsutine interaction - First ...   \n",
       "199  801133624  Antiretrovirals - Hepatotoxicity: 17 case reports   \n",
       "200  801124677  Antiretrovirals - Fatal immune reconstitution ...   \n",
       "201  801124651  Atazanavir/raltegravir interaction - Elevated ...   \n",
       "202  801124515  Atazanavir - Urinary calculi leading to acute ...   \n",
       "203  801123866  Abacavir/atazanavir - Hypersensitivity reactio...   \n",
       "204  801020559  Antiretrovirals - HIV-associated lipodystrophy...   \n",
       "205  801122108  Once-daily atazanavir/ritonavir for HIV-associ...   \n",
       "206  801117480  Antiretrovirals - Acne vulgaris and rosacea re...   \n",
       "207  801111780  Atazanavir/emtricitabine/tenofovir - First rep...   \n",
       "208  801111644  Atazanavir/tenofovir - Acute renal failure: 2 ...   \n",
       "209  801110441  Atazanavir/ritonavir/tenofovir - Urinary calcu...   \n",
       "210  801109834  Antiretrovirals - Hepatotoxicity (first report...   \n",
       "211  801104260  Methadone interaction - Interaction with ataza...   \n",
       "212  801100890  Tacrolimus interaction - Interaction with conc...   \n",
       "213  801058885  Renal function decline with tenofovir + ritona...   \n",
       "214  801097500      Atazanavir - Crystal nephropathy: case report   \n",
       "215  801097209  Atazanavir - First report of menorrhagia: case...   \n",
       "216  801058688  Antiretrovirals - Human T lymphotropic virus t...   \n",
       "217  801058648      Atazanavir - Urinary calculi: 11 case reports   \n",
       "218  801091646  Atazanavir - Hyperbilirubinaemia in a patient ...   \n",
       "219  801093103  Atazanavir/tenofovir disoproxil fumarate - Acu...   \n",
       "220  801091090  Antiretrovirals - Immune reconstitution syndro...   \n",
       "221  801071770  Atazanavir/ritonavir - Alopecia (first report ...   \n",
       "222  801071372            Atazanavir - Renal calculi: case report   \n",
       "223  801058124  Atazanavir - First report of torsade de pointe...   \n",
       "224  801026802          Atazanavir - Urinary calculi: case report   \n",
       "225  801035373          Atazanavir - Urinary calculi: case report   \n",
       "226  801013749  Atazanavir and indinavir uptake reduced by aci...   \n",
       "227  801044632  Antiretrovirals - Lymphoid pneumonitis associa...   \n",
       "228  801066893  Atazanavir interaction - Interaction with conc...   \n",
       "229  801064647  Atazanavir - First report of skin eruptions: 3...   \n",
       "230  801038189  Atazanavir interaction - Interaction with conc...   \n",
       "231  801037182  Buprenorphine - First report of an interaction...   \n",
       "232  801017516  Tenofovir interaction - Interaction with conco...   \n",
       "233  801031367  Atazanavir - Hyperphosphatasemia of infancy an...   \n",
       "234  801026038  Antiretrovirals - Cardiomyopathy (first report...   \n",
       "235  801018519  PPIs, H<SUB>2</SUB>-receptor antagonists inter...   \n",
       "236  800999108  Coadministration of omeprazole reduces atazana...   \n",
       "237  800979180  Atazanavir - First report of hepatitis: case r...   \n",
       "238  809028534  CPMP EU-wide reviews for COX-2 inhibitors and ...   \n",
       "239  800863910       Tenofovir: reduced atazanavir concentrations   \n",
       "240  800841000  Atazanavir attains anti-HIV effects without al...   \n",
       "\n",
       "                       Record Type Release Date  \\\n",
       "0                  ADR Case Report   2020-09-02   \n",
       "1                  ADR Case Report   2020-08-26   \n",
       "2    Special Situation Case Report   2020-08-26   \n",
       "3                  ADR Case Report   2020-07-10   \n",
       "4                  ADR Case Report   2020-07-01   \n",
       "5                  ADR Case Report   2020-06-01   \n",
       "6                  ADR Case Report   2020-05-13   \n",
       "7    Special Situation Case Report   2020-05-06   \n",
       "8                  ADR Case Report   2020-04-24   \n",
       "9                  ADR Case Report   2020-04-22   \n",
       "10                 ADR Case Report   2020-04-09   \n",
       "11                 ADR Case Report   2020-02-14   \n",
       "12                 ADR Case Report   2020-02-13   \n",
       "13                 ADR Case Report   2020-02-04   \n",
       "14                 ADR Case Report   2020-01-24   \n",
       "15                 ADR Case Report   2020-01-17   \n",
       "16   Special Situation Case Report   2019-12-27   \n",
       "17                 ADR Case Report   2019-12-13   \n",
       "18                 ADR Case Report   2019-11-18   \n",
       "19                 ADR Case Report   2019-11-15   \n",
       "20                 ADR Case Report   2019-11-15   \n",
       "21   Special Situation Case Report   2019-10-16   \n",
       "22                 ADR Case Report   2019-10-16   \n",
       "23                            News   2019-10-14   \n",
       "24                 ADR Case Report   2019-10-09   \n",
       "25   Special Situation Case Report   2019-09-13   \n",
       "26                 ADR Case Report   2019-08-13   \n",
       "27                 ADR Case Report   2019-07-26   \n",
       "28                 ADR Case Report   2019-07-19   \n",
       "29                 ADR Case Report   2019-06-21   \n",
       "30                 ADR Case Report   2019-06-17   \n",
       "31                 ADR Case Report   2019-05-14   \n",
       "32                 ADR Case Report   2019-04-15   \n",
       "33                 ADR Case Report   2019-04-05   \n",
       "34                 ADR Case Report   2019-02-20   \n",
       "35                 ADR Case Report   2019-02-01   \n",
       "36                 ADR Case Report   2018-12-31   \n",
       "37                 ADR Case Report   2018-12-04   \n",
       "38                 ADR Case Report   2018-11-16   \n",
       "39                 ADR Case Report   2018-09-21   \n",
       "40                 ADR Case Report   2018-08-10   \n",
       "41                            News   2018-08-08   \n",
       "42                 ADR Case Report   2018-07-27   \n",
       "43                            News   2018-05-03   \n",
       "44                 ADR Case Report   2018-03-29   \n",
       "45                 ADR Case Report   2018-03-06   \n",
       "46                 ADR Case Report   2018-02-27   \n",
       "47                 ADR Case Report   2018-02-16   \n",
       "48                 ADR Case Report   2018-01-25   \n",
       "49                 ADR Case Report   2018-01-15   \n",
       "50                 ADR Case Report   2018-01-15   \n",
       "51                            News   2017-12-18   \n",
       "52                 ADR Case Report   2017-11-10   \n",
       "53                 ADR Case Report   2017-10-13   \n",
       "54                 ADR Case Report   2017-10-11   \n",
       "55                 ADR Case Report   2017-10-10   \n",
       "56                 ADR Case Report   2017-10-09   \n",
       "57                 ADR Case Report   2017-09-04   \n",
       "58                 ADR Case Report   2017-08-31   \n",
       "59                            News   2017-08-07   \n",
       "60                 ADR Case Report   2017-07-07   \n",
       "61                 ADR Case Report   2017-07-07   \n",
       "62                 ADR Case Report   2017-05-28   \n",
       "63                 ADR Case Report   2017-05-28   \n",
       "64                 ADR Case Report   2017-05-15   \n",
       "65                 ADR Case Report   2017-05-15   \n",
       "66                 ADR Case Report   2017-05-07   \n",
       "67                 ADR Case Report   2017-04-29   \n",
       "68                 ADR Case Report   2017-04-27   \n",
       "69                 ADR Case Report   2017-04-13   \n",
       "70                 ADR Case Report   2017-04-07   \n",
       "71                 ADR Case Report   2017-03-07   \n",
       "72                 ADR Case Report   2017-03-03   \n",
       "73                 ADR Case Report   2017-02-09   \n",
       "74                 ADR Case Report   2016-12-06   \n",
       "75                 ADR Case Report   2016-11-15   \n",
       "76                 ADR Case Report   2016-09-12   \n",
       "77                 ADR Case Report   2016-08-15   \n",
       "78                 ADR Case Report   2016-08-08   \n",
       "79                 ADR Case Report   2016-07-19   \n",
       "80                 ADR Case Report   2016-07-04   \n",
       "81                 ADR Case Report   2016-06-24   \n",
       "82                 ADR Case Report   2016-05-29   \n",
       "83                 ADR Case Report   2016-05-27   \n",
       "84                 ADR Case Report   2016-05-23   \n",
       "85                 ADR Case Report   2016-05-07   \n",
       "86                 ADR Case Report   2016-04-06   \n",
       "87                 ADR Case Report   2016-01-28   \n",
       "88                 ADR Case Report   2016-01-13   \n",
       "89                 ADR Case Report   2016-01-05   \n",
       "90                 ADR Case Report   2016-01-02   \n",
       "91                 ADR Case Report   2015-12-17   \n",
       "92                 ADR Case Report   2015-12-10   \n",
       "93                 ADR Case Report   2015-11-16   \n",
       "94                 ADR Case Report   2015-11-10   \n",
       "95                 ADR Case Report   2015-11-04   \n",
       "96                 ADR Case Report   2015-10-13   \n",
       "97                 ADR Case Report   2015-10-13   \n",
       "98                 ADR Case Report   2015-10-06   \n",
       "99                 ADR Case Report   2015-09-30   \n",
       "100                ADR Case Report   2015-09-14   \n",
       "101                ADR Case Report   2015-07-15   \n",
       "102                           News   2015-06-11   \n",
       "103                ADR Case Report   2015-03-26   \n",
       "104                ADR Case Report   2015-03-23   \n",
       "105                ADR Case Report   2015-03-08   \n",
       "106                ADR Case Report   2015-02-25   \n",
       "107                           News   2015-01-27   \n",
       "108                ADR Case Report   2015-01-13   \n",
       "109                ADR Case Report   2014-12-10   \n",
       "110                ADR Case Report   2014-11-25   \n",
       "111                ADR Case Report   2014-10-04   \n",
       "112                ADR Case Report   2014-09-18   \n",
       "113                ADR Case Report   2014-09-01   \n",
       "114                ADR Case Report   2014-07-11   \n",
       "115                ADR Case Report   2014-07-03   \n",
       "116                ADR Case Report   2014-05-29   \n",
       "117                ADR Case Report   2014-05-20   \n",
       "118                ADR Case Report   2014-04-11   \n",
       "119                ADR Case Report   2014-03-24   \n",
       "120                ADR Case Report   2014-03-05   \n",
       "121                ADR Case Report   2014-02-21   \n",
       "122                ADR Case Report   2014-01-03   \n",
       "123                ADR Case Report   2013-11-28   \n",
       "124                ADR Case Report   2013-11-26   \n",
       "125                ADR Case Report   2013-11-15   \n",
       "126                ADR Case Report   2013-10-17   \n",
       "127                ADR Case Report   2013-09-19   \n",
       "128                ADR Case Report   2013-08-20   \n",
       "129                ADR Case Report   2013-07-26   \n",
       "130                ADR Case Report   2013-07-24   \n",
       "131                ADR Case Report   2013-06-10   \n",
       "132                ADR Case Report   2013-05-21   \n",
       "133                ADR Case Report   2013-04-30   \n",
       "134                ADR Case Report   2013-04-29   \n",
       "135                           News   2013-04-05   \n",
       "136                ADR Case Report   2013-03-21   \n",
       "137                ADR Case Report   2013-02-04   \n",
       "138                ADR Case Report   2013-01-14   \n",
       "139                ADR Case Report   2013-01-04   \n",
       "140                ADR Case Report   2012-12-27   \n",
       "141                ADR Case Report   2012-11-29   \n",
       "142                ADR Case Report   2012-11-02   \n",
       "143                ADR Case Report   2012-10-05   \n",
       "144                ADR Case Report   2012-09-17   \n",
       "145                ADR Case Report   2012-07-30   \n",
       "146                ADR Case Report   2012-07-26   \n",
       "147                ADR Case Report   2012-06-20   \n",
       "148                ADR Case Report   2012-06-06   \n",
       "149                ADR Case Report   2012-06-01   \n",
       "150                ADR Case Report   2012-05-21   \n",
       "151                           News   2012-05-02   \n",
       "152                ADR Case Report   2012-03-20   \n",
       "153                ADR Case Report   2012-02-27   \n",
       "154                ADR Case Report   2012-02-17   \n",
       "155                ADR Case Report   2012-01-13   \n",
       "156                ADR Case Report   2012-01-11   \n",
       "157                ADR Case Report   2011-12-15   \n",
       "158                ADR Case Report   2011-12-07   \n",
       "159                ADR Case Report   2011-11-14   \n",
       "160                ADR Case Report   2011-11-09   \n",
       "161                ADR Case Report   2011-10-28   \n",
       "162                ADR Case Report   2011-09-23   \n",
       "163                           News   2011-08-23   \n",
       "164                ADR Case Report   2011-08-09   \n",
       "165                ADR Case Report   2011-07-06   \n",
       "166                ADR Case Report   2011-06-03   \n",
       "167                ADR Case Report   2011-05-31   \n",
       "168                ADR Case Report   2011-05-10   \n",
       "169                ADR Case Report   2011-04-08   \n",
       "170                ADR Case Report   2011-04-07   \n",
       "171                ADR Case Report   2011-03-07   \n",
       "172                ADR Case Report   2011-02-23   \n",
       "173                           News   2010-12-20   \n",
       "174                ADR Case Report   2010-12-03   \n",
       "175                ADR Case Report   2010-10-15   \n",
       "176                           News   2010-09-27   \n",
       "177                ADR Case Report   2010-07-21   \n",
       "178                ADR Case Report   2010-05-13   \n",
       "179                           News   2010-05-04   \n",
       "180                ADR Case Report   2010-04-28   \n",
       "181                ADR Case Report   2010-04-16   \n",
       "182                ADR Case Report   2010-03-18   \n",
       "183                           News   2010-03-18   \n",
       "184                           News   2010-03-11   \n",
       "185                ADR Case Report   2010-02-24   \n",
       "186                ADR Case Report   2010-01-28   \n",
       "187                ADR Case Report   2010-01-08   \n",
       "188                ADR Case Report   2009-12-21   \n",
       "189                ADR Case Report   2009-12-02   \n",
       "190                ADR Case Report   2009-09-24   \n",
       "191                ADR Case Report   2009-09-10   \n",
       "192                           News   2009-08-19   \n",
       "193                ADR Case Report   2009-07-22   \n",
       "194                ADR Case Report   2009-05-21   \n",
       "195                ADR Case Report   2009-05-12   \n",
       "196                ADR Case Report   2009-04-21   \n",
       "197                ADR Case Report   2009-02-11   \n",
       "198                ADR Case Report   2009-01-28   \n",
       "199                ADR Case Report   2008-12-08   \n",
       "200                ADR Case Report   2008-11-12   \n",
       "201                ADR Case Report   2008-11-10   \n",
       "202                ADR Case Report   2008-11-06   \n",
       "203                ADR Case Report   2008-09-19   \n",
       "204                ADR Case Report   2008-09-04   \n",
       "205                           News   2008-08-19   \n",
       "206                ADR Case Report   2008-08-13   \n",
       "207                ADR Case Report   2008-06-26   \n",
       "208                ADR Case Report   2008-06-18   \n",
       "209                ADR Case Report   2008-05-14   \n",
       "210                ADR Case Report   2008-05-05   \n",
       "211                ADR Case Report   2008-02-29   \n",
       "212                ADR Case Report   2008-02-14   \n",
       "213                           News   2008-01-31   \n",
       "214                ADR Case Report   2007-11-09   \n",
       "215                ADR Case Report   2007-11-08   \n",
       "216                ADR Case Report   2007-10-17   \n",
       "217                ADR Case Report   2007-10-02   \n",
       "218                ADR Case Report   2007-09-27   \n",
       "219                ADR Case Report   2007-09-20   \n",
       "220                ADR Case Report   2007-07-25   \n",
       "221                ADR Case Report   2007-06-14   \n",
       "222                ADR Case Report   2007-06-07   \n",
       "223                ADR Case Report   2007-02-23   \n",
       "224                ADR Case Report   2006-11-17   \n",
       "225                ADR Case Report   2006-11-16   \n",
       "226                           News   2006-11-10   \n",
       "227                ADR Case Report   2006-09-19   \n",
       "228                ADR Case Report   2006-06-19   \n",
       "229                ADR Case Report   2006-05-31   \n",
       "230                ADR Case Report   2006-04-11   \n",
       "231                ADR Case Report   2006-03-28   \n",
       "232                ADR Case Report   2006-03-23   \n",
       "233                ADR Case Report   2006-01-31   \n",
       "234                ADR Case Report   2005-12-22   \n",
       "235                           News   2005-08-16   \n",
       "236                           News   2005-01-12   \n",
       "237                ADR Case Report   2004-09-06   \n",
       "238                           News   2003-11-28   \n",
       "239                           News   2003-09-24   \n",
       "240                           News   2001-12-06   \n",
       "\n",
       "                                                 Drugs  \\\n",
       "0    Atazanavir adverse reactions (Serious), Atazan...   \n",
       "1    Atazanavir adverse reactions (Serious), Atazan...   \n",
       "2    Atazanavir adverse reactions (Serious), Atazan...   \n",
       "3    Abacavir adverse reactions (Serious), Abacavir...   \n",
       "4    Abacavir adverse reactions (Serious), Abacavir...   \n",
       "5    Atazanavir adverse reactions, Cobicistat adver...   \n",
       "6    Atazanavir adverse reactions (Serious), Emtric...   \n",
       "7    Atazanavir adverse reactions, Cobicistat adver...   \n",
       "8    Abacavir adverse reactions (Serious), Atazanav...   \n",
       "9    Abacavir drug interactions (Serious), Atazanav...   \n",
       "10   Atazanavir adverse reactions, Atazanavir/riton...   \n",
       "11   Atazanavir adverse reactions (Serious), Ritona...   \n",
       "12              Atazanavir adverse reactions (Serious)   \n",
       "13   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "14   Abacavir drug interactions (Serious), Atazanav...   \n",
       "15   Atazanavir drug interactions, Tacrolimus drug ...   \n",
       "16   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "17   Atazanavir adverse reactions (Serious), Ledipa...   \n",
       "18   Atazanavir adverse reactions (Serious), Didano...   \n",
       "19   Abacavir adverse reactions (Serious), Abacavir...   \n",
       "20   Atazanavir adverse reactions, Lamivudine adver...   \n",
       "21   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "22   Atazanavir adverse reactions, Dolutegravir adv...   \n",
       "23   Atazanavir adverse reactions, Bictegravir adve...   \n",
       "24   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "25   Abacavir adverse reactions, Atazanavir adverse...   \n",
       "26   Atazanavir adverse reactions (Serious), Daruna...   \n",
       "27   Atazanavir adverse reactions, Lopinavir advers...   \n",
       "28   Abacavir drug interactions, Atazanavir drug in...   \n",
       "29   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "30   Atazanavir adverse reactions (Serious), Emtric...   \n",
       "31   Abacavir adverse reactions, Atazanavir adverse...   \n",
       "32   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "33   Atazanavir drug interactions, Atazanavir/riton...   \n",
       "34   Atazanavir adverse reactions (Serious), Emtric...   \n",
       "35   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "36   Abacavir adverse reactions (Serious), Amisulpr...   \n",
       "37              Atazanavir adverse reactions (Serious)   \n",
       "38   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "39   Abacavir adverse reactions, Atazanavir adverse...   \n",
       "40   Atazanavir adverse reactions (Serious), Ritona...   \n",
       "41   Abacavir adverse reactions, Atazanavir adverse...   \n",
       "42   Atazanavir drug interactions (Serious), Atazan...   \n",
       "43   Atazanavir adverse reactions, Atazanavir/emtri...   \n",
       "44              Atazanavir adverse reactions (Serious)   \n",
       "45              Atazanavir adverse reactions (Serious)   \n",
       "46   Atazanavir drug interactions (Serious), Atazan...   \n",
       "47   Abacavir adverse reactions (Serious), Allopuri...   \n",
       "48   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "49   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "50   Atazanavir drug interactions (Serious), Atazan...   \n",
       "51   Atazanavir adverse reactions, Atazanavir/emtri...   \n",
       "52              Atazanavir adverse reactions (Serious)   \n",
       "53   Atazanavir drug interactions (Serious), Atazan...   \n",
       "54              Atazanavir adverse reactions (Serious)   \n",
       "55   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "56   Atazanavir drug interactions (Serious), Atazan...   \n",
       "57   Atazanavir drug interactions (Serious), Caffei...   \n",
       "58   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "59   Atazanavir adverse reactions, Atazanavir/cobic...   \n",
       "60   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "61   Atazanavir drug interactions (Serious), Lamivu...   \n",
       "62              Atazanavir adverse reactions (Serious)   \n",
       "63   Abacavir adverse reactions (Serious), Abacavir...   \n",
       "64              Atazanavir adverse reactions (Serious)   \n",
       "65   Atazanavir overdose, Efavirenz overdose (Serio...   \n",
       "66   Abacavir adverse reactions (Serious), Abacavir...   \n",
       "67   Atazanavir drug interactions (Serious), Atazan...   \n",
       "68   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "69   Abacavir adverse reactions, Atazanavir adverse...   \n",
       "70   Atazanavir adverse reactions (Serious), Lamivu...   \n",
       "71   Atazanavir drug interactions, Lurasidone drug ...   \n",
       "72              Atazanavir adverse reactions (Serious)   \n",
       "73   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "74   Atazanavir adverse reactions (Serious), Ritona...   \n",
       "75   Atazanavir adverse reactions (Serious), Emtric...   \n",
       "76   Abacavir adverse reactions (Serious), Abacavir...   \n",
       "77   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "78              Atazanavir adverse reactions (Serious)   \n",
       "79   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "80   Atazanavir drug interactions (Serious), Atazan...   \n",
       "81   Atazanavir drug interactions (Serious), Dasabu...   \n",
       "82   Atazanavir adverse reactions (Serious), Ritona...   \n",
       "83   Abacavir drug interactions, Atazanavir drug in...   \n",
       "84   Atazanavir drug interactions (Serious), Ivabra...   \n",
       "85              Atazanavir adverse reactions (Serious)   \n",
       "86   Atazanavir adverse reactions, Atazanavir/riton...   \n",
       "87   Atazanavir adverse reactions (Serious), Emtric...   \n",
       "88   Atazanavir adverse reactions (Serious), Efavir...   \n",
       "89   Atazanavir adverse reactions (Serious), Cotrim...   \n",
       "90   Atazanavir adverse reactions, Ritonavir advers...   \n",
       "91   Atazanavir adverse reactions, Darunavir advers...   \n",
       "92   Atazanavir adverse reactions (Serious), Daruna...   \n",
       "93   Atazanavir drug interactions, Atazanavir/riton...   \n",
       "94   Atazanavir adverse reactions (Serious), Emtric...   \n",
       "95              Atazanavir adverse reactions (Serious)   \n",
       "96   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "97   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "98   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "99   Abacavir drug interactions (Serious), Atazanav...   \n",
       "100  Atazanavir drug interactions (Serious), Everol...   \n",
       "101  Atazanavir adverse reactions, Nevirapine adver...   \n",
       "102                       Atazanavir adverse reactions   \n",
       "103  Atazanavir drug interactions (Serious), Ritona...   \n",
       "104             Atazanavir adverse reactions (Serious)   \n",
       "105  Atazanavir adverse reactions (Serious), Efavir...   \n",
       "106  Atazanavir drug interactions (Serious), Atazan...   \n",
       "107  Atazanavir adverse reactions, Darunavir advers...   \n",
       "108  Atazanavir adverse reactions (Serious), Atazan...   \n",
       "109             Atazanavir adverse reactions (Serious)   \n",
       "110  Abacavir adverse reactions (Serious), Abacavir...   \n",
       "111  Amiodarone drug interactions, Atazanavir drug ...   \n",
       "112  Atazanavir adverse reactions (Serious), Atazan...   \n",
       "113  Atazanavir drug interactions (Serious), Daruna...   \n",
       "114  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "115  Atazanavir drug interactions (Serious), Atazan...   \n",
       "116  Atazanavir adverse reactions (Serious), Ritona...   \n",
       "117  Atazanavir drug interactions (Serious), Daruna...   \n",
       "118  Atazanavir adverse reactions (Serious), Daruna...   \n",
       "119  Atazanavir drug interactions (Serious), Atazan...   \n",
       "120  Atazanavir adverse reactions (Serious), Atazan...   \n",
       "121             Atazanavir adverse reactions (Serious)   \n",
       "122  Atazanavir drug interactions (Serious), Atazan...   \n",
       "123  Atazanavir drug interactions (Serious), Atazan...   \n",
       "124             Atazanavir adverse reactions (Serious)   \n",
       "125  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "126  Abacavir adverse reactions (Serious), Atazanav...   \n",
       "127  Atazanavir drug interactions, Emtricitabine dr...   \n",
       "128  Abacavir drug interactions (Serious), Atazanav...   \n",
       "129             Atazanavir adverse reactions (Serious)   \n",
       "130  Atazanavir drug interactions, Atazanavir/riton...   \n",
       "131  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "132             Atazanavir adverse reactions (Serious)   \n",
       "133             Atazanavir adverse reactions (Serious)   \n",
       "134  Atazanavir overdose (Serious), Atazanavir/rito...   \n",
       "135  Atazanavir adverse reactions, Darunavir advers...   \n",
       "136  Atazanavir adverse reactions (Serious), Efavir...   \n",
       "137  Atazanavir adverse reactions (Serious), Lamivu...   \n",
       "138  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "139  Atazanavir adverse reactions (Serious), Tenofo...   \n",
       "140  Atazanavir drug interactions (Serious), Atazan...   \n",
       "141  Atazanavir adverse reactions, Didanosine adver...   \n",
       "142  Atazanavir adverse reactions (Serious), Didano...   \n",
       "143  Atazanavir adverse reactions (Serious), Lamivu...   \n",
       "144  Abacavir adverse reactions (Serious), Atazanav...   \n",
       "145  Atazanavir adverse reactions (Serious), Tenofo...   \n",
       "146  Atazanavir adverse reactions (Serious), Ralteg...   \n",
       "147  Atazanavir adverse reactions (Serious), Ralteg...   \n",
       "148             Atazanavir adverse reactions (Serious)   \n",
       "149  Atazanavir adverse reactions (Serious), Atazan...   \n",
       "150             Atazanavir adverse reactions (Serious)   \n",
       "151  Atazanavir adverse reactions, Atazanavir/riton...   \n",
       "152  Atazanavir adverse reactions (Serious), Dapson...   \n",
       "153  Atazanavir adverse reactions, Efavirenz advers...   \n",
       "154             Atazanavir adverse reactions (Serious)   \n",
       "155  Alpidem adverse reactions, Alprazolam adverse ...   \n",
       "156                       Atazanavir adverse reactions   \n",
       "157  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "158  Atazanavir drug interactions (Serious), Ritona...   \n",
       "159  Atazanavir adverse reactions (Serious), Efavir...   \n",
       "160  Atazanavir adverse reactions, Emtricitabine ad...   \n",
       "161  Atazanavir drug interactions (Serious), Ritona...   \n",
       "162  Atazanavir adverse reactions (Serious), Daruna...   \n",
       "163  Atazanavir adverse reactions, Darunavir advers...   \n",
       "164                       Atazanavir adverse reactions   \n",
       "165  Acenocoumarol drug interactions (Serious), Ata...   \n",
       "166  Atazanavir drug interactions (Serious), Oxycod...   \n",
       "167  Atazanavir drug interactions (Serious), Lamivu...   \n",
       "168  Atazanavir drug interactions (Serious), Atazan...   \n",
       "169  Atazanavir drug interactions, Atazanavir/riton...   \n",
       "170  Atazanavir adverse reactions, Raltegravir adve...   \n",
       "171  Atazanavir adverse reactions (Serious), Atazan...   \n",
       "172                       Atazanavir adverse reactions   \n",
       "173                       Atazanavir adverse reactions   \n",
       "174  Atazanavir drug interactions (Serious), Didano...   \n",
       "175  Abacavir adverse reactions (Serious), Adefovir...   \n",
       "176  Atazanavir adverse reactions, Atazanavir thera...   \n",
       "177  Atazanavir drug interactions (Serious), Quetia...   \n",
       "178  Abacavir adverse reactions (Serious), Amprenav...   \n",
       "179  Atazanavir adverse reactions, Darunavir advers...   \n",
       "180  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "181             Atazanavir adverse reactions (Serious)   \n",
       "182  Atazanavir drug interactions (Serious), Ritona...   \n",
       "183  Atazanavir adverse reactions, Indinavir advers...   \n",
       "184  Abacavir adverse reactions, Atazanavir adverse...   \n",
       "185             Atazanavir adverse reactions (Serious)   \n",
       "186  Atazanavir adverse reactions (Serious), Efavir...   \n",
       "187  Atazanavir drug interactions (Serious), Quetia...   \n",
       "188  Atazanavir adverse reactions, Raltegravir adve...   \n",
       "189  Atazanavir drug interactions (Serious), Flutic...   \n",
       "190  Abacavir adverse reactions (Serious), Atazanav...   \n",
       "191  Abacavir adverse reactions (Serious), Atazanav...   \n",
       "192  Atazanavir pharmacokinetics, Posaconazole phar...   \n",
       "193  Abacavir adverse reactions, Atazanavir adverse...   \n",
       "194  Abacavir adverse reactions, Atazanavir adverse...   \n",
       "195                       Atazanavir adverse reactions   \n",
       "196  Abacavir adverse reactions (Serious), Atazanav...   \n",
       "197  Atazanavir drug interactions (Serious), Ergota...   \n",
       "198  Atazanavir drug interactions (Serious), Hirsut...   \n",
       "199  Abacavir adverse reactions (Serious), Amprenav...   \n",
       "200  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "201  Atazanavir drug interactions (Serious), Ralteg...   \n",
       "202             Atazanavir adverse reactions (Serious)   \n",
       "203  Abacavir adverse reactions, Atazanavir adverse...   \n",
       "204  Atazanavir adverse reactions (Serious), Didano...   \n",
       "205  Atazanavir adverse reactions, Atazanavir thera...   \n",
       "206  Abacavir adverse reactions, Atazanavir adverse...   \n",
       "207  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "208  Atazanavir adverse reactions (Serious), Tenofo...   \n",
       "209  Atazanavir adverse reactions (Serious), Ritona...   \n",
       "210  Abacavir adverse reactions (Serious), Aplaviro...   \n",
       "211  Atazanavir drug interactions (Serious), Fluraz...   \n",
       "212  Atazanavir drug interactions (Serious), Tacrol...   \n",
       "213  Amprenavir adverse reactions, Atazanavir adver...   \n",
       "214                       Atazanavir adverse reactions   \n",
       "215                       Atazanavir adverse reactions   \n",
       "216  Abacavir adverse reactions (Serious), Atazanav...   \n",
       "217                       Atazanavir adverse reactions   \n",
       "218                       Atazanavir adverse reactions   \n",
       "219  Atazanavir adverse reactions (Serious), Tenofo...   \n",
       "220  Atazanavir adverse reactions (Serious), Emtric...   \n",
       "221  Atazanavir adverse reactions, Ritonavir advers...   \n",
       "222             Atazanavir adverse reactions (Serious)   \n",
       "223             Atazanavir adverse reactions (Serious)   \n",
       "224                       Atazanavir adverse reactions   \n",
       "225             Atazanavir adverse reactions (Serious)   \n",
       "226  Atazanavir drug interactions, Atazanavir pharm...   \n",
       "227  Abacavir adverse reactions, Atazanavir adverse...   \n",
       "228  Atazanavir drug interactions, Ritonavir drug i...   \n",
       "229                       Atazanavir adverse reactions   \n",
       "230  Atazanavir drug interactions, Esomeprazole dru...   \n",
       "231  Atazanavir drug interactions, Buprenorphine dr...   \n",
       "232  Atazanavir drug interactions (Serious), Didano...   \n",
       "233                       Atazanavir adverse reactions   \n",
       "234  Atazanavir adverse reactions (Serious), Lamivu...   \n",
       "235                       Atazanavir drug interactions   \n",
       "236  Atazanavir drug interactions, Atazanavir pharm...   \n",
       "237                       Atazanavir adverse reactions   \n",
       "238  Atazanavir therapeutic use, Colesevelam therap...   \n",
       "239  Atazanavir drug interactions, Atazanavir pharm...   \n",
       "240  Atazanavir adverse reactions, Atazanavir thera...   \n",
       "\n",
       "                                        Adverse Events  Mechanism of Action  \\\n",
       "0    Chronic granulomatous disease drug-induced, In...                  NaN   \n",
       "1                                 Anaemia drug-induced                  NaN   \n",
       "2                                                  NaN                  NaN   \n",
       "3    Dizziness drug-induced, Drowsiness drug-induce...                  NaN   \n",
       "4                             Weight gain drug-induced                  NaN   \n",
       "5    Anxiety drug-induced, Appetite disorders drug-...                  NaN   \n",
       "6    Hypertriglyceridaemia drug-induced, Pancreatit...                  NaN   \n",
       "7                                                  NaN                  NaN   \n",
       "8          Immune reconstitution syndrome drug-induced                  NaN   \n",
       "9    Abnormal laboratory parameters drug-induced, H...                  NaN   \n",
       "10         Abnormal laboratory parameters drug-induced                  NaN   \n",
       "11   Fanconi syndrome drug-induced, Rhabdomyolysis ...                  NaN   \n",
       "12                           Urolithiasis drug-induced                  NaN   \n",
       "13   Hepatic fibrosis drug-induced, Non-alcoholic f...                  NaN   \n",
       "14   Abnormal laboratory parameters drug-induced, D...                  NaN   \n",
       "15         Abnormal laboratory parameters drug-induced                  NaN   \n",
       "16                                                 NaN                  NaN   \n",
       "17   Headache drug-induced, Hyperbilirubinaemia dru...                  NaN   \n",
       "18   Hypertriglyceridaemia drug-induced, Lipodystro...                  NaN   \n",
       "19             Gastrointestinal disorders drug-induced                  NaN   \n",
       "20        Human papillomavirus infections drug-induced                  NaN   \n",
       "21                                                 NaN                  NaN   \n",
       "22                 Neurological disorders drug-induced                  NaN   \n",
       "23                    Neural tube defects drug-induced                  NaN   \n",
       "24                    Neural tube defects drug-induced                  NaN   \n",
       "25                                                 NaN                  NaN   \n",
       "26                                                 NaN                  NaN   \n",
       "27                          Renal calculi drug-induced                  NaN   \n",
       "28         Abnormal laboratory parameters drug-induced                  NaN   \n",
       "29   Ataxia drug-induced, Encephalitis drug-induced...                  NaN   \n",
       "30          Nausea drug-induced, Vomiting drug-induced                  NaN   \n",
       "31       Exanthema drug-induced, Pruritus drug-induced                  NaN   \n",
       "32                                                 NaN                  NaN   \n",
       "33            Coma drug-induced, Sedation drug-induced                  NaN   \n",
       "34         Immune reconstitution syndrome drug-induced                  NaN   \n",
       "35                              Exanthema drug-induced                  NaN   \n",
       "36   Abnormal laboratory parameters drug-induced, B...                  NaN   \n",
       "37                          Renal calculi drug-induced                  NaN   \n",
       "38                                                 NaN                  NaN   \n",
       "39   Immune reconstitution syndrome drug-induced, N...                  NaN   \n",
       "40   Genitourinary disorders drug-induced, Glomerul...                  NaN   \n",
       "41   Anaemia drug-induced, Renal impairment drug-in...                  NaN   \n",
       "42         Abnormal laboratory parameters drug-induced                  NaN   \n",
       "43   Pregnancy complications drug-induced, Preterm ...                  NaN   \n",
       "44   Exanthema drug-induced, Hyperbilirubinaemia dr...                  NaN   \n",
       "45                 Interstitial nephritis drug-induced                  NaN   \n",
       "46                       Fanconi syndrome drug-induced                  NaN   \n",
       "47                       Renal impairment drug-induced                  NaN   \n",
       "48                                                 NaN                  NaN   \n",
       "49   Anaplastic large cell lymphoma drug-induced, A...                  NaN   \n",
       "50   Kidney disorders drug-induced, Proteinuria dru...                  NaN   \n",
       "51                       Kidney disorders drug-induced                  NaN   \n",
       "52   Acute kidney injury drug-induced, Kidney disor...                  NaN   \n",
       "53   Anaemia drug-induced, Cholelithiasis drug-indu...                  NaN   \n",
       "54                       Ureteral calculi drug-induced                  NaN   \n",
       "55                                                 NaN                  NaN   \n",
       "56   Fanconi syndrome drug-induced, Febrile neutrop...                  NaN   \n",
       "57       Ergotism drug-induced, Ischaemia drug-induced                  NaN   \n",
       "58   Hypertriglyceridaemia drug-induced, Pancreatit...                  NaN   \n",
       "59                          Renal failure drug-induced                  NaN   \n",
       "60   Anaemia drug-induced, Atopic dermatitis drug-i...                  NaN   \n",
       "61   Acute kidney injury drug-induced, Diarrhoea dr...                  NaN   \n",
       "62   Cholangitis drug-induced, Cholelithiasis drug-...                  NaN   \n",
       "63   Anxiety drug-induced, Exanthema drug-induced, ...                  NaN   \n",
       "64                         Cholelithiasis drug-induced                  NaN   \n",
       "65   Abnormal laboratory parameters drug-induced, C...                  NaN   \n",
       "66   Abnormal laboratory parameters drug-induced, F...                  NaN   \n",
       "67   Adrenal insufficiency drug-induced, Cushing sy...                  NaN   \n",
       "68   Atherosclerosis drug-induced, Myocardial infar...                  NaN   \n",
       "69         Abnormal laboratory parameters drug-induced                  NaN   \n",
       "70   Ataxia drug-induced, Immune reconstitution syn...                  NaN   \n",
       "71                Basal ganglia disorders drug-induced                  NaN   \n",
       "72                          Renal calculi drug-induced                  NaN   \n",
       "73         Abnormal laboratory parameters drug-induced                  NaN   \n",
       "74           Acute intermittent porphyria drug-induced                  NaN   \n",
       "75   Diarrhoea drug-induced, Immune reconstitution ...                  NaN   \n",
       "76                                                 NaN                  NaN   \n",
       "77   Hepatitis B drug-induced, Immune reconstitutio...                  NaN   \n",
       "78   Pyelonephritis drug-induced, Urolithiasis drug...                  NaN   \n",
       "79                               Erythema drug-induced                  NaN   \n",
       "80                                                 NaN                  NaN   \n",
       "81                    Hyperbilirubinaemia drug-induced                  NaN   \n",
       "82                          Renal calculi drug-induced                  NaN   \n",
       "83      Acne drug-induced, Skin eruptions drug-induced                  NaN   \n",
       "84   Bradycardia drug-induced, Heart failure drug-i...                  NaN   \n",
       "85                           Pancreatitis drug-induced                  NaN   \n",
       "86   Kidney disorders drug-induced, Nausea drug-ind...                  NaN   \n",
       "87                            Hyperplasia drug-induced                  NaN   \n",
       "88   Burkitt's lymphoma drug-induced, Immune recons...                  NaN   \n",
       "89   Bone marrow disorders drug-induced, Immune rec...                  NaN   \n",
       "90   Digestive system disorders drug-induced, Hyper...                  NaN   \n",
       "91                              Urticaria drug-induced                  NaN   \n",
       "92                       Hypersensitivity drug-induced                  NaN   \n",
       "93   Abnormal laboratory parameters drug-induced, R...                  NaN   \n",
       "94                          Osteonecrosis drug-induced                  NaN   \n",
       "95                          Renal calculi drug-induced                  NaN   \n",
       "96   Immune reconstitution syndrome drug-induced, L...                  NaN   \n",
       "97                 Interstitial nephritis drug-induced                  NaN   \n",
       "98                               Jaundice drug-induced                  NaN   \n",
       "99   Acute kidney injury drug-induced, Elevated ami...                  NaN   \n",
       "100        Oral ulcer drug-induced, Ulcer drug-induced                  NaN   \n",
       "101  Elevated aminotransferase levels drug-induced,...                  NaN   \n",
       "102            Developmental disabilities drug-induced                  NaN   \n",
       "103  Febrile neutropenia drug-induced, Neurological...                  NaN   \n",
       "104  Acute kidney injury drug-induced, Urolithiasis...                  NaN   \n",
       "105                 Drug hypersensitivity drug-induced                  NaN   \n",
       "106  Adrenal insufficiency drug-induced, Cushing sy...                  NaN   \n",
       "107              Fetal growth retardation drug-induced                  NaN   \n",
       "108  Graves' disease drug-induced, Immune reconstit...                  NaN   \n",
       "109                   Hyperbilirubinaemia drug-induced                  NaN   \n",
       "110                        HIV infections drug-induced                  NaN   \n",
       "111        Abnormal laboratory parameters drug-induced                  NaN   \n",
       "112                         Renal calculi drug-induced                  NaN   \n",
       "113                              Ergotism drug-induced                  NaN   \n",
       "114  Abnormal laboratory parameters drug-induced, A...                  NaN   \n",
       "115  Acute kidney injury drug-induced, Liver injury...                  NaN   \n",
       "116                   Atrial fibrillation drug-induced                  NaN   \n",
       "117  Diarrhoea drug-induced, Fatigue drug-induced, ...                  NaN   \n",
       "118                      Kidney disorders drug-induced                  NaN   \n",
       "119                              Ergotism drug-induced                  NaN   \n",
       "120  Neutropenia drug-induced, Prurigo drug-induced...                  NaN   \n",
       "121                         Renal calculi drug-induced                  NaN   \n",
       "122                                                NaN                  NaN   \n",
       "123  Cushing syndrome drug-induced, DRESS syndrome ...                  NaN   \n",
       "124                     Gilbert's disease drug-induced                  NaN   \n",
       "125                         Lipodystrophy drug-induced                  NaN   \n",
       "126  Autoimmune disorders drug-induced, Ear disorde...                  NaN   \n",
       "127                                                NaN                  NaN   \n",
       "128                              Priapism drug-induced                  NaN   \n",
       "129                   Hyperbilirubinaemia drug-induced                  NaN   \n",
       "130                        HIV infections drug-induced                  NaN   \n",
       "131  Hepatic necrosis drug-induced, Hyperbilirubina...                  NaN   \n",
       "132  Atrioventricular block drug-induced, QT interv...                  NaN   \n",
       "133                   Atrial fibrillation drug-induced                  NaN   \n",
       "134  Calculi drug-induced, Salivary gland disorders...                  NaN   \n",
       "135  Exanthema drug-induced, Gastrointestinal disor...                  NaN   \n",
       "136               Porphyria cutanea tarda drug-induced                  NaN   \n",
       "137  Lipomatosis drug-induced, Spinal disorders dru...                  NaN   \n",
       "138  Immune reconstitution syndrome drug-induced, L...                  NaN   \n",
       "139                      Renal impairment drug-induced                  NaN   \n",
       "140                      Cushing syndrome drug-induced                  NaN   \n",
       "141                        Polyneuropathy drug-induced                  NaN   \n",
       "142                          Pancreatitis drug-induced                  NaN   \n",
       "143  Gouty arthritis drug-induced, Immune reconstit...                  NaN   \n",
       "144                            Depression drug-induced                  NaN   \n",
       "145                         Renal failure drug-induced                  NaN   \n",
       "146  Immune reconstitution syndrome drug-induced, K...                  NaN   \n",
       "147  Leucocytosis drug-induced, Skin eruptions drug...                  NaN   \n",
       "148                          Encephalitis drug-induced                  NaN   \n",
       "149  Biliary tract disorders drug-induced, Calculi ...                  NaN   \n",
       "150  Hyperbilirubinaemia drug-induced, Hyperlipidae...                  NaN   \n",
       "151                                                NaN                  NaN   \n",
       "152  Haemolysis drug-induced, Hyperbilirubinaemia d...                  NaN   \n",
       "153                 Drug hypersensitivity drug-induced                  NaN   \n",
       "154  Haemolysis drug-induced, Hyperbilirubinaemia d...                  NaN   \n",
       "155                            Aggression drug-induced                  NaN   \n",
       "156                          Urolithiasis drug-induced                  NaN   \n",
       "157          Vanishing bile duct syndrome drug-induced                  NaN   \n",
       "158  Drowsiness drug-induced, Renal failure drug-in...                  NaN   \n",
       "159  Immune reconstitution syndrome drug-induced, M...                  NaN   \n",
       "160        Abnormal laboratory parameters drug-induced                  NaN   \n",
       "161  Adrenal insufficiency drug-induced, Cushing sy...                  NaN   \n",
       "162  Acute generalised exanthematous pustulosis dru...                  NaN   \n",
       "163  CNS disorders drug-induced, Congenital abnorma...                  NaN   \n",
       "164                     Neonatal jaundice drug-induced                  NaN   \n",
       "165           Blood coagulation disorders drug-induced                  NaN   \n",
       "166  QT interval prolongation drug-induced, Torsade...                  NaN   \n",
       "167  Abnormal laboratory parameters drug-induced, A...                  NaN   \n",
       "168                       Urinary calculi drug-induced                  NaN   \n",
       "169                              Insomnia drug-induced                  NaN   \n",
       "170                       Lipohypertrophy drug-induced                  NaN   \n",
       "171                Interstitial nephritis drug-induced                  NaN   \n",
       "172                               Calculi drug-induced                  NaN   \n",
       "173              Cardiovascular disorders drug-induced                  NaN   \n",
       "174  Kidney disorders drug-induced, Mitochondrial d...                  NaN   \n",
       "175                         Liver failure drug-induced                  NaN   \n",
       "176  Diarrhoea drug-induced, Various toxicities dru...                  NaN   \n",
       "177  Coma drug-induced, Hypotension drug-induced, P...                  NaN   \n",
       "178  Progressive multifocal leukoencephalopathy dru...                  NaN   \n",
       "179                       Liver disorders drug-induced                  NaN   \n",
       "180        Immune reconstitution syndrome drug-induced                  NaN   \n",
       "181                                                NaN                  NaN   \n",
       "182                   Hyperbilirubinaemia drug-induced                  NaN   \n",
       "183                      Kidney disorders drug-induced                  NaN   \n",
       "184  CNS disorders drug-induced, Drug hypersensitiv...                  NaN   \n",
       "185                      Renal impairment drug-induced                  NaN   \n",
       "186        Immune reconstitution syndrome drug-induced                  NaN   \n",
       "187  Appetite disorders drug-induced, Confusion dru...                  NaN   \n",
       "188                         Renal calculi drug-induced                  NaN   \n",
       "189  Adrenal insufficiency drug-induced, Cushing sy...                  NaN   \n",
       "190                   Parkinson's disease drug-induced                  NaN   \n",
       "191  Blepharoptosis drug-induced, Deglutition disor...                  NaN   \n",
       "192                                                NaN                  NaN   \n",
       "193                         Genital ulcer drug-induced                  NaN   \n",
       "194  Aphthous stomatitis drug-induced, Blepharoedem...                  NaN   \n",
       "195                         Renal calculi drug-induced                  NaN   \n",
       "196        Immune reconstitution syndrome drug-induced                  NaN   \n",
       "197  Cushing syndrome drug-induced, Ergotism drug-i...                  NaN   \n",
       "198                                                NaN                  NaN   \n",
       "199  Fatty liver drug-induced, Hepatic fibrosis dru...                  NaN   \n",
       "200  Death drug-induced, Immune reconstitution synd...                  NaN   \n",
       "201                Elevated liver enzymes drug-induced                  NaN   \n",
       "202  Renal failure drug-induced, Urinary calculi dr...                  NaN   \n",
       "203                 Drug hypersensitivity drug-induced                  NaN   \n",
       "204  Anaemia drug-induced, HIV-associated lipodystr...                  NaN   \n",
       "205  HIV-associated lipodystrophy syndrome drug-ind...                  NaN   \n",
       "206  Acne vulgaris drug-induced, Immune reconstitut...                  NaN   \n",
       "207  Immune reconstitution syndrome drug-induced, T...                  NaN   \n",
       "208                         Renal failure drug-induced                  NaN   \n",
       "209                       Urinary calculi drug-induced                  NaN   \n",
       "210                       Liver disorders drug-induced                  NaN   \n",
       "211                   Torsades de pointes drug-induced                  NaN   \n",
       "212                      Renal impairment drug-induced                  NaN   \n",
       "213  Abnormal laboratory parameters drug-induced, R...                  NaN   \n",
       "214                      Kidney disorders drug-induced                  NaN   \n",
       "215                           Menorrhagia drug-induced                  NaN   \n",
       "216  Immune reconstitution syndrome drug-induced, N...                  NaN   \n",
       "217                       Urinary calculi drug-induced                  NaN   \n",
       "218                   Hyperbilirubinaemia drug-induced                  NaN   \n",
       "219                Interstitial nephritis drug-induced                  NaN   \n",
       "220        Immune reconstitution syndrome drug-induced                  NaN   \n",
       "221                              Alopecia drug-induced                  NaN   \n",
       "222  Kidney disorders drug-induced, Renal calculi d...                  NaN   \n",
       "223                   Torsades de pointes drug-induced                  NaN   \n",
       "224                       Urinary calculi drug-induced                  NaN   \n",
       "225                       Urinary calculi drug-induced                  NaN   \n",
       "226                                                NaN                  NaN   \n",
       "227  Immune reconstitution syndrome drug-induced, P...                  NaN   \n",
       "228                         Lipodystrophy drug-induced                  NaN   \n",
       "229                        Skin eruptions drug-induced                  NaN   \n",
       "230                                                NaN                  NaN   \n",
       "231                            Somnolence drug-induced                  NaN   \n",
       "232                         Renal failure drug-induced                  NaN   \n",
       "233                   Metabolic disorders drug-induced                  NaN   \n",
       "234                      Cardiomyopathies drug-induced                  NaN   \n",
       "235                                                NaN                  NaN   \n",
       "236                                                NaN                  NaN   \n",
       "237                             Hepatitis drug-induced                  NaN   \n",
       "238  Hypersensitivity drug-induced, Hypospadias dru...                  NaN   \n",
       "239                                                NaN                  NaN   \n",
       "240                       Hyperlipidaemia drug-induced                  NaN   \n",
       "\n",
       "     Number of Cases Serious First Report  ... Reporter Country  \\\n",
       "0                1.0     Yes           No  ...              USA   \n",
       "1                2.0     Yes           No  ...            India   \n",
       "2                6.0     Yes           No  ...            India   \n",
       "3                4.0     Yes           No  ...        Singapore   \n",
       "4                1.0     Yes           No  ...           Israel   \n",
       "5                7.0      No           No  ...   United Kingdom   \n",
       "6                1.0     Yes           No  ...              USA   \n",
       "7                3.0      No           No  ...              USA   \n",
       "8               22.0     Yes           No  ...           France   \n",
       "9                1.0     Yes           No  ...           Canada   \n",
       "10               1.0      No           No  ...              USA   \n",
       "11               1.0     Yes           No  ...           France   \n",
       "12               1.0     Yes           No  ...           France   \n",
       "13               5.0     Yes           No  ...         Thailand   \n",
       "14               1.0     Yes           No  ...              USA   \n",
       "15               1.0      No           No  ...              USA   \n",
       "16               2.0     Yes           No  ...           Taiwan   \n",
       "17               2.0     Yes           No  ...            Japan   \n",
       "18               1.0     Yes           No  ...           Brazil   \n",
       "19               2.0     Yes           No  ...         Portugal   \n",
       "20               1.0      No           No  ...           Brazil   \n",
       "21               2.0     Yes           No  ...            Italy   \n",
       "22               1.0      No           No  ...            Italy   \n",
       "23               NaN      No           No  ...              NaN   \n",
       "24               3.0     Yes           No  ...           Canada   \n",
       "25              14.0      No           No  ...              USA   \n",
       "26              14.0     Yes           No  ...           France   \n",
       "27               1.0     Yes           No  ...              USA   \n",
       "28               1.0      No           No  ...              USA   \n",
       "29              11.0     Yes           No  ...            India   \n",
       "30               1.0     Yes           No  ...              USA   \n",
       "31               8.0     Yes           No  ...      Netherlands   \n",
       "32               2.0     Yes           No  ...           Uganda   \n",
       "33               3.0     Yes           No  ...              USA   \n",
       "34               1.0     Yes           No  ...        Australia   \n",
       "35               1.0     Yes           No  ...            Kenya   \n",
       "36               1.0     Yes           No  ...   United Kingdom   \n",
       "37               1.0     Yes           No  ...              USA   \n",
       "38               4.0     Yes           No  ...           France   \n",
       "39               3.0      No           No  ...         Portugal   \n",
       "40               1.0     Yes           No  ...        Australia   \n",
       "41               NaN      No           No  ...              NaN   \n",
       "42               1.0     Yes           No  ...              USA   \n",
       "43               NaN      No           No  ...              NaN   \n",
       "44               2.0     Yes           No  ...   United Kingdom   \n",
       "45               2.0     Yes           No  ...            Japan   \n",
       "46              13.0     Yes           No  ...        Australia   \n",
       "47              24.0     Yes           No  ...          Germany   \n",
       "48               6.0     Yes           No  ...          Germany   \n",
       "49              21.0     Yes           No  ...           France   \n",
       "50               3.0     Yes           No  ...         Thailand   \n",
       "51               NaN      No           No  ...              NaN   \n",
       "52               1.0     Yes           No  ...              USA   \n",
       "53               1.0     Yes           No  ...            Italy   \n",
       "54               1.0     Yes           No  ...              USA   \n",
       "55               9.0     Yes           No  ...   United Kingdom   \n",
       "56               1.0     Yes           No  ...        Argentina   \n",
       "57               1.0     Yes           No  ...            Spain   \n",
       "58               1.0     Yes           No  ...         Portugal   \n",
       "59               NaN      No           No  ...              NaN   \n",
       "60               7.0     Yes           No  ...            India   \n",
       "61               1.0     Yes           No  ...              USA   \n",
       "62               1.0     Yes           No  ...   United Kingdom   \n",
       "63               1.0     Yes           No  ...   United Kingdom   \n",
       "64               1.0     Yes           No  ...           France   \n",
       "65               4.0     Yes           No  ...           Sweden   \n",
       "66              10.0     Yes           No  ...              USA   \n",
       "67              19.0     Yes           No  ...   United Kingdom   \n",
       "68               1.0     Yes           No  ...              USA   \n",
       "69               1.0      No           No  ...            Spain   \n",
       "70               1.0     Yes           No  ...            India   \n",
       "71               1.0      No           No  ...           Canada   \n",
       "72               1.0     Yes           No  ...           France   \n",
       "73              11.0     Yes           No  ...            Italy   \n",
       "74               1.0     Yes          Yes  ...              USA   \n",
       "75               1.0     Yes           No  ...              USA   \n",
       "76               6.0     Yes           No  ...              USA   \n",
       "77               1.0     Yes           No  ...           France   \n",
       "78               1.0     Yes           No  ...            Japan   \n",
       "79               1.0     Yes           No  ...            India   \n",
       "80               1.0     Yes           No  ...            Italy   \n",
       "81               1.0     Yes           No  ...            Italy   \n",
       "82               1.0     Yes           No  ...              USA   \n",
       "83               2.0      No           No  ...           France   \n",
       "84               1.0     Yes           No  ...            Spain   \n",
       "85               1.0     Yes           No  ...            India   \n",
       "86               4.0     Yes           No  ...      South Korea   \n",
       "87               1.0     Yes           No  ...              USA   \n",
       "88               3.0     Yes           No  ...              USA   \n",
       "89               1.0     Yes           No  ...            India   \n",
       "90              10.0     Yes           No  ...           France   \n",
       "91               1.0      No           No  ...            Italy   \n",
       "92               2.0     Yes           No  ...            Italy   \n",
       "93               1.0     Yes           No  ...            Italy   \n",
       "94               1.0     Yes           No  ...      Puerto Rico   \n",
       "95               3.0     Yes           No  ...   United Kingdom   \n",
       "96               1.0     Yes           No  ...   United Kingdom   \n",
       "97               1.0     Yes           No  ...            Japan   \n",
       "98               2.0     Yes           No  ...           France   \n",
       "99               6.0     Yes           No  ...           Rwanda   \n",
       "100              1.0     Yes           No  ...           Brazil   \n",
       "101              2.0      No           No  ...   United Kingdom   \n",
       "102              NaN      No           No  ...              NaN   \n",
       "103              1.0     Yes           No  ...              USA   \n",
       "104              1.0     Yes           No  ...            Japan   \n",
       "105              4.0     Yes           No  ...            India   \n",
       "106              9.0     Yes           No  ...              USA   \n",
       "107              NaN      No           No  ...              NaN   \n",
       "108              1.0     Yes           No  ...         Portugal   \n",
       "109              1.0     Yes           No  ...              USA   \n",
       "110              1.0     Yes           No  ...            India   \n",
       "111              1.0      No           No  ...           Canada   \n",
       "112              1.0     Yes           No  ...            Italy   \n",
       "113             23.0     Yes           No  ...         Thailand   \n",
       "114              1.0     Yes           No  ...      Netherlands   \n",
       "115              1.0     Yes           No  ...            Spain   \n",
       "116              1.0     Yes           No  ...   United Kingdom   \n",
       "117              6.0     Yes           No  ...            Italy   \n",
       "118              5.0     Yes           No  ...           Canada   \n",
       "119              4.0     Yes           No  ...        Argentina   \n",
       "120              2.0     Yes           No  ...            Italy   \n",
       "121              1.0     Yes           No  ...              USA   \n",
       "122              1.0     Yes           No  ...           Canada   \n",
       "123              1.0     Yes           No  ...   United Kingdom   \n",
       "124              1.0     Yes           No  ...              USA   \n",
       "125              1.0     Yes           No  ...              USA   \n",
       "126              1.0     Yes          Yes  ...            Italy   \n",
       "127              1.0      No           No  ...            Japan   \n",
       "128              1.0     Yes           No  ...              USA   \n",
       "129              1.0     Yes           No  ...          Germany   \n",
       "130              1.0      No           No  ...        Australia   \n",
       "131              1.0     Yes           No  ...            Japan   \n",
       "132              1.0     Yes           No  ...         Thailand   \n",
       "133              1.0     Yes           No  ...   United Kingdom   \n",
       "134              1.0     Yes           No  ...           France   \n",
       "135              NaN      No           No  ...              NaN   \n",
       "136              3.0     Yes          Yes  ...           Brazil   \n",
       "137              1.0     Yes           No  ...              USA   \n",
       "138              1.0     Yes           No  ...            Japan   \n",
       "139              1.0     Yes           No  ...            Japan   \n",
       "140              1.0     Yes           No  ...            Spain   \n",
       "141              1.0      No           No  ...          Germany   \n",
       "142              3.0     Yes           No  ...   United Kingdom   \n",
       "143              1.0     Yes           No  ...           Brazil   \n",
       "144              1.0     Yes           No  ...          Germany   \n",
       "145              1.0     Yes           No  ...         Portugal   \n",
       "146              1.0     Yes           No  ...              USA   \n",
       "147              1.0     Yes          Yes  ...           France   \n",
       "148              2.0     Yes           No  ...            Spain   \n",
       "149              1.0     Yes           No  ...           France   \n",
       "150              1.0     Yes           No  ...            Italy   \n",
       "151              NaN      No           No  ...              NaN   \n",
       "152              2.0     Yes           No  ...              USA   \n",
       "153              2.0      No           No  ...            Italy   \n",
       "154              1.0     Yes           No  ...           France   \n",
       "155             56.0     Yes           No  ...           France   \n",
       "156              1.0      No           No  ...           Canada   \n",
       "157              1.0     Yes          Yes  ...              USA   \n",
       "158              1.0     Yes           No  ...   United Kingdom   \n",
       "159              1.0     Yes           No  ...           Taiwan   \n",
       "160              1.0      No           No  ...              USA   \n",
       "161              1.0     Yes           No  ...              USA   \n",
       "162              1.0     Yes          Yes  ...           France   \n",
       "163              NaN      No           No  ...              NaN   \n",
       "164              6.0      No           No  ...           France   \n",
       "165              1.0     Yes          Yes  ...      Netherlands   \n",
       "166              1.0     Yes          Yes  ...              USA   \n",
       "167              1.0     Yes          Yes  ...           France   \n",
       "168              4.0     Yes           No  ...            Italy   \n",
       "169              3.0      No           No  ...           France   \n",
       "170              1.0      No           No  ...            Italy   \n",
       "171              1.0     Yes           No  ...           France   \n",
       "172              2.0      No           No  ...            Italy   \n",
       "173              NaN      No           No  ...              NaN   \n",
       "174              1.0     Yes           No  ...      Netherlands   \n",
       "175              2.0     Yes           No  ...              USA   \n",
       "176              NaN      No           No  ...              NaN   \n",
       "177              1.0     Yes           No  ...          Belgium   \n",
       "178              8.0     Yes           No  ...              USA   \n",
       "179              NaN      No           No  ...              NaN   \n",
       "180              1.0     Yes           No  ...              USA   \n",
       "181              1.0     Yes          Yes  ...           Canada   \n",
       "182              1.0     Yes           No  ...            Italy   \n",
       "183              NaN      No           No  ...              NaN   \n",
       "184              NaN      No           No  ...              NaN   \n",
       "185              1.0     Yes           No  ...            Spain   \n",
       "186              3.0     Yes           No  ...              USA   \n",
       "187              2.0     Yes          Yes  ...              USA   \n",
       "188              1.0      No          Yes  ...      Switzerland   \n",
       "189              1.0     Yes           No  ...           France   \n",
       "190              3.0     Yes           No  ...        Australia   \n",
       "191              3.0     Yes           No  ...           Canada   \n",
       "192              NaN      No           No  ...              NaN   \n",
       "193              1.0      No           No  ...              USA   \n",
       "194              3.0      No           No  ...           Canada   \n",
       "195              1.0      No           No  ...            Spain   \n",
       "196              7.0     Yes           No  ...           Canada   \n",
       "197              3.0     Yes           No  ...            Spain   \n",
       "198              1.0     Yes          Yes  ...            Spain   \n",
       "199             17.0     Yes           No  ...              USA   \n",
       "200              1.0     Yes           No  ...              USA   \n",
       "201              1.0     Yes           No  ...              USA   \n",
       "202              1.0     Yes           No  ...            Japan   \n",
       "203              4.0      No           No  ...              USA   \n",
       "204              1.0     Yes          Yes  ...              USA   \n",
       "205              NaN      No           No  ...              NaN   \n",
       "206              5.0      No           No  ...          England   \n",
       "207              1.0     Yes          Yes  ...           France   \n",
       "208              2.0     Yes           No  ...            Spain   \n",
       "209              1.0     Yes           No  ...            Italy   \n",
       "210             18.0     Yes          Yes  ...   United Kingdom   \n",
       "211              1.0     Yes          Yes  ...          Ireland   \n",
       "212              1.0     Yes          Yes  ...            Spain   \n",
       "213              NaN      No           No  ...              NaN   \n",
       "214              1.0      No           No  ...           France   \n",
       "215              1.0      No          Yes  ...           Greece   \n",
       "216              1.0     Yes           No  ...            Spain   \n",
       "217             11.0      No           No  ...           France   \n",
       "218              1.0      No           No  ...      Switzerland   \n",
       "219              3.0     Yes           No  ...      Switzerland   \n",
       "220              1.0     Yes          Yes  ...              USA   \n",
       "221              1.0      No          Yes  ...              USA   \n",
       "222              1.0     Yes           No  ...              USA   \n",
       "223              1.0     Yes          Yes  ...              USA   \n",
       "224              1.0      No           No  ...           France   \n",
       "225              1.0     Yes           No  ...              USA   \n",
       "226              NaN      No           No  ...              NaN   \n",
       "227              1.0      No           No  ...          Germany   \n",
       "228              1.0      No           No  ...           France   \n",
       "229              3.0      No          Yes  ...           France   \n",
       "230              1.0      No           No  ...              USA   \n",
       "231              3.0      No          Yes  ...              USA   \n",
       "232              5.0     Yes           No  ...              USA   \n",
       "233              1.0      No           No  ...          England   \n",
       "234              2.0     Yes          Yes  ...          Germany   \n",
       "235              NaN      No           No  ...              NaN   \n",
       "236              NaN      No           No  ...              NaN   \n",
       "237              1.0      No          Yes  ...           France   \n",
       "238              NaN      No           No  ...              NaN   \n",
       "239              NaN      No           No  ...              NaN   \n",
       "240              NaN      No           No  ...              NaN   \n",
       "\n",
       "     Source Country Country of publication  \\\n",
       "0               NaN                    USA   \n",
       "1               NaN                    USA   \n",
       "2               NaN                    USA   \n",
       "3               NaN                England   \n",
       "4               NaN                    USA   \n",
       "5               NaN                England   \n",
       "6               NaN                    USA   \n",
       "7               NaN                    USA   \n",
       "8               NaN                    USA   \n",
       "9               NaN                 Turkey   \n",
       "10              NaN                England   \n",
       "11              NaN                 France   \n",
       "12              NaN                 France   \n",
       "13              NaN                    USA   \n",
       "14              NaN                    USA   \n",
       "15              NaN                    USA   \n",
       "16              NaN            Netherlands   \n",
       "17              NaN                England   \n",
       "18              NaN                England   \n",
       "19              NaN                    USA   \n",
       "20              NaN                 Brazil   \n",
       "21              NaN                    USA   \n",
       "22              NaN                    USA   \n",
       "23   United Kingdom                    USA   \n",
       "24              NaN                England   \n",
       "25              NaN                    USA   \n",
       "26              NaN                England   \n",
       "27              NaN                England   \n",
       "28              NaN                England   \n",
       "29              NaN                 Canada   \n",
       "30              NaN                    USA   \n",
       "31              NaN                    USA   \n",
       "32              NaN         United Kingdom   \n",
       "33              NaN                    USA   \n",
       "34              NaN            Netherlands   \n",
       "35              NaN            New Zealand   \n",
       "36              NaN                England   \n",
       "37              NaN                    USA   \n",
       "38              NaN                England   \n",
       "39              NaN                    USA   \n",
       "40              NaN                England   \n",
       "41     South Africa            New Zealand   \n",
       "42              NaN                Denmark   \n",
       "43              USA                    USA   \n",
       "44              NaN                England   \n",
       "45              NaN                  Japan   \n",
       "46              NaN                England   \n",
       "47              NaN                Germany   \n",
       "48              NaN                Germany   \n",
       "49              NaN                    USA   \n",
       "50              NaN                    USA   \n",
       "51          Unknown                    USA   \n",
       "52              NaN                    USA   \n",
       "53              NaN                  Italy   \n",
       "54              NaN                 Canada   \n",
       "55              NaN                England   \n",
       "56              NaN                England   \n",
       "57              NaN                  Chile   \n",
       "58              NaN                Germany   \n",
       "59           Canada                 Canada   \n",
       "60              NaN                  India   \n",
       "61              NaN                    USA   \n",
       "62              NaN                England   \n",
       "63              NaN                England   \n",
       "64              NaN                 Canada   \n",
       "65              NaN                    USA   \n",
       "66              NaN                England   \n",
       "67              NaN                England   \n",
       "68              NaN                    USA   \n",
       "69              NaN                    USA   \n",
       "70              NaN         United Kingdom   \n",
       "71              NaN                England   \n",
       "72              NaN                England   \n",
       "73              NaN            Netherlands   \n",
       "74              NaN                England   \n",
       "75              NaN                    USA   \n",
       "76              NaN                    USA   \n",
       "77              NaN                  Japan   \n",
       "78              NaN                  Japan   \n",
       "79              NaN                  India   \n",
       "80              NaN                England   \n",
       "81              NaN                    USA   \n",
       "82              NaN                    USA   \n",
       "83              NaN                Ireland   \n",
       "84              NaN                  Spain   \n",
       "85              NaN                 France   \n",
       "86              NaN            South Korea   \n",
       "87              NaN                    USA   \n",
       "88              NaN                    USA   \n",
       "89              NaN                 Poland   \n",
       "90              NaN                England   \n",
       "91              NaN                  Italy   \n",
       "92              NaN                  Italy   \n",
       "93              NaN                    USA   \n",
       "94              NaN            Puerto Rico   \n",
       "95              NaN                England   \n",
       "96              NaN                England   \n",
       "97              NaN         United Kingdom   \n",
       "98              NaN                England   \n",
       "99              NaN                    USA   \n",
       "100             NaN                 Brazil   \n",
       "101             NaN                    USA   \n",
       "102             USA                    USA   \n",
       "103             NaN                    USA   \n",
       "104             NaN            Switzerland   \n",
       "105             NaN                 Poland   \n",
       "106             NaN                    USA   \n",
       "107     New Zealand       New Zealand, USA   \n",
       "108             NaN                 Poland   \n",
       "109             NaN                    USA   \n",
       "110             NaN                  India   \n",
       "111             NaN                England   \n",
       "112             NaN                    USA   \n",
       "113             NaN                    USA   \n",
       "114             NaN            Netherlands   \n",
       "115             NaN                    USA   \n",
       "116             NaN                England   \n",
       "117             NaN                England   \n",
       "118             NaN                    USA   \n",
       "119             NaN              Argentina   \n",
       "120             NaN                Germany   \n",
       "121             NaN                England   \n",
       "122             NaN                England   \n",
       "123             NaN                England   \n",
       "124             NaN                    USA   \n",
       "125             NaN                    USA   \n",
       "126             NaN                England   \n",
       "127             NaN                  Japan   \n",
       "128             NaN                    USA   \n",
       "129             NaN                England   \n",
       "130             NaN                    USA   \n",
       "131             NaN            Netherlands   \n",
       "132             NaN               Thailand   \n",
       "133             NaN                England   \n",
       "134             NaN                England   \n",
       "135             USA                    USA   \n",
       "136             NaN                 Brazil   \n",
       "137             NaN            Netherlands   \n",
       "138             NaN                  Japan   \n",
       "139             NaN                  Japan   \n",
       "140             NaN                 Canada   \n",
       "141             NaN                Germany   \n",
       "142             NaN                    NaN   \n",
       "143             NaN                 Brazil   \n",
       "144             NaN                England   \n",
       "145             NaN                    USA   \n",
       "146             NaN                    USA   \n",
       "147             NaN                    USA   \n",
       "148             NaN                    USA   \n",
       "149             NaN                England   \n",
       "150             NaN                England   \n",
       "151             USA                    NaN   \n",
       "152             NaN                    USA   \n",
       "153             NaN                    NaN   \n",
       "154             NaN                    USA   \n",
       "155             NaN                    USA   \n",
       "156             NaN                 Canada   \n",
       "157             NaN                England   \n",
       "158             NaN                England   \n",
       "159             NaN            Netherlands   \n",
       "160             NaN                    USA   \n",
       "161             NaN                    USA   \n",
       "162             NaN                England   \n",
       "163     New Zealand   New Zealand, England   \n",
       "164             NaN                Ireland   \n",
       "165             NaN                England   \n",
       "166             NaN                    USA   \n",
       "167             NaN                 Greece   \n",
       "168             NaN                England   \n",
       "169             NaN                    USA   \n",
       "170             NaN                England   \n",
       "171             NaN                England   \n",
       "172             NaN                    USA   \n",
       "173          France                    USA   \n",
       "174             NaN                    NaN   \n",
       "175             NaN                  China   \n",
       "176     Netherlands                    USA   \n",
       "177             NaN            Netherlands   \n",
       "178             NaN            Netherlands   \n",
       "179           Spain                    NaN   \n",
       "180             NaN                    NaN   \n",
       "181             NaN                    USA   \n",
       "182             NaN                England   \n",
       "183         Denmark                    NaN   \n",
       "184     Switzerland                    USA   \n",
       "185             NaN                  Spain   \n",
       "186             NaN                    USA   \n",
       "187             NaN                    USA   \n",
       "188             NaN                    NaN   \n",
       "189             NaN                 France   \n",
       "190             NaN                    USA   \n",
       "191             NaN                    USA   \n",
       "192             USA                    USA   \n",
       "193             NaN                    USA   \n",
       "194             NaN                 Canada   \n",
       "195             NaN                  Spain   \n",
       "196             NaN                    USA   \n",
       "197             NaN                  Spain   \n",
       "198             NaN                    USA   \n",
       "199             NaN                    USA   \n",
       "200             NaN                    USA   \n",
       "201             NaN                    USA   \n",
       "202             NaN                Germany   \n",
       "203             NaN                    USA   \n",
       "204             NaN                    USA   \n",
       "205         England                    NaN   \n",
       "206             NaN                England   \n",
       "207             NaN                    USA   \n",
       "208             NaN                  Spain   \n",
       "209             NaN                England   \n",
       "210             NaN                    USA   \n",
       "211             NaN                Ireland   \n",
       "212             NaN                    USA   \n",
       "213             USA                    USA   \n",
       "214             NaN                    USA   \n",
       "215             NaN                England   \n",
       "216             NaN                    USA   \n",
       "217             NaN                    USA   \n",
       "218             NaN                England   \n",
       "219             NaN                Germany   \n",
       "220             NaN                    USA   \n",
       "221             NaN                    USA   \n",
       "222             NaN                    USA   \n",
       "223             NaN                    USA   \n",
       "224             NaN                    USA   \n",
       "225             NaN                    USA   \n",
       "226             USA                    USA   \n",
       "227             NaN                England   \n",
       "228             NaN                England   \n",
       "229             NaN                    USA   \n",
       "230             NaN                    USA   \n",
       "231             NaN                    USA   \n",
       "232             NaN                    USA   \n",
       "233             NaN                    USA   \n",
       "234             NaN                England   \n",
       "235             USA                    USA   \n",
       "236     New Zealand            New Zealand   \n",
       "237             NaN                    USA   \n",
       "238         England                    NaN   \n",
       "239             USA                    NaN   \n",
       "240     New Zealand                    NaN   \n",
       "\n",
       "                                            Drug Class  \\\n",
       "0    Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "1    Amides , Anti-infectives , Antiretrovirals , A...   \n",
       "2    3-ring heterocyclic compounds , Amides , Anti-...   \n",
       "3    Alkynes , Antipsoriatics , Antiretrovirals , B...   \n",
       "4    Amides , Antiretrovirals , Antivirals , Carbam...   \n",
       "5    Antiretrovirals , Carbamates , Furans , Morpho...   \n",
       "6    Antiretrovirals , Deoxyribonucleosides , Napht...   \n",
       "7    Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "8    3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "9    Adenine nucleotides , Amides , Anti-inflammato...   \n",
       "10   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "11   Amides , Antiretrovirals , Antivirals , Carbam...   \n",
       "12   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "13   3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "14   Acetanilides , Amides , Antiretrovirals , Carb...   \n",
       "15   Antiasthmatics , Antipsoriatics , Antiretrovir...   \n",
       "16   Amides , Antiretrovirals , Oligopeptides , Pyr...   \n",
       "17   Antiretrovirals , Antivirals , Azabicyclo comp...   \n",
       "18   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "19   3-ring heterocyclic compounds , Amides , Anti-...   \n",
       "20   Adenine nucleotides , Antiretrovirals , Deoxyr...   \n",
       "21   3-ring heterocyclic compounds , Amides , Antir...   \n",
       "22   3-ring heterocyclic compounds , Amides , Antir...   \n",
       "23   3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "24   Adenine nucleotides , Amides , Antipsoriatics ...   \n",
       "25   3-ring heterocyclic compounds , Amides , Anti-...   \n",
       "26   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "27   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "28   3-ring heterocyclic compounds , Amides , Antia...   \n",
       "29   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "30   Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "31   Adenine nucleotides , Amides , Anti-infectives...   \n",
       "32   3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "33   Amides , Analgesics , Antidepressants , Antips...   \n",
       "34   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "35   Alkynes , Amides , Antiretrovirals , Carbamate...   \n",
       "36   Adenine nucleotides , Amides , Antidementias ,...   \n",
       "37   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "38   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "39   Adenine nucleotides , Amides , Antipsoriatics ...   \n",
       "40   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "41   Amides , Antipsoriatics , Antiretrovirals , An...   \n",
       "42   Amides , Antiasthmatics , Antipsoriatics , Ant...   \n",
       "43   Amides , Antiretrovirals , Azides , Carbamates...   \n",
       "44   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "45   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "46   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "47   2 pyridinylmethylsulfinylbenzimidazoles , Adju...   \n",
       "48   Alkynes , Amides , Anti-infectives , Antiretro...   \n",
       "49   3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "50   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "51   Adenine nucleotides , Alkynes , Amides , Anti-...   \n",
       "52   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "53   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "54   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "55   Amides , Antiretrovirals , Oligopeptides , Pyr...   \n",
       "56   Adenine nucleotides , Amides , Antineoplastics...   \n",
       "57   Amides , Analgesics , Antimigraines , Antiretr...   \n",
       "58   Amides , Antiretrovirals , Carbamates , Cyclop...   \n",
       "59   Antiretrovirals , Carbamates , Morpholines , O...   \n",
       "60   3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "61   Amides , Antiasthmatics , Antipsoriatics , Ant...   \n",
       "62   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "63   Amides , Anti-infectives , Antiretrovirals , A...   \n",
       "64   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "65   Antiretrovirals , Benzoxazines , Deoxyribonucl...   \n",
       "66   2 ring heterocyclic compounds , Abortifacients...   \n",
       "67   Amides , Analgesics , Androstadienes , Anti-in...   \n",
       "68   Alkynes , Amides , Antipsoriatics , Antiretrov...   \n",
       "69   Antiretrovirals , Cyclopentanes , Cyclopropane...   \n",
       "70   3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "71   Antidepressants , Antineoplastics , Antipsycho...   \n",
       "72   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "73   Antiretrovirals , Naphthyridines , Oligopeptid...   \n",
       "74   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "75   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "76   3-ring heterocyclic compounds , Amides , Antir...   \n",
       "77   Adenine nucleotides , Antipsoriatics , Antiret...   \n",
       "78   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "79   Amides , Antipsoriatics , Antiretrovirals , Ca...   \n",
       "80   Amides , Anorectics , Antiretrovirals , Carbam...   \n",
       "81   Anilides , Antiretrovirals , Antivirals , Aza ...   \n",
       "82   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "83   Alkynes , Amides , Antineoplastics , Antipsori...   \n",
       "84   Amides , Antiretrovirals , Benzazepines , Brad...   \n",
       "85   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "86   Adenine nucleotides , Amides , Antihyperlipida...   \n",
       "87   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "88   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "89   Adenine nucleotides , Amides , Antibacterials ...   \n",
       "90   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "91   Amides , Antiretrovirals , Carbamates , Cycloh...   \n",
       "92   3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "93   Amides , Antiretrovirals , Antivirals , Carbam...   \n",
       "94   Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "95   Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "96   Antipsoriatics , Antiretrovirals , Cyclopentan...   \n",
       "97   Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "98   Antiretrovirals , Naphthyridines , Oligopeptid...   \n",
       "99   Amides , Anti-ischaemics , Antibacterials , An...   \n",
       "100  Amides , Antineoplastics , Antiretrovirals , C...   \n",
       "101  3-ring heterocyclic compounds , Antiretroviral...   \n",
       "102  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "103  Amides , Antineoplastics , Antiretrovirals , C...   \n",
       "104  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "105  Alkynes , Antiretrovirals , Azides , Benzoxazi...   \n",
       "106  Amides , Anti-infectives , Antiretrovirals , A...   \n",
       "107  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "108  Alkynes , Amides , Antiretrovirals , Azides , ...   \n",
       "109  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "110  3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "111  Antiretrovirals , Benzofurans , Class III anti...   \n",
       "112  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "113  Alkynes , Amides , Antimigraines , Antiretrovi...   \n",
       "114  Adenine nucleotides , Amides , Antineoplastics...   \n",
       "115  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "116  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "117  Amides , Antineoplastics , Antiretrovirals , B...   \n",
       "118  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "119  Amides , Analgesics , Anti-infectives , Antimi...   \n",
       "120  Amides , Antineoplastics , Antiretrovirals , A...   \n",
       "121  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "122  Absorbents , Amides , Antiretrovirals , Carbam...   \n",
       "123  Amides , Anti-inflammatories , Antiallergics ,...   \n",
       "124  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "125  Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "126  Antipsoriatics , Antiretrovirals , Cyclopentan...   \n",
       "127  Antiretrovirals , Deoxyribonucleosides , Nucle...   \n",
       "128  Amides , Antihypertensives , Antiretrovirals ,...   \n",
       "129  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "130  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "131  Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "132  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "133  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "134  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "135  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "136  Alkynes , Amides , Antiretrovirals , Antiviral...   \n",
       "137  Amides , Antiretrovirals , Azides , Carbamates...   \n",
       "138  Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "139  Antiretrovirals , Oligopeptides , Phosphonic a...   \n",
       "140  Amides , Androstadienes , Antiallergics , Anti...   \n",
       "141  3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "142  3-ring heterocyclic compounds , Amides , Antir...   \n",
       "143  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "144  Amides , Antipsoriatics , Antiretrovirals , Az...   \n",
       "145  Adenine nucleotides , Antiretrovirals , Oligop...   \n",
       "146  Adenine nucleotides , Antiretrovirals , Naphth...   \n",
       "147  Amides , Antiretrovirals , Carbamates , Naphth...   \n",
       "148  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "149  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "150  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "151  Amides , Anti-infectives , Antiretrovirals , A...   \n",
       "152  Anti-inflammatories , Antiacnes , Antibacteria...   \n",
       "153  Alkynes , Amides , Antiretrovirals , Azides , ...   \n",
       "154  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "155  2 pyridinylmethylsulfinylbenzimidazoles , 3-ri...   \n",
       "156  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "157  Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "158  Amides , Antiasthmatics , Antipsoriatics , Ant...   \n",
       "159  Alkynes , Antiretrovirals , Azides , Benzoxazi...   \n",
       "160  Amides , Antihyperlipidaemics , Antihypertensi...   \n",
       "161  Amides , Anti-inflammatories , Antiallergics ,...   \n",
       "162  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "163  3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "164  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "165  Alkynes , Amides , Anti-ischaemics , Anticoagu...   \n",
       "166  Alkaloids , Antiretrovirals , Morphine derivat...   \n",
       "167  Amides , Antineoplastics , Antiretrovirals , B...   \n",
       "168  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "169  Amides , Antiretrovirals , Carbamates , Naphth...   \n",
       "170  Antiretrovirals , Naphthyridines , Oligopeptid...   \n",
       "171  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "172  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "173  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "174  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "175  Adenine nucleotides , Amides , Analgesics , An...   \n",
       "176  Antiretrovirals , Azides , Deoxyribonucleoside...   \n",
       "177  Amides , Analgesics , Antidepressants , Antips...   \n",
       "178  Alkynes , Amides , Antipsoriatics , Antiretrov...   \n",
       "179  3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "180  Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "181  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "182  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "183  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "184  3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "185  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "186  Adenine nucleotides , Alkynes , Amides , Antir...   \n",
       "187  Amides , Analgesics , Antidepressants , Antips...   \n",
       "188  Antiretrovirals , Naphthyridines , Oligopeptid...   \n",
       "189  Amides , Analgesics , Androstadienes , Anti-in...   \n",
       "190  3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "191  3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "192  Amides , Antifungals , Antiretrovirals , Carba...   \n",
       "193  Adenine nucleotides , Amides , Antipsoriatics ...   \n",
       "194  Antipsoriatics , Antiretrovirals , Azides , Cy...   \n",
       "195  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "196  Adenine nucleotides , Alkynes , Amides , Antip...   \n",
       "197  2 pyridinylmethylsulfinylbenzimidazoles , Amid...   \n",
       "198  Alkaloids , Amides , Antiretrovirals , Carbama...   \n",
       "199  3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "200  Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "201  Antiretrovirals , Naphthyridines , Oligopeptid...   \n",
       "202  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "203  Antipsoriatics , Antiretrovirals , Cyclopentan...   \n",
       "204  3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "205  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "206  Alkynes , Amides , Antipsoriatics , Antiretrov...   \n",
       "207  Adenine nucleotides , Antiretrovirals , Deoxyr...   \n",
       "208  Adenine nucleotides , Antiretrovirals , Oligop...   \n",
       "209  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "210  3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "211  Amides , Antiretrovirals , Benzodiazepinones ,...   \n",
       "212  Antiasthmatics , Antipsoriatics , Antiretrovir...   \n",
       "213  3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "214  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "215  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "216  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "217  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "218  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "219  Antiretrovirals , Oligopeptides , Phosphonic a...   \n",
       "220  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "221  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "222  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "223  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "224  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "225  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "226  2 pyridinylmethylsulfinylbenzimidazoles , Anti...   \n",
       "227  Amides , Antipsoriatics , Antiretrovirals , Ca...   \n",
       "228  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "229  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "230  2 pyridinylmethylsulfinylbenzimidazoles , Anti...   \n",
       "231  Amides , Antiretrovirals , Carbamates , Cyclop...   \n",
       "232  Adenine nucleotides , Amides , Antiretrovirals...   \n",
       "233  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "234  Antiretrovirals , Azides , Deoxyribonucleoside...   \n",
       "235  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "236  2 pyridinylmethylsulfinylbenzimidazoles , Amid...   \n",
       "237  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "238  Alkynes , Amines , Antiallergics , Antihypergl...   \n",
       "239  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "240  Antiretrovirals , Deoxyribonucleosides , Dideo...   \n",
       "\n",
       "                                    Age Group Route Of Administration  \\\n",
       "0                                         NaN                     NaN   \n",
       "1                                         NaN                     NaN   \n",
       "2                                         NaN                     NaN   \n",
       "3                                         NaN                     NaN   \n",
       "4                                         NaN                    Oral   \n",
       "5                                         NaN                     NaN   \n",
       "6                                         NaN                     NaN   \n",
       "7                                         NaN                     NaN   \n",
       "8                                         NaN                     NaN   \n",
       "9                                         NaN                    Oral   \n",
       "10                                        NaN                     NaN   \n",
       "11                                        NaN                     NaN   \n",
       "12                                        NaN                     NaN   \n",
       "13                      Adolescents, Children                     NaN   \n",
       "14                                        NaN       Intravenous, Oral   \n",
       "15                                        NaN                    Oral   \n",
       "16                                        NaN                     NaN   \n",
       "17                                        NaN                    Oral   \n",
       "18                                   Children                     NaN   \n",
       "19                                        NaN                     NaN   \n",
       "20                                        NaN                     NaN   \n",
       "21                                        NaN                     NaN   \n",
       "22                                        NaN                     NaN   \n",
       "23                                        NaN                     NaN   \n",
       "24                                   Neonates          Transplacental   \n",
       "25                                        NaN                     NaN   \n",
       "26                                        NaN                     NaN   \n",
       "27                                        NaN                     NaN   \n",
       "28                                        NaN                     NaN   \n",
       "29                       Adolescents, Elderly                     NaN   \n",
       "30                                        NaN                     NaN   \n",
       "31                                    Elderly                     NaN   \n",
       "32                                        NaN                     NaN   \n",
       "33                                        NaN                     NaN   \n",
       "34                                        NaN                     NaN   \n",
       "35                                        NaN                     NaN   \n",
       "36                                        NaN                     NaN   \n",
       "37                                    Elderly                     NaN   \n",
       "38                                        NaN                     NaN   \n",
       "39                                        NaN                     NaN   \n",
       "40                                        NaN                     NaN   \n",
       "41                                        NaN                     NaN   \n",
       "42                                        NaN                     NaN   \n",
       "43                                        NaN                     NaN   \n",
       "44                                   Children                     NaN   \n",
       "45                                    Elderly                     NaN   \n",
       "46                                        NaN                     NaN   \n",
       "47                                    Elderly                     NaN   \n",
       "48                                        NaN                     NaN   \n",
       "49   Adolescents, Children, Infants, Neonates                     NaN   \n",
       "50                                Adolescents                     NaN   \n",
       "51                                        NaN                     NaN   \n",
       "52                                        NaN                     NaN   \n",
       "53                                        NaN                     NaN   \n",
       "54                                        NaN                     NaN   \n",
       "55                                        NaN                     NaN   \n",
       "56                                        NaN                     NaN   \n",
       "57                                        NaN                     NaN   \n",
       "58                                        NaN                     NaN   \n",
       "59                                        NaN                     NaN   \n",
       "60                                        NaN                     NaN   \n",
       "61                                        NaN                     NaN   \n",
       "62                                        NaN                     NaN   \n",
       "63                                        NaN                     NaN   \n",
       "64                                        NaN                     NaN   \n",
       "65                                Adolescents                    Oral   \n",
       "66                                    Elderly                     NaN   \n",
       "67                                        NaN          Nasal, Topical   \n",
       "68                                        NaN                     NaN   \n",
       "69                                        NaN                     NaN   \n",
       "70                                Adolescents                     NaN   \n",
       "71                                        NaN                     NaN   \n",
       "72                                        NaN                     NaN   \n",
       "73                                        NaN                     NaN   \n",
       "74                                        NaN                     NaN   \n",
       "75                                        NaN                     NaN   \n",
       "76                                        NaN                     NaN   \n",
       "77                                        NaN                     NaN   \n",
       "78                                    Elderly                    Oral   \n",
       "79                                        NaN                     NaN   \n",
       "80                                        NaN                     NaN   \n",
       "81                                        NaN                     NaN   \n",
       "82                                        NaN                     NaN   \n",
       "83                                        NaN                    Oral   \n",
       "84                                        NaN                     NaN   \n",
       "85                                        NaN                     NaN   \n",
       "86                                        NaN                     NaN   \n",
       "87                                        NaN                     NaN   \n",
       "88                                        NaN                     NaN   \n",
       "89                                        NaN                     NaN   \n",
       "90                                        NaN                     NaN   \n",
       "91                                        NaN                     NaN   \n",
       "92                                        NaN                     NaN   \n",
       "93                                        NaN                     NaN   \n",
       "94                                        NaN                     NaN   \n",
       "95                                        NaN                     NaN   \n",
       "96                                        NaN                     NaN   \n",
       "97                                    Elderly                     NaN   \n",
       "98                                        NaN                     NaN   \n",
       "99                                        NaN                     NaN   \n",
       "100                                       NaN                     NaN   \n",
       "101                                       NaN                     NaN   \n",
       "102                                   Infants                     NaN   \n",
       "103                                       NaN                     NaN   \n",
       "104                                       NaN                     NaN   \n",
       "105                                       NaN                     NaN   \n",
       "106                                       NaN                     NaN   \n",
       "107                                       NaN                     NaN   \n",
       "108                                       NaN                     NaN   \n",
       "109                                  Neonates                     NaN   \n",
       "110                                       NaN                     NaN   \n",
       "111                                   Elderly       Intravenous, Oral   \n",
       "112                                       NaN                     NaN   \n",
       "113                                       NaN                     NaN   \n",
       "114                                       NaN                     NaN   \n",
       "115                                       NaN                     NaN   \n",
       "116                                       NaN                     NaN   \n",
       "117                                       NaN                     NaN   \n",
       "118                                       NaN                     NaN   \n",
       "119                                       NaN                     NaN   \n",
       "120                                       NaN                     NaN   \n",
       "121                                       NaN                     NaN   \n",
       "122                                       NaN                     NaN   \n",
       "123                                       NaN                     NaN   \n",
       "124                                       NaN                     NaN   \n",
       "125                                   Elderly                     NaN   \n",
       "126                                       NaN                     NaN   \n",
       "127                                       NaN                     NaN   \n",
       "128                                       NaN                     NaN   \n",
       "129                                       NaN                     NaN   \n",
       "130                                       NaN                     NaN   \n",
       "131                                       NaN                     NaN   \n",
       "132                                       NaN                     NaN   \n",
       "133                                       NaN                     NaN   \n",
       "134                                       NaN                     NaN   \n",
       "135                                       NaN                     NaN   \n",
       "136                                       NaN                     NaN   \n",
       "137                                       NaN                     NaN   \n",
       "138                                       NaN                     NaN   \n",
       "139                                       NaN                     NaN   \n",
       "140                                       NaN                     NaN   \n",
       "141                                       NaN                     NaN   \n",
       "142                                       NaN                     NaN   \n",
       "143                                       NaN                     NaN   \n",
       "144                                       NaN                     NaN   \n",
       "145                                   Elderly                     NaN   \n",
       "146                                       NaN                     NaN   \n",
       "147                                       NaN                     NaN   \n",
       "148                                       NaN                     NaN   \n",
       "149                                       NaN                     NaN   \n",
       "150                                       NaN                     NaN   \n",
       "151                                       NaN                     NaN   \n",
       "152                                       NaN                     NaN   \n",
       "153                                       NaN                     NaN   \n",
       "154                                       NaN                     NaN   \n",
       "155            Adolescents, Children, Elderly              Ophthalmic   \n",
       "156                                       NaN                     NaN   \n",
       "157                                       NaN                     NaN   \n",
       "158                                       NaN                     NaN   \n",
       "159                                       NaN                     NaN   \n",
       "160                                       NaN                     NaN   \n",
       "161                                       NaN                     NaN   \n",
       "162                                       NaN                     NaN   \n",
       "163                                  Neonates                     NaN   \n",
       "164                                  Neonates                     NaN   \n",
       "165                                       NaN                     NaN   \n",
       "166                                       NaN                     NaN   \n",
       "167                                       NaN                     NaN   \n",
       "168                                       NaN                     NaN   \n",
       "169                                   Elderly                     NaN   \n",
       "170                                       NaN                     NaN   \n",
       "171                                       NaN                     NaN   \n",
       "172                                   Elderly                     NaN   \n",
       "173                                       NaN                     NaN   \n",
       "174                                       NaN                     NaN   \n",
       "175                                       NaN                     NaN   \n",
       "176                                       NaN                     NaN   \n",
       "177                                       NaN                     NaN   \n",
       "178                                       NaN                     NaN   \n",
       "179                                       NaN                     NaN   \n",
       "180                                       NaN                     NaN   \n",
       "181                                       NaN                     NaN   \n",
       "182                                       NaN                     NaN   \n",
       "183                                       NaN                     NaN   \n",
       "184                                       NaN                     NaN   \n",
       "185                                       NaN                     NaN   \n",
       "186                                       NaN                     NaN   \n",
       "187                                       NaN                     NaN   \n",
       "188                                       NaN                     NaN   \n",
       "189                                       NaN                     NaN   \n",
       "190                                       NaN                     NaN   \n",
       "191                                       NaN                     NaN   \n",
       "192                                       NaN                     NaN   \n",
       "193                                       NaN                     NaN   \n",
       "194                                       NaN                     NaN   \n",
       "195                                       NaN                     NaN   \n",
       "196                                       NaN                     NaN   \n",
       "197                                       NaN                     NaN   \n",
       "198                                       NaN                     NaN   \n",
       "199                                       NaN                     NaN   \n",
       "200                                       NaN                     NaN   \n",
       "201                                       NaN                     NaN   \n",
       "202                                       NaN                     NaN   \n",
       "203                                       NaN                     NaN   \n",
       "204                                       NaN                     NaN   \n",
       "205                                       NaN                     NaN   \n",
       "206                                       NaN                     NaN   \n",
       "207                                       NaN                     NaN   \n",
       "208                                       NaN                     NaN   \n",
       "209                                       NaN                     NaN   \n",
       "210                                       NaN                     NaN   \n",
       "211                                       NaN                     NaN   \n",
       "212                                       NaN                     NaN   \n",
       "213                                       NaN                     NaN   \n",
       "214                                       NaN                     NaN   \n",
       "215                                       NaN                     NaN   \n",
       "216                                       NaN                     NaN   \n",
       "217                                       NaN                     NaN   \n",
       "218                                       NaN                     NaN   \n",
       "219                                       NaN                     NaN   \n",
       "220                                       NaN                     NaN   \n",
       "221                                       NaN                     NaN   \n",
       "222                                       NaN                     NaN   \n",
       "223                                       NaN                     NaN   \n",
       "224                                       NaN                     NaN   \n",
       "225                                       NaN                     NaN   \n",
       "226                                       NaN                     NaN   \n",
       "227                                       NaN                     NaN   \n",
       "228                                   Elderly                     NaN   \n",
       "229                                       NaN                     NaN   \n",
       "230                                   Elderly                     NaN   \n",
       "231                                       NaN                     NaN   \n",
       "232                                   Elderly                     NaN   \n",
       "233                                       NaN                     NaN   \n",
       "234                                       NaN                     NaN   \n",
       "235                                       NaN                     NaN   \n",
       "236                                       NaN                     NaN   \n",
       "237                                       NaN                     NaN   \n",
       "238                                       NaN                     NaN   \n",
       "239                                       NaN                     NaN   \n",
       "240                                       NaN                     NaN   \n",
       "\n",
       "    Treatment Special Situation  \\\n",
       "0         NaN               NaN   \n",
       "1         NaN               NaN   \n",
       "2         NaN               NaN   \n",
       "3         NaN               NaN   \n",
       "4         NaN               NaN   \n",
       "5         NaN               NaN   \n",
       "6         NaN               NaN   \n",
       "7         NaN               NaN   \n",
       "8         NaN               NaN   \n",
       "9         NaN               NaN   \n",
       "10        NaN               NaN   \n",
       "11        NaN               NaN   \n",
       "12        NaN               NaN   \n",
       "13        NaN               NaN   \n",
       "14        NaN               NaN   \n",
       "15        NaN               NaN   \n",
       "16        NaN               NaN   \n",
       "17        NaN               NaN   \n",
       "18        NaN               NaN   \n",
       "19        NaN               NaN   \n",
       "20        NaN               NaN   \n",
       "21        NaN               NaN   \n",
       "22        NaN               NaN   \n",
       "23        NaN               NaN   \n",
       "24        NaN               NaN   \n",
       "25        NaN               NaN   \n",
       "26        NaN               NaN   \n",
       "27        NaN               NaN   \n",
       "28        NaN               NaN   \n",
       "29        NaN               NaN   \n",
       "30        NaN               NaN   \n",
       "31        NaN               NaN   \n",
       "32        NaN               NaN   \n",
       "33        NaN               NaN   \n",
       "34        NaN               NaN   \n",
       "35        NaN               NaN   \n",
       "36        NaN               NaN   \n",
       "37        NaN               NaN   \n",
       "38        NaN               NaN   \n",
       "39        NaN               NaN   \n",
       "40        NaN               NaN   \n",
       "41        NaN               NaN   \n",
       "42        NaN               NaN   \n",
       "43        NaN               NaN   \n",
       "44        NaN               NaN   \n",
       "45        NaN               NaN   \n",
       "46        NaN               NaN   \n",
       "47        NaN               NaN   \n",
       "48        NaN               NaN   \n",
       "49        NaN               NaN   \n",
       "50        NaN               NaN   \n",
       "51        NaN               NaN   \n",
       "52        NaN               NaN   \n",
       "53        NaN               NaN   \n",
       "54        NaN               NaN   \n",
       "55        NaN               NaN   \n",
       "56        NaN               NaN   \n",
       "57        NaN               NaN   \n",
       "58        NaN               NaN   \n",
       "59        NaN               NaN   \n",
       "60        NaN               NaN   \n",
       "61        NaN               NaN   \n",
       "62        NaN               NaN   \n",
       "63        NaN               NaN   \n",
       "64        NaN               NaN   \n",
       "65        NaN               NaN   \n",
       "66        NaN               NaN   \n",
       "67        NaN               NaN   \n",
       "68        NaN               NaN   \n",
       "69        NaN               NaN   \n",
       "70        NaN               NaN   \n",
       "71        NaN               NaN   \n",
       "72        NaN               NaN   \n",
       "73        NaN               NaN   \n",
       "74        NaN               NaN   \n",
       "75        NaN               NaN   \n",
       "76        NaN               NaN   \n",
       "77        NaN               NaN   \n",
       "78        NaN               NaN   \n",
       "79        NaN               NaN   \n",
       "80        NaN               NaN   \n",
       "81        NaN               NaN   \n",
       "82        NaN               NaN   \n",
       "83        NaN               NaN   \n",
       "84        NaN               NaN   \n",
       "85        NaN               NaN   \n",
       "86        NaN               NaN   \n",
       "87        NaN               NaN   \n",
       "88        NaN               NaN   \n",
       "89        NaN               NaN   \n",
       "90        NaN               NaN   \n",
       "91        NaN               NaN   \n",
       "92        NaN               NaN   \n",
       "93        NaN               NaN   \n",
       "94        NaN               NaN   \n",
       "95        NaN               NaN   \n",
       "96        NaN               NaN   \n",
       "97        NaN               NaN   \n",
       "98        NaN               NaN   \n",
       "99        NaN               NaN   \n",
       "100       NaN               NaN   \n",
       "101       NaN               NaN   \n",
       "102       NaN               NaN   \n",
       "103       NaN               NaN   \n",
       "104       NaN               NaN   \n",
       "105       NaN               NaN   \n",
       "106       NaN               NaN   \n",
       "107       NaN               NaN   \n",
       "108       NaN               NaN   \n",
       "109       NaN               NaN   \n",
       "110       NaN               NaN   \n",
       "111       NaN               NaN   \n",
       "112       NaN               NaN   \n",
       "113       NaN               NaN   \n",
       "114       NaN               NaN   \n",
       "115       NaN               NaN   \n",
       "116       NaN               NaN   \n",
       "117       NaN               NaN   \n",
       "118       NaN               NaN   \n",
       "119       NaN               NaN   \n",
       "120       NaN               NaN   \n",
       "121       NaN               NaN   \n",
       "122       NaN               NaN   \n",
       "123       NaN               NaN   \n",
       "124       NaN               NaN   \n",
       "125       NaN               NaN   \n",
       "126       NaN               NaN   \n",
       "127       NaN               NaN   \n",
       "128       NaN               NaN   \n",
       "129       NaN               NaN   \n",
       "130       NaN               NaN   \n",
       "131       NaN               NaN   \n",
       "132       NaN               NaN   \n",
       "133       NaN               NaN   \n",
       "134       NaN               NaN   \n",
       "135       NaN               NaN   \n",
       "136       NaN               NaN   \n",
       "137       NaN               NaN   \n",
       "138       NaN               NaN   \n",
       "139       NaN               NaN   \n",
       "140       NaN               NaN   \n",
       "141       NaN               NaN   \n",
       "142       NaN               NaN   \n",
       "143       NaN               NaN   \n",
       "144       NaN               NaN   \n",
       "145       NaN               NaN   \n",
       "146       NaN               NaN   \n",
       "147       NaN               NaN   \n",
       "148       NaN               NaN   \n",
       "149       NaN               NaN   \n",
       "150       NaN               NaN   \n",
       "151       NaN               NaN   \n",
       "152       NaN               NaN   \n",
       "153       NaN               NaN   \n",
       "154       NaN               NaN   \n",
       "155       NaN               NaN   \n",
       "156       NaN               NaN   \n",
       "157       NaN               NaN   \n",
       "158       NaN               NaN   \n",
       "159       NaN               NaN   \n",
       "160       NaN               NaN   \n",
       "161       NaN               NaN   \n",
       "162       NaN               NaN   \n",
       "163       NaN               NaN   \n",
       "164       NaN               NaN   \n",
       "165       NaN               NaN   \n",
       "166       NaN               NaN   \n",
       "167       NaN               NaN   \n",
       "168       NaN               NaN   \n",
       "169       NaN               NaN   \n",
       "170       NaN               NaN   \n",
       "171       NaN               NaN   \n",
       "172       NaN               NaN   \n",
       "173       NaN               NaN   \n",
       "174       NaN               NaN   \n",
       "175       NaN               NaN   \n",
       "176       NaN               NaN   \n",
       "177       NaN               NaN   \n",
       "178       NaN               NaN   \n",
       "179       NaN               NaN   \n",
       "180       NaN               NaN   \n",
       "181       NaN               NaN   \n",
       "182       NaN               NaN   \n",
       "183       NaN               NaN   \n",
       "184       NaN               NaN   \n",
       "185       NaN               NaN   \n",
       "186       NaN               NaN   \n",
       "187       NaN               NaN   \n",
       "188       NaN               NaN   \n",
       "189       NaN               NaN   \n",
       "190       NaN               NaN   \n",
       "191       NaN               NaN   \n",
       "192       NaN               NaN   \n",
       "193       NaN               NaN   \n",
       "194       NaN               NaN   \n",
       "195       NaN               NaN   \n",
       "196       NaN               NaN   \n",
       "197       NaN               NaN   \n",
       "198       NaN               NaN   \n",
       "199       NaN               NaN   \n",
       "200       NaN               NaN   \n",
       "201       NaN               NaN   \n",
       "202       NaN               NaN   \n",
       "203       NaN               NaN   \n",
       "204       NaN               NaN   \n",
       "205       NaN               NaN   \n",
       "206       NaN               NaN   \n",
       "207       NaN               NaN   \n",
       "208       NaN               NaN   \n",
       "209       NaN               NaN   \n",
       "210       NaN               NaN   \n",
       "211       NaN               NaN   \n",
       "212       NaN               NaN   \n",
       "213       NaN               NaN   \n",
       "214       NaN               NaN   \n",
       "215       NaN               NaN   \n",
       "216       NaN               NaN   \n",
       "217       NaN               NaN   \n",
       "218       NaN               NaN   \n",
       "219       NaN               NaN   \n",
       "220       NaN               NaN   \n",
       "221       NaN               NaN   \n",
       "222       NaN               NaN   \n",
       "223       NaN               NaN   \n",
       "224       NaN               NaN   \n",
       "225       NaN               NaN   \n",
       "226       NaN               NaN   \n",
       "227       NaN               NaN   \n",
       "228       NaN               NaN   \n",
       "229       NaN               NaN   \n",
       "230       NaN               NaN   \n",
       "231       NaN               NaN   \n",
       "232       NaN               NaN   \n",
       "233       NaN               NaN   \n",
       "234       NaN               NaN   \n",
       "235       NaN               NaN   \n",
       "236       NaN               NaN   \n",
       "237       NaN               NaN   \n",
       "238       NaN               NaN   \n",
       "239       NaN               NaN   \n",
       "240       NaN               NaN   \n",
       "\n",
       "                                            References  \\\n",
       "0    1. Varghese V, Rodriguez R, Self S, Velez JCQ....   \n",
       "1    1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...   \n",
       "2    1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...   \n",
       "3    1. Ho S, Wong JG, Ng OT, Lee CC, Leo YS, Lye D...   \n",
       "4    1. Israel S, Elinav H, Elazary R, Porat D, Gib...   \n",
       "5    1. Tyler S, Sivaraj V, Kulasegaram R. Central ...   \n",
       "6    1. Joury A, Alshehri M, Mahendra A, Anteet M, ...   \n",
       "7    1. Badell ML, Sheth AN, Momplaisir F, Rahangda...   \n",
       "8    1. Melzani A, De Reynal De Saint Michel R, Nta...   \n",
       "9    1. Senechal I, Chateauvert N, Gervais P, Voisi...   \n",
       "10   1. Mandimika C, Ogbuagu O. Successful sofosbuv...   \n",
       "11   1. Favarel-Garrigues M, Hentzien M, Berger J-L...   \n",
       "12   1. Brunel V, Massy N, Malval B. Atazanavir uro...   \n",
       "13   1. Sudjaritruk T, Bunupuradah T, Aurpibul L, K...   \n",
       "14   1. Kramer ME, Holtan EE, Ives AL, Wall RT. Per...   \n",
       "15   1. Tsapepas DS, Webber AB, Aull MJ, Figueiro J...   \n",
       "16   1. Chen GJ, Sun HY, Chang SY, Cheng A, Huang Y...   \n",
       "17   1. Ishida H, Ishihara A, Tanaka S, Iwasaki T, ...   \n",
       "18   1. Filho ENS, Young EC, De Almeida Pinto Borge...   \n",
       "19   1. Cardoso M, Baptista T, Diogo I, Aleixo MJ, ...   \n",
       "20   1. Do Vale DA, Ferracini LMA, Da Silva Rodrigu...   \n",
       "21   1. Castagna A, Rusconi S, Gulminetti R, Bonora...   \n",
       "22   1. Castagna A, Rusconi S, Gulminetti R, Bonora...   \n",
       "23   1. van De Ven NS, Pozniak AL, Levi JA, Clayden...   \n",
       "24   1. Money D, Lee T, O'Brien C, Brophy J, Bitnun...   \n",
       "25   1. Vannappagari V, Thorne C. Pregnancy and Neo...   \n",
       "26   1. Castain L, Perrier M, Charpentier C, Palich...   \n",
       "27   1. Zhao AM, Angoff NR. Renal stone composed of...   \n",
       "28   1. Jimenez HR, Natali KM, Zahran AAR. Drug int...   \n",
       "29   1. Manesh A, Barnabas R, Mani S, Karthik R, Ab...   \n",
       "30   1. Badowski M, Kassem S, Taylor C, Mckamey L, ...   \n",
       "31   1. Buijs BS, Van Den Berk GE, Boateng CP, Hoep...   \n",
       "32   1. Ssebambulidde K, Segawa I, Laker E, Lamorde...   \n",
       "33   1. Sampson MR, Cao KY, Gish PL, Hyon K, Mishra...   \n",
       "34   1. Stewart A, Sowden D, Caffery M, Bint M, Bro...   \n",
       "35   1. Irungu K. Severe skin rash associated with ...   \n",
       "36   1. Whiskey E, O'Flynn D, Taylor D. Clozapine, ...   \n",
       "37   1. Grant MT, Eisner BH, Bechis SK. Ureteral Ob...   \n",
       "38   1. Grude M, Chaix ML, Marcelin AG, Flandre P, ...   \n",
       "39   1. Garrido PM, Borges-Costa J. Eruptive melano...   \n",
       "40   1. Chu GJ, Henderson C, Evans L, Howlin K, Mur...   \n",
       "41   1. Onoya D, Hirasen K, van den Berg L, Miot J,...   \n",
       "42   1. Kuten SA, Patel SJ, Baru A, Gaber AO, Crutc...   \n",
       "43   1. Rough K, Seage GR 3rd, Williams PL, Hernand...   \n",
       "44   1. European Pregnancy and Paediatric HIV Cohor...   \n",
       "45   1. Hara M, Momoki K, Ubukata M, Ohta A, Tonook...   \n",
       "46   1. Medland NA, Chow EPF, Walker RG, Chen M, Re...   \n",
       "47   1. Douros A, Bronder E, Klimpel A, Erley C, Ga...   \n",
       "48   1. Widera M, Dirks M, Bleekmann B, Jablonka R,...   \n",
       "49   1. Hleyhel M, Goujon S, Delteil C, Vasiljevic ...   \n",
       "50   1. Bunupuradah T, Phupitakphol T, Sophonphan J...   \n",
       "51   1. LaFleur J, Bress AP, Esker S, Knippenberg K...   \n",
       "52   1. Santoriello D, Al-Nabulsi M, Reddy A, Salam...   \n",
       "53   1. Vavassori A, Lanza P, Izzo I, Casari S, Odo...   \n",
       "54   1. Ziegelmann M, Carrasco A, Knoedler J, Kramb...   \n",
       "55   1. El Bouzidi K, Collier D, Nastouli E, Copas ...   \n",
       "56   1. Cordova E, Morganti L, Odzak A, Arcondo F, ...   \n",
       "57   1. Cifuentes M D, Blanco L S, Ramirez F C. [Er...   \n",
       "58   1. Pereira M, Guerra I. Clinical case: Acute p...   \n",
       "59   1. Health Canada. Evotaz (atazanavir and cobic...   \n",
       "60   1. Amrutha PC, Rakesh TP, Kidangazhiyathmana A...   \n",
       "61   1. Haroon N, Singh A, Bhat ZY. Tacrolimus toxi...   \n",
       "62   1. Howlett P, Simons R, Wilkinson M, Kulasegar...   \n",
       "63   1. McCarty E, Todd S. Complexities of establis...   \n",
       "64   1. Bianchi C, Levesque K, Boucher M, Ferreira ...   \n",
       "65   1. Ostberg L, Hojer J. Acute tenofovir overdos...   \n",
       "66   1. Gupta NK, Nolan A, Omuro A, Reid EG, Wang C...   \n",
       "67   1. Elliot ER, Theodoraki A, Jain LR, Marshall ...   \n",
       "68   1. Griffith DC, Aronis KN, Orozco AM, Traill T...   \n",
       "69   1. Llibre JM, Cozzi-Lepri A, Pedersen C, Risto...   \n",
       "70   1. Pereira NMD, Shah I, Kulkarni S. Opsoclonus...   \n",
       "71   1. Naccarato M, Hall E, Wai A, Ostrowski M, Ca...   \n",
       "72   1. Vallet A, Noel N, Bahi R, Teicher E, Querta...   \n",
       "73   1. Marinaro L, Calcagno A, Ripamonti D, Cender...   \n",
       "74   1. Bharti S, Malhotra P, Hirsch B. Acute inter...   \n",
       "75   1. Austria AM, Lynch SM. Disseminated MAC: Bro...   \n",
       "76   1. Lazenby GB, Mmeje O, Fisher BM, Weinberg A,...   \n",
       "77   1. Lepelletier C, Salmona M, Bercot B, Maylin ...   \n",
       "78   1. Noma Y, Tambo M, Kitamura J, Okegawa T, Nut...   \n",
       "79   1. Jose SK, Marfatia YS. Erythema elevatum diu...   \n",
       "80   1. Gervasoni C, Cattaneo D, Di Cristo V, Casto...   \n",
       "81   1. Cattaneo D, Riva A, Clementi E, Milazzo L, ...   \n",
       "82   1. Stephens JR, Coward RM, Viprakasit DP. Prot...   \n",
       "83   1. Crequit P, Ruppert A-M, Rozensztajn N, Goun...   \n",
       "84   1. Romero-Leon JM, Galvez-Contreras MC, Diez-G...   \n",
       "85   1. Sahni H, Kirti K, Palshetkar R. Right flank...   \n",
       "86   1. Jin S, Kim MH, Park JH, Jung HJ, Lee HJ, Ki...   \n",
       "87   1. Lee MW, Izzy M, Kalia H. Nodular regenerati...   \n",
       "88   1. Vishnu P, Dorer RP, Aboulafia DM. Immune Re...   \n",
       "89   1. Brahmachari U, Saha S, Guchhait B, Guha SK....   \n",
       "90   1. Le MP, Mandelbrot L, Descamps D, Soulie C, ...   \n",
       "91   1. Latini A, Colafigli M, Dona MG, Frasca M, A...   \n",
       "92   1. D'Erme AM, Severino M, Tiradritti L, Tchoi ...   \n",
       "93   1. Gervasoni C, Cattaneo D, Micheli V, Cristo ...   \n",
       "94   1. Declet VR, Salas AS. Knee avascular necrosi...   \n",
       "95   1. Arumainayagam N, Gresty H, Shamsuddin A, Ga...   \n",
       "96   1. Sethupathi M, Yoganathan K. Late onset of c...   \n",
       "97   1. Hara M, Suganuma A, Yanagisawa N, Imamura A...   \n",
       "98   1. Gantner P, Koeppel C, Partisani M, Batard M...   \n",
       "99   1. Amendezo E, Kambutse I, Maniraguha Y, Habim...   \n",
       "100  1. Pasin VP, Pereira AR, de Carvalho KA, de Pa...   \n",
       "101  1. Samuel M, Bradshaw D, Perry M, Chan SY, Dha...   \n",
       "102  1. Himes SK, Huo Y, Siberry GK, Williams PL, R...   \n",
       "103  1. Uldrick TS, Little RF. How I treat classica...   \n",
       "104  1. Inagaki I, Adachi M, Ito H, Yasuda M, Tsuru...   \n",
       "105  1. Dutta N, De R, Pain S, Modak D, Guha SK. A ...   \n",
       "106  1. Hyle EP, Wood BR, Backman ES, Noubary F, Hw...   \n",
       "107  1. Papp E, Mohammadi H, Loutfy MR, Yudin MH, M...   \n",
       "108  1. Almeida Ferreira M, Carvalho AC, Silva SV, ...   \n",
       "109  1. Atrio JM, Sperling RS, Posada R, Rodriguez ...   \n",
       "110  1. Dutta N, De R, Mukherjee P, Bhowmik A, Modo...   \n",
       "111  1. Naccarato M, Yoong D, La Porte C, Fong I. A...   \n",
       "112  1. Lanzafame M, Bonora S, Lattuada E, Calcagno...   \n",
       "113  1. Avihingsanon A, Ramautarsing RA, Suwanpimol...   \n",
       "114  1. Burger DM, Arends JE, Jacobs BS, Van Elst-L...   \n",
       "115  1. den Eynde EV, Ferrer E, Podzamczer D. Acute...   \n",
       "116  1. Atazanavir: Atrial fibrillation: case repor...   \n",
       "117  1. Mancuso A, Zavaglia C, Bai F, Puoti M, Bell...   \n",
       "118  1. Foisy MM, Hughes C, Hills-Nieminen C, Singh...   \n",
       "119  1. Finn BC, Vadala S, Meraldi A, Bruetman JE, ...   \n",
       "120  1. Cenderello G, Pontali E, Cassola G, Torresi...   \n",
       "121  1. Wang LC, Osterberg EC, David SG, Rosoff JS....   \n",
       "122  1. Tseng AL, La Porte C, Salit IE. Significant...   \n",
       "123  1. Raltegravir: First report of DRESS syndrome...   \n",
       "124  1. Shameem R, Sonpal N, Alemu B, Ahmadi L. Gil...   \n",
       "125  1. Ahmed I, Gandrabura T. Visual vignette. End...   \n",
       "126  1. Ferretti F, Gerevini S, Colombo B, Testa M,...   \n",
       "127  1. Kunimoto Y, Yasui H, Touda N, Okazaki M, Na...   \n",
       "128  1. Coralic Z, Lenhoff T, Kanzaria HK, Gerona R...   \n",
       "129  1. Bradbeer C, Ngwenya S, Baker P, George M. A...   \n",
       "130  1. Duncan A, Mills J. An unusual case of HIV v...   \n",
       "131  1. Uchino K, Tateishi R, Nakagawa H, Shindoh J...   \n",
       "132  1. Santimaleeworagun W, Pattharachayakul S, Ch...   \n",
       "133  1. Phillips M, Saxon C, Lee V. Atazanavir and ...   \n",
       "134  1. Le MP, Stitou H, Soulie C, Katlama C, Peyta...   \n",
       "135  1. Johnston SS, Juday T, Esker S, Espindle D, ...   \n",
       "136  1. Filho FB, Santos MVPQ, De Matos Pinto de Ca...   \n",
       "137  1. Billings F, Hoyt MR. Epidural lipomatosis c...   \n",
       "138  1. Yoshida M, Hoshina T, Tamura K, Kawano S, K...   \n",
       "139  1. Kanzaki G, Tsuboi N, Miyazaki Y, Yokoo T, U...   \n",
       "140  1. Canalejo Castrillero E, Pacheco MS. Cushing...   \n",
       "141  1. Munchhoff M, Bogner J. Case report: Painful...   \n",
       "142  1. Beh Y, Allan S. HIV, Highly Active Antiretr...   \n",
       "143  1. Eyer-Silva WA, Salgado MCF, Pinto JFC, Ferr...   \n",
       "144  1. Kaestner F, Anneken K, Mostert C, Reichelt ...   \n",
       "145  1. Coelho S, Aparicio SR, Manso R, Soto K. Qui...   \n",
       "146  1. Stover KR, Molitorisz S, Swiatlo E, Muzny C...   \n",
       "147  1. Rouanet I, Jantac M, Lechiche C, Hope-Rapp ...   \n",
       "148  1. del Palacio Tamarit M, Quereda C, Gonzalez-...   \n",
       "149  1. Courbon E, Laylavoix F, Soulie C, Le beller...   \n",
       "150  1. Cattaneo D, Meraviglia P, Cozzi V, Baldelli...   \n",
       "151  1. Boceprevir plus HIV protease inhibitor use ...   \n",
       "152  1. East J, Blanton LS. Symptomatic hyperbiliru...   \n",
       "153  1. Testi S, Severino M, D''Erme A, Gola M, Ior...   \n",
       "154  1. Javelle E, Oliver M, Savini H, Aubry C, Bad...   \n",
       "155  1. Rouve N, Bagheri H, Telmon N, Pathak A, Fra...   \n",
       "156  1. Koblic PM, Gold WL, La Porte CJL, Lee TC. M...   \n",
       "157  1. Gnanaraj J, Fiedler P, Virata M. Vanishing ...   \n",
       "158  1. Cousins D, Topping K, Lee V, Sweeney J, Law...   \n",
       "159  1. Hung W-L, Lin Y-H, Wang P-Y, Chang M-H. HIV...   \n",
       "160  1. Bruno CB, Schapiro JM, Saberi P. An increas...   \n",
       "161  1. Levine D, Ananthakrishnan S, Garg A. Iatrog...   \n",
       "162  1. Bourkia M, Charles L, Lambotte O, Orostegui...   \n",
       "163  1. Drake A, Roxby A, Kiarie J, John-Stewart G,...   \n",
       "164  1. Mandelbrot L, Mazy F, Floch-Tudal C, Meier ...   \n",
       "165  1. Welzen MEB, Van Den Berk GEL, Hamers RL, Bu...   \n",
       "166  1. Dabiesingh DS, Psevdos G, Sharp VL. Atazana...   \n",
       "167  1. Ozenne V, Gervais A, Peytavin G, Castelnau ...   \n",
       "168  1. Fabbiani M, Bracciale L, Doino M, D'Avino A...   \n",
       "169  1. Eiden C, Peyriere H, Peytavin G, Reynes J. ...   \n",
       "170  1. Ceccarelli G, D'Ettorre G, Marchetti F, Riz...   \n",
       "171  1. Viglietti D, Verine J, De Castro N, Scemla ...   \n",
       "172  1. Pastori D, Esposito A, Cagliuso M, Conti V,...   \n",
       "173  1. de Saint-Martin L, Bressollette L, Perfezou...   \n",
       "174  1. de Jong E, Haverkort ME, Heine Rt, Jansen R...   \n",
       "175  1. Anderson AM, Mosunjac MB, Palmore MP, Osbor...   \n",
       "176  1. Sonder GJ, Prins JM, Regez RM, Brinkman K, ...   \n",
       "177  1. Hantson P, Di Fazio V, Wallemacq P. Toxicok...   \n",
       "178  1. Sidhu N, McCutchan JA. Unmasking of PML by ...   \n",
       "179  1. Vispo E, Mena A, Maida I, Blanco F, Cordoba...   \n",
       "180  1. Mass MK. CNS Immune Reconstitution Inflamma...   \n",
       "181  1. Jacques AC, Giguere P, Zhang G, Touchie C, ...   \n",
       "182  1. Uglietti A, Novati S, Gulminetti R, Maserat...   \n",
       "183  1. Kirk O, Mocroft A, Reiss P, De Wit S, Sedla...   \n",
       "184  1. Elzi L, Marzolini C, Furrer H, Ledergerber ...   \n",
       "185  1. Cervero M, Navas E, Agud JL, Garcia-Benaya ...   \n",
       "186  1. Jagannathan P, Davis E, Jacobson M, Huang L...   \n",
       "187  1. Pollack TM, McCoy C, Stead W. Clinically si...   \n",
       "188  1. Huber M, Beatrice J, BRUNNER A, Muller N. A...   \n",
       "189  1. Collet-Gaudillat C, Roussin-Bretagne S, Des...   \n",
       "190  1. Tisch S, Brew B. Parkinsonism in HIV-infect...   \n",
       "191  1. Antiretrovirals: Chronic progressive extern...   \n",
       "192  1. Krishna G, Moton A, Ma L, Martinho M, Seibe...   \n",
       "193  1. Adler RS, D'Aquilante DA, Kovarik CL. Antir...   \n",
       "194  1. Walkty A, Smith D, Lopko B, Kasper K. Sever...   \n",
       "195  1. Valencia ME, Moreno V. Atazanavir-induced n...   \n",
       "196  1. McCombe JA, Auer RN, Maingat FG, Houston S,...   \n",
       "197  1. Conejo MM, Cuerda VJM, Martinez JA, Rubio R...   \n",
       "198  1. Galera RML, Pascuet ER, Mur JIE, Ronsano JB...   \n",
       "199  1. Akhtar MA, Mathieson K, Arey B, Post J, Pre...   \n",
       "200  1. Rogers JS, Zakaria S, Thom KA, Flammer KM, ...   \n",
       "201  1. Fleischbein E, O'Brien J, Martelino R, Fens...   \n",
       "202  1. Moriyama Y, Minamidate Y, Yasuda M, Ehara H...   \n",
       "203  1. Young B, Squires K, Patel P, Dejesus E, Bel...   \n",
       "204  1. Fuller J. A 39-year-old man with HIV-associ...   \n",
       "205  1. Moyle G, Girard J-M, Andrade J, Salvato P, ...   \n",
       "206  1. Scott C, Staughton RCD, Bunker CJ, Asboe D....   \n",
       "207  1. Prendki V, Dumas J-L, Bouges-Michel C, Boch...   \n",
       "208  1. Vallecillo-Sanchez G, Guelar-Grimberg A, Go...   \n",
       "209  1. D'Ettorre G, Zaffiri L, Ceccarelli G, Masse...   \n",
       "210  1. Nichols WG, Steel HM, Bonny T, Adkison K, C...   \n",
       "211  1. Falconer M, Molloy D, Ingerhaug J, Barry M....   \n",
       "212  1. Moreno A, Barcena R, Quereda C, Casado JL, ...   \n",
       "213  1. Goicoechea M, Liu S, Best B, Sun S, Jain S,...   \n",
       "214  1. Izzedine H, Ben M'rad M, Bardier A, Daudon ...   \n",
       "215  1. Paparizos VA, Kourkounti S, Leuow K, Kyriak...   \n",
       "216  1. Toro C, Blanco F, Garcia-Gasco P, Sheldon J...   \n",
       "217  1. Couzigou C, Daudon M, Meynard JL, Borsa-Leb...   \n",
       "218  1. Kummer O, Mossdorf E, Battegay M, Elzi L, B...   \n",
       "219  1. Schmid S, Opravil M, Moddel M, Huber M, Pfa...   \n",
       "220  1. Xhani D, Hage CA, Knox KS. A 30-year-old ma...   \n",
       "221  1. Torres HA, Barnett BJ, Arduino RC. Alopecia...   \n",
       "222  1. Anderson PL, Lichtenstein KA, Gerig NE, Kis...   \n",
       "223  1. Ly T, Ruiz ME. Prolonged QT interval and to...   \n",
       "224  1. PACANOWSKI J, Poirier J-M, Petit I, Meynard...   \n",
       "225  1. Chang HR, Pella PM. Atazanavir urolithiasis...   \n",
       "226  1. Fulco PP, Vora UB, Bearman GML. Acid suppre...   \n",
       "227  1. Ingiliz P, Appenrodt B, Gruenhage F, Vogel ...   \n",
       "228  1. Dellamonica P. Can boosted atazanavir induc...   \n",
       "229  1. Ouagari Z, Tubiana R, Mohand HA, Dominguez ...   \n",
       "230  1. Kiser JJ, Lichtenstein KA, Anderson PL, Fle...   \n",
       "231  1. Bruce RD, Altice FL. Three case reports of ...   \n",
       "232  1. Zimmermann AE, Pizzoferrato T, Bedford J, M...   \n",
       "233  1. Trower K, Wilmot R, Barlow G, Thaker H. A c...   \n",
       "234  1. Breuckmann F, Neumann T, Kondratieva J, Wie...   \n",
       "235  1. Khanlou H, FARTHING C. Co-administration of...   \n",
       "236  1. Bristol-Myers Squibb Company. REYATAZ (Rm) ...   \n",
       "237  1. Eholie SP, Lacombe K, Serfaty L, Wendum D, ...   \n",
       "238  1. Meeting of the Committee for Proprietary Me...   \n",
       "239  1. US Food and Drug Administration. Re: import...   \n",
       "240  1. Pantaleo G, Sanne I, Cahn P, Percival L, Ph...   \n",
       "\n",
       "                                                   URL  \n",
       "0    https://adisinsight.springer.com/drugsafety/80...  \n",
       "1    https://adisinsight.springer.com/drugsafety/80...  \n",
       "2    https://adisinsight.springer.com/drugsafety/80...  \n",
       "3    https://adisinsight.springer.com/drugsafety/80...  \n",
       "4    https://adisinsight.springer.com/drugsafety/80...  \n",
       "5    https://adisinsight.springer.com/drugsafety/80...  \n",
       "6    https://adisinsight.springer.com/drugsafety/80...  \n",
       "7    https://adisinsight.springer.com/drugsafety/80...  \n",
       "8    https://adisinsight.springer.com/drugsafety/80...  \n",
       "9    https://adisinsight.springer.com/drugsafety/80...  \n",
       "10   https://adisinsight.springer.com/drugsafety/80...  \n",
       "11   https://adisinsight.springer.com/drugsafety/80...  \n",
       "12   https://adisinsight.springer.com/drugsafety/80...  \n",
       "13   https://adisinsight.springer.com/drugsafety/80...  \n",
       "14   https://adisinsight.springer.com/drugsafety/80...  \n",
       "15   https://adisinsight.springer.com/drugsafety/80...  \n",
       "16   https://adisinsight.springer.com/drugsafety/80...  \n",
       "17   https://adisinsight.springer.com/drugsafety/80...  \n",
       "18   https://adisinsight.springer.com/drugsafety/80...  \n",
       "19   https://adisinsight.springer.com/drugsafety/80...  \n",
       "20   https://adisinsight.springer.com/drugsafety/80...  \n",
       "21   https://adisinsight.springer.com/drugsafety/80...  \n",
       "22   https://adisinsight.springer.com/drugsafety/80...  \n",
       "23   https://adisinsight.springer.com/drugsafety/80...  \n",
       "24   https://adisinsight.springer.com/drugsafety/80...  \n",
       "25   https://adisinsight.springer.com/drugsafety/80...  \n",
       "26   https://adisinsight.springer.com/drugsafety/80...  \n",
       "27   https://adisinsight.springer.com/drugsafety/80...  \n",
       "28   https://adisinsight.springer.com/drugsafety/80...  \n",
       "29   https://adisinsight.springer.com/drugsafety/80...  \n",
       "30   https://adisinsight.springer.com/drugsafety/80...  \n",
       "31   https://adisinsight.springer.com/drugsafety/80...  \n",
       "32   https://adisinsight.springer.com/drugsafety/80...  \n",
       "33   https://adisinsight.springer.com/drugsafety/80...  \n",
       "34   https://adisinsight.springer.com/drugsafety/80...  \n",
       "35   https://adisinsight.springer.com/drugsafety/80...  \n",
       "36   https://adisinsight.springer.com/drugsafety/80...  \n",
       "37   https://adisinsight.springer.com/drugsafety/80...  \n",
       "38   https://adisinsight.springer.com/drugsafety/80...  \n",
       "39   https://adisinsight.springer.com/drugsafety/80...  \n",
       "40   https://adisinsight.springer.com/drugsafety/80...  \n",
       "41   https://adisinsight.springer.com/drugsafety/80...  \n",
       "42   https://adisinsight.springer.com/drugsafety/80...  \n",
       "43   https://adisinsight.springer.com/drugsafety/80...  \n",
       "44   https://adisinsight.springer.com/drugsafety/80...  \n",
       "45   https://adisinsight.springer.com/drugsafety/80...  \n",
       "46   https://adisinsight.springer.com/drugsafety/80...  \n",
       "47   https://adisinsight.springer.com/drugsafety/80...  \n",
       "48   https://adisinsight.springer.com/drugsafety/80...  \n",
       "49   https://adisinsight.springer.com/drugsafety/80...  \n",
       "50   https://adisinsight.springer.com/drugsafety/80...  \n",
       "51   https://adisinsight.springer.com/drugsafety/80...  \n",
       "52   https://adisinsight.springer.com/drugsafety/80...  \n",
       "53   https://adisinsight.springer.com/drugsafety/80...  \n",
       "54   https://adisinsight.springer.com/drugsafety/80...  \n",
       "55   https://adisinsight.springer.com/drugsafety/80...  \n",
       "56   https://adisinsight.springer.com/drugsafety/80...  \n",
       "57   https://adisinsight.springer.com/drugsafety/80...  \n",
       "58   https://adisinsight.springer.com/drugsafety/80...  \n",
       "59   https://adisinsight.springer.com/drugsafety/80...  \n",
       "60   https://adisinsight.springer.com/drugsafety/80...  \n",
       "61   https://adisinsight.springer.com/drugsafety/80...  \n",
       "62   https://adisinsight.springer.com/drugsafety/80...  \n",
       "63   https://adisinsight.springer.com/drugsafety/80...  \n",
       "64   https://adisinsight.springer.com/drugsafety/80...  \n",
       "65   https://adisinsight.springer.com/drugsafety/80...  \n",
       "66   https://adisinsight.springer.com/drugsafety/80...  \n",
       "67   https://adisinsight.springer.com/drugsafety/80...  \n",
       "68   https://adisinsight.springer.com/drugsafety/80...  \n",
       "69   https://adisinsight.springer.com/drugsafety/80...  \n",
       "70   https://adisinsight.springer.com/drugsafety/80...  \n",
       "71   https://adisinsight.springer.com/drugsafety/80...  \n",
       "72   https://adisinsight.springer.com/drugsafety/80...  \n",
       "73   https://adisinsight.springer.com/drugsafety/80...  \n",
       "74   https://adisinsight.springer.com/drugsafety/80...  \n",
       "75   https://adisinsight.springer.com/drugsafety/80...  \n",
       "76   https://adisinsight.springer.com/drugsafety/80...  \n",
       "77   https://adisinsight.springer.com/drugsafety/80...  \n",
       "78   https://adisinsight.springer.com/drugsafety/80...  \n",
       "79   https://adisinsight.springer.com/drugsafety/80...  \n",
       "80   https://adisinsight.springer.com/drugsafety/80...  \n",
       "81   https://adisinsight.springer.com/drugsafety/80...  \n",
       "82   https://adisinsight.springer.com/drugsafety/80...  \n",
       "83   https://adisinsight.springer.com/drugsafety/80...  \n",
       "84   https://adisinsight.springer.com/drugsafety/80...  \n",
       "85   https://adisinsight.springer.com/drugsafety/80...  \n",
       "86   https://adisinsight.springer.com/drugsafety/80...  \n",
       "87   https://adisinsight.springer.com/drugsafety/80...  \n",
       "88   https://adisinsight.springer.com/drugsafety/80...  \n",
       "89   https://adisinsight.springer.com/drugsafety/80...  \n",
       "90   https://adisinsight.springer.com/drugsafety/80...  \n",
       "91   https://adisinsight.springer.com/drugsafety/80...  \n",
       "92   https://adisinsight.springer.com/drugsafety/80...  \n",
       "93   https://adisinsight.springer.com/drugsafety/80...  \n",
       "94   https://adisinsight.springer.com/drugsafety/80...  \n",
       "95   https://adisinsight.springer.com/drugsafety/80...  \n",
       "96   https://adisinsight.springer.com/drugsafety/80...  \n",
       "97   https://adisinsight.springer.com/drugsafety/80...  \n",
       "98   https://adisinsight.springer.com/drugsafety/80...  \n",
       "99   https://adisinsight.springer.com/drugsafety/80...  \n",
       "100  https://adisinsight.springer.com/drugsafety/80...  \n",
       "101  https://adisinsight.springer.com/drugsafety/80...  \n",
       "102  https://adisinsight.springer.com/drugsafety/80...  \n",
       "103  https://adisinsight.springer.com/drugsafety/80...  \n",
       "104  https://adisinsight.springer.com/drugsafety/80...  \n",
       "105  https://adisinsight.springer.com/drugsafety/80...  \n",
       "106  https://adisinsight.springer.com/drugsafety/80...  \n",
       "107  https://adisinsight.springer.com/drugsafety/80...  \n",
       "108  https://adisinsight.springer.com/drugsafety/80...  \n",
       "109  https://adisinsight.springer.com/drugsafety/80...  \n",
       "110  https://adisinsight.springer.com/drugsafety/80...  \n",
       "111  https://adisinsight.springer.com/drugsafety/80...  \n",
       "112  https://adisinsight.springer.com/drugsafety/80...  \n",
       "113  https://adisinsight.springer.com/drugsafety/80...  \n",
       "114  https://adisinsight.springer.com/drugsafety/80...  \n",
       "115  https://adisinsight.springer.com/drugsafety/80...  \n",
       "116  https://adisinsight.springer.com/drugsafety/80...  \n",
       "117  https://adisinsight.springer.com/drugsafety/80...  \n",
       "118  https://adisinsight.springer.com/drugsafety/80...  \n",
       "119  https://adisinsight.springer.com/drugsafety/80...  \n",
       "120  https://adisinsight.springer.com/drugsafety/80...  \n",
       "121  https://adisinsight.springer.com/drugsafety/80...  \n",
       "122  https://adisinsight.springer.com/drugsafety/80...  \n",
       "123  https://adisinsight.springer.com/drugsafety/80...  \n",
       "124  https://adisinsight.springer.com/drugsafety/80...  \n",
       "125  https://adisinsight.springer.com/drugsafety/80...  \n",
       "126  https://adisinsight.springer.com/drugsafety/80...  \n",
       "127  https://adisinsight.springer.com/drugsafety/80...  \n",
       "128  https://adisinsight.springer.com/drugsafety/80...  \n",
       "129  https://adisinsight.springer.com/drugsafety/80...  \n",
       "130  https://adisinsight.springer.com/drugsafety/80...  \n",
       "131  https://adisinsight.springer.com/drugsafety/80...  \n",
       "132  https://adisinsight.springer.com/drugsafety/80...  \n",
       "133  https://adisinsight.springer.com/drugsafety/80...  \n",
       "134  https://adisinsight.springer.com/drugsafety/80...  \n",
       "135  https://adisinsight.springer.com/drugsafety/80...  \n",
       "136  https://adisinsight.springer.com/drugsafety/80...  \n",
       "137  https://adisinsight.springer.com/drugsafety/80...  \n",
       "138  https://adisinsight.springer.com/drugsafety/80...  \n",
       "139  https://adisinsight.springer.com/drugsafety/80...  \n",
       "140  https://adisinsight.springer.com/drugsafety/80...  \n",
       "141  https://adisinsight.springer.com/drugsafety/80...  \n",
       "142  https://adisinsight.springer.com/drugsafety/80...  \n",
       "143  https://adisinsight.springer.com/drugsafety/80...  \n",
       "144  https://adisinsight.springer.com/drugsafety/80...  \n",
       "145  https://adisinsight.springer.com/drugsafety/80...  \n",
       "146  https://adisinsight.springer.com/drugsafety/80...  \n",
       "147  https://adisinsight.springer.com/drugsafety/80...  \n",
       "148  https://adisinsight.springer.com/drugsafety/80...  \n",
       "149  https://adisinsight.springer.com/drugsafety/80...  \n",
       "150  https://adisinsight.springer.com/drugsafety/80...  \n",
       "151  https://adisinsight.springer.com/drugsafety/80...  \n",
       "152  https://adisinsight.springer.com/drugsafety/80...  \n",
       "153  https://adisinsight.springer.com/drugsafety/80...  \n",
       "154  https://adisinsight.springer.com/drugsafety/80...  \n",
       "155  https://adisinsight.springer.com/drugsafety/80...  \n",
       "156  https://adisinsight.springer.com/drugsafety/80...  \n",
       "157  https://adisinsight.springer.com/drugsafety/80...  \n",
       "158  https://adisinsight.springer.com/drugsafety/80...  \n",
       "159  https://adisinsight.springer.com/drugsafety/80...  \n",
       "160  https://adisinsight.springer.com/drugsafety/80...  \n",
       "161  https://adisinsight.springer.com/drugsafety/80...  \n",
       "162  https://adisinsight.springer.com/drugsafety/80...  \n",
       "163  https://adisinsight.springer.com/drugsafety/80...  \n",
       "164  https://adisinsight.springer.com/drugsafety/80...  \n",
       "165  https://adisinsight.springer.com/drugsafety/80...  \n",
       "166  https://adisinsight.springer.com/drugsafety/80...  \n",
       "167  https://adisinsight.springer.com/drugsafety/80...  \n",
       "168  https://adisinsight.springer.com/drugsafety/80...  \n",
       "169  https://adisinsight.springer.com/drugsafety/80...  \n",
       "170  https://adisinsight.springer.com/drugsafety/80...  \n",
       "171  https://adisinsight.springer.com/drugsafety/80...  \n",
       "172  https://adisinsight.springer.com/drugsafety/80...  \n",
       "173  https://adisinsight.springer.com/drugsafety/80...  \n",
       "174  https://adisinsight.springer.com/drugsafety/80...  \n",
       "175  https://adisinsight.springer.com/drugsafety/80...  \n",
       "176  https://adisinsight.springer.com/drugsafety/80...  \n",
       "177  https://adisinsight.springer.com/drugsafety/80...  \n",
       "178  https://adisinsight.springer.com/drugsafety/80...  \n",
       "179  https://adisinsight.springer.com/drugsafety/80...  \n",
       "180  https://adisinsight.springer.com/drugsafety/80...  \n",
       "181  https://adisinsight.springer.com/drugsafety/80...  \n",
       "182  https://adisinsight.springer.com/drugsafety/80...  \n",
       "183  https://adisinsight.springer.com/drugsafety/80...  \n",
       "184  https://adisinsight.springer.com/drugsafety/80...  \n",
       "185  https://adisinsight.springer.com/drugsafety/80...  \n",
       "186  https://adisinsight.springer.com/drugsafety/80...  \n",
       "187  https://adisinsight.springer.com/drugsafety/80...  \n",
       "188  https://adisinsight.springer.com/drugsafety/80...  \n",
       "189  https://adisinsight.springer.com/drugsafety/80...  \n",
       "190  https://adisinsight.springer.com/drugsafety/80...  \n",
       "191  https://adisinsight.springer.com/drugsafety/80...  \n",
       "192  https://adisinsight.springer.com/drugsafety/80...  \n",
       "193  https://adisinsight.springer.com/drugsafety/80...  \n",
       "194  https://adisinsight.springer.com/drugsafety/80...  \n",
       "195  https://adisinsight.springer.com/drugsafety/80...  \n",
       "196  https://adisinsight.springer.com/drugsafety/80...  \n",
       "197  https://adisinsight.springer.com/drugsafety/80...  \n",
       "198  https://adisinsight.springer.com/drugsafety/80...  \n",
       "199  https://adisinsight.springer.com/drugsafety/80...  \n",
       "200  https://adisinsight.springer.com/drugsafety/80...  \n",
       "201  https://adisinsight.springer.com/drugsafety/80...  \n",
       "202  https://adisinsight.springer.com/drugsafety/80...  \n",
       "203  https://adisinsight.springer.com/drugsafety/80...  \n",
       "204  https://adisinsight.springer.com/drugsafety/80...  \n",
       "205  https://adisinsight.springer.com/drugsafety/80...  \n",
       "206  https://adisinsight.springer.com/drugsafety/80...  \n",
       "207  https://adisinsight.springer.com/drugsafety/80...  \n",
       "208  https://adisinsight.springer.com/drugsafety/80...  \n",
       "209  https://adisinsight.springer.com/drugsafety/80...  \n",
       "210  https://adisinsight.springer.com/drugsafety/80...  \n",
       "211  https://adisinsight.springer.com/drugsafety/80...  \n",
       "212  https://adisinsight.springer.com/drugsafety/80...  \n",
       "213  https://adisinsight.springer.com/drugsafety/80...  \n",
       "214  https://adisinsight.springer.com/drugsafety/80...  \n",
       "215  https://adisinsight.springer.com/drugsafety/80...  \n",
       "216  https://adisinsight.springer.com/drugsafety/80...  \n",
       "217  https://adisinsight.springer.com/drugsafety/80...  \n",
       "218  https://adisinsight.springer.com/drugsafety/80...  \n",
       "219  https://adisinsight.springer.com/drugsafety/80...  \n",
       "220  https://adisinsight.springer.com/drugsafety/80...  \n",
       "221  https://adisinsight.springer.com/drugsafety/80...  \n",
       "222  https://adisinsight.springer.com/drugsafety/80...  \n",
       "223  https://adisinsight.springer.com/drugsafety/80...  \n",
       "224  https://adisinsight.springer.com/drugsafety/80...  \n",
       "225  https://adisinsight.springer.com/drugsafety/80...  \n",
       "226  https://adisinsight.springer.com/drugsafety/80...  \n",
       "227  https://adisinsight.springer.com/drugsafety/80...  \n",
       "228  https://adisinsight.springer.com/drugsafety/80...  \n",
       "229  https://adisinsight.springer.com/drugsafety/80...  \n",
       "230  https://adisinsight.springer.com/drugsafety/80...  \n",
       "231  https://adisinsight.springer.com/drugsafety/80...  \n",
       "232  https://adisinsight.springer.com/drugsafety/80...  \n",
       "233  https://adisinsight.springer.com/drugsafety/80...  \n",
       "234  https://adisinsight.springer.com/drugsafety/80...  \n",
       "235  https://adisinsight.springer.com/drugsafety/80...  \n",
       "236  https://adisinsight.springer.com/drugsafety/80...  \n",
       "237  https://adisinsight.springer.com/drugsafety/80...  \n",
       "238  https://adisinsight.springer.com/drugsafety/80...  \n",
       "239  https://adisinsight.springer.com/drugsafety/80...  \n",
       "240  https://adisinsight.springer.com/drugsafety/80...  \n",
       "\n",
       "[241 rows x 23 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atazanavir"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Report Id</th>\n",
       "      <th>Mechanism of Action</th>\n",
       "      <th>Number of Cases</th>\n",
       "      <th>Treatment</th>\n",
       "      <th>Special Situation</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>2.410000e+02</td>\n",
       "      <td>0.0</td>\n",
       "      <td>217.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>8.027507e+08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.087558</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>9.826541e+05</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5.468486</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>8.008410e+08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>8.030117e+08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>8.031010e+08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>8.032637e+08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.000000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>8.090285e+08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>56.000000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          Report Id  Mechanism of Action  Number of Cases  Treatment  \\\n",
       "count  2.410000e+02                  0.0       217.000000        0.0   \n",
       "mean   8.027507e+08                  NaN         3.087558        NaN   \n",
       "std    9.826541e+05                  NaN         5.468486        NaN   \n",
       "min    8.008410e+08                  NaN         1.000000        NaN   \n",
       "25%    8.030117e+08                  NaN         1.000000        NaN   \n",
       "50%    8.031010e+08                  NaN         1.000000        NaN   \n",
       "75%    8.032637e+08                  NaN         3.000000        NaN   \n",
       "max    8.090285e+08                  NaN        56.000000        NaN   \n",
       "\n",
       "       Special Situation  \n",
       "count                0.0  \n",
       "mean                 NaN  \n",
       "std                  NaN  \n",
       "min                  NaN  \n",
       "25%                  NaN  \n",
       "50%                  NaN  \n",
       "75%                  NaN  \n",
       "max                  NaN  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atazanavir.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 241 entries, 0 to 240\n",
      "Data columns (total 23 columns):\n",
      " #   Column                   Non-Null Count  Dtype  \n",
      "---  ------                   --------------  -----  \n",
      " 0   Report Id                241 non-null    int64  \n",
      " 1   Safety Report Name       241 non-null    object \n",
      " 2   Record Type              241 non-null    object \n",
      " 3   Release Date             241 non-null    object \n",
      " 4   Drugs                    241 non-null    object \n",
      " 5   Adverse Events           218 non-null    object \n",
      " 6   Mechanism of Action      0 non-null      float64\n",
      " 7   Number of Cases          217 non-null    float64\n",
      " 8   Serious                  241 non-null    object \n",
      " 9   First Report             241 non-null    object \n",
      " 10  Overdose                 241 non-null    object \n",
      " 11  Drug Interaction         241 non-null    object \n",
      " 12  Narrative and comments   241 non-null    object \n",
      " 13  Reporter Country         217 non-null    object \n",
      " 14  Source Country           24 non-null     object \n",
      " 15  Country of publication   229 non-null    object \n",
      " 16  Drug Class               241 non-null    object \n",
      " 17  Age Group                29 non-null     object \n",
      " 18  Route Of Administration  12 non-null     object \n",
      " 19  Treatment                0 non-null      float64\n",
      " 20  Special Situation        0 non-null      float64\n",
      " 21  References               241 non-null    object \n",
      " 22  URL                      241 non-null    object \n",
      "dtypes: float64(4), int64(1), object(18)\n",
      "memory usage: 43.4+ KB\n"
     ]
    }
   ],
   "source": [
    "atazanavir.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0      02 Sep 2020\n",
       "1      26 Aug 2020\n",
       "2      26 Aug 2020\n",
       "3      10 Jul 2020\n",
       "4      01 Jul 2020\n",
       "          ...     \n",
       "236    12 Jan 2005\n",
       "237    06 Sep 2004\n",
       "238    28 Nov 2003\n",
       "239    24 Sep 2003\n",
       "240    06 Dec 2001\n",
       "Name: Release Date, Length: 241, dtype: object"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atazanavir[\"Release Date\"] "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     2020-09-02\n",
       "1     2020-08-26\n",
       "2     2020-08-26\n",
       "3     2020-07-10\n",
       "4     2020-07-01\n",
       "         ...    \n",
       "236   2005-01-12\n",
       "237   2004-09-06\n",
       "238   2003-11-28\n",
       "239   2003-09-24\n",
       "240   2001-12-06\n",
       "Name: Release Date, Length: 241, dtype: datetime64[ns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.to_datetime(atazanavir[\"Release Date\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "atazanavir[\"Release Date\"] = pd.to_datetime(atazanavir[\"Release Date\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x7fe1658f24c0>"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "atazanavir[\"Release Date\"].hist(bins=50)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "1 de enero 2019 al 31 diciembre 2019\n",
    "1 de enero 2020 al 31 septiembre 2020"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0      True\n",
       "1      True\n",
       "2      True\n",
       "3      True\n",
       "4      True\n",
       "       ... \n",
       "236    True\n",
       "237    True\n",
       "238    True\n",
       "239    True\n",
       "240    True\n",
       "Name: Release Date, Length: 241, dtype: bool"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atazanavir[\"Release Date\"]<\"2020-10-30\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Report Id</th>\n",
       "      <th>Safety Report Name</th>\n",
       "      <th>Record Type</th>\n",
       "      <th>Release Date</th>\n",
       "      <th>Drugs</th>\n",
       "      <th>Adverse Events</th>\n",
       "      <th>Mechanism of Action</th>\n",
       "      <th>Number of Cases</th>\n",
       "      <th>Serious</th>\n",
       "      <th>First Report</th>\n",
       "      <th>...</th>\n",
       "      <th>Reporter Country</th>\n",
       "      <th>Source Country</th>\n",
       "      <th>Country of publication</th>\n",
       "      <th>Drug Class</th>\n",
       "      <th>Age Group</th>\n",
       "      <th>Route Of Administration</th>\n",
       "      <th>Treatment</th>\n",
       "      <th>Special Situation</th>\n",
       "      <th>References</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>803500083</td>\n",
       "      <td>Atazanavir/ritonavir - Atazanavir crystal-indu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-09-02</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Chronic granulomatous disease drug-induced, In...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Varghese V, Rodriguez R, Self S, Velez JCQ....</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>803499015</td>\n",
       "      <td>Antiretrovirals - Anaemia and viral rebound: 2...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-08-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Anaemia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Anti-infectives , Antiretrovirals , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>803499019</td>\n",
       "      <td>Antiretrovirals - Virologic failure: 6 case re...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-08-26</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Amides , Anti-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>803488559</td>\n",
       "      <td>Antiretrovirals - Drug resistance, virologic r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-10</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>Dizziness drug-induced, Drowsiness drug-induce...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Singapore</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Alkynes , Antipsoriatics , Antiretrovirals , B...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ho S, Wong JG, Ng OT, Lee CC, Leo YS, Lye D...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>803485910</td>\n",
       "      <td>Antiretrovirals - Weight gain: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-01</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Abacavir...</td>\n",
       "      <td>Weight gain drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Israel</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Antivirals , Carbam...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Israel S, Elinav H, Elazary R, Porat D, Gib...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>803478784</td>\n",
       "      <td>Atazanavir/cobicistat/darunavir - Various toxi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-01</td>\n",
       "      <td>Atazanavir adverse reactions, Cobicistat adver...</td>\n",
       "      <td>Anxiety drug-induced, Appetite disorders drug-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Antiretrovirals , Carbamates , Furans , Morpho...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tyler S, Sivaraj V, Kulasegaram R. Central ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>803474501</td>\n",
       "      <td>Atazanavir/emtricitabine/raltegravir - Hypertr...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-05-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Emtric...</td>\n",
       "      <td>Hypertriglyceridaemia drug-induced, Pancreatit...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiretrovirals , Deoxyribonucleosides , Napht...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Joury A, Alshehri M, Mahendra A, Anteet M, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>803473063</td>\n",
       "      <td>Antiretrovirals - Exposure during pregnancy: 3...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-05-06</td>\n",
       "      <td>Atazanavir adverse reactions, Cobicistat adver...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Deoxyr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Badell ML, Sheth AN, Momplaisir F, Rahangda...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>803470701</td>\n",
       "      <td>Antiretrovirals - Paradoxical or unmasking of ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>Abacavir adverse reactions (Serious), Atazanav...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Adenine nucleo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Melzani A, De Reynal De Saint Michel R, Nta...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>803469994</td>\n",
       "      <td>Antivirals/immunosuppressants interaction - Dr...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>Abacavir drug interactions (Serious), Atazanav...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, H...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Turkey</td>\n",
       "      <td>Adenine nucleotides , Amides , Anti-inflammato...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Senechal I, Chateauvert N, Gervais P, Voisi...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>803468110</td>\n",
       "      <td>Atazanavir/ritonavir - Indirect bilirubin leve...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-09</td>\n",
       "      <td>Atazanavir adverse reactions, Atazanavir/riton...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Antiretrovirals , Carbamates , Oligop...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Mandimika C, Ogbuagu O. Successful sofosbuv...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>803455694</td>\n",
       "      <td>Atazanavir/ritonavir/tenofovir disoproxil fuma...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-02-14</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Ritona...</td>\n",
       "      <td>Fanconi syndrome drug-induced, Rhabdomyolysis ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Amides , Antiretrovirals , Antivirals , Carbam...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Favarel-Garrigues M, Hentzien M, Berger J-L...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>803455935</td>\n",
       "      <td>Atazanavir - Urolithiasis: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-02-13</td>\n",
       "      <td>Atazanavir adverse reactions (Serious)</td>\n",
       "      <td>Urolithiasis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Antiretrovirals , Oligopeptides , Pyridines , ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Brunel V, Massy N, Malval B. Atazanavir uro...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>803453169</td>\n",
       "      <td>Antiretroviral - Non alcoholic fatty liver dis...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>Atazanavir adverse reactions (Serious), Atazan...</td>\n",
       "      <td>Hepatic fibrosis drug-induced, Non-alcoholic f...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Thailand</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>3-ring heterocyclic compounds , Alkynes , Amid...</td>\n",
       "      <td>Adolescents, Children</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sudjaritruk T, Bunupuradah T, Aurpibul L, K...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>803449989</td>\n",
       "      <td>Antivirals/lidocaine interaction - Various tox...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-24</td>\n",
       "      <td>Abacavir drug interactions (Serious), Atazanav...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, D...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acetanilides , Amides , Antiretrovirals , Carb...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kramer ME, Holtan EE, Ives AL, Wall RT. Per...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>803449175</td>\n",
       "      <td>Atazanavir/tacrolimus interaction - Increase i...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-17</td>\n",
       "      <td>Atazanavir drug interactions, Tacrolimus drug ...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Antiasthmatics , Antipsoriatics , Antiretrovir...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tsapepas DS, Webber AB, Aull MJ, Figueiro J...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>16 rows  23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Report Id                                 Safety Report Name  \\\n",
       "0   803500083  Atazanavir/ritonavir - Atazanavir crystal-indu...   \n",
       "1   803499015  Antiretrovirals - Anaemia and viral rebound: 2...   \n",
       "2   803499019  Antiretrovirals - Virologic failure: 6 case re...   \n",
       "3   803488559  Antiretrovirals - Drug resistance, virologic r...   \n",
       "4   803485910         Antiretrovirals - Weight gain: case report   \n",
       "5   803478784  Atazanavir/cobicistat/darunavir - Various toxi...   \n",
       "6   803474501  Atazanavir/emtricitabine/raltegravir - Hypertr...   \n",
       "7   803473063  Antiretrovirals - Exposure during pregnancy: 3...   \n",
       "8   803470701  Antiretrovirals - Paradoxical or unmasking of ...   \n",
       "9   803469994  Antivirals/immunosuppressants interaction - Dr...   \n",
       "10  803468110  Atazanavir/ritonavir - Indirect bilirubin leve...   \n",
       "11  803455694  Atazanavir/ritonavir/tenofovir disoproxil fuma...   \n",
       "12  803455935             Atazanavir - Urolithiasis: case report   \n",
       "13  803453169  Antiretroviral - Non alcoholic fatty liver dis...   \n",
       "14  803449989  Antivirals/lidocaine interaction - Various tox...   \n",
       "15  803449175  Atazanavir/tacrolimus interaction - Increase i...   \n",
       "\n",
       "                      Record Type Release Date  \\\n",
       "0                 ADR Case Report   2020-09-02   \n",
       "1                 ADR Case Report   2020-08-26   \n",
       "2   Special Situation Case Report   2020-08-26   \n",
       "3                 ADR Case Report   2020-07-10   \n",
       "4                 ADR Case Report   2020-07-01   \n",
       "5                 ADR Case Report   2020-06-01   \n",
       "6                 ADR Case Report   2020-05-13   \n",
       "7   Special Situation Case Report   2020-05-06   \n",
       "8                 ADR Case Report   2020-04-24   \n",
       "9                 ADR Case Report   2020-04-22   \n",
       "10                ADR Case Report   2020-04-09   \n",
       "11                ADR Case Report   2020-02-14   \n",
       "12                ADR Case Report   2020-02-13   \n",
       "13                ADR Case Report   2020-02-04   \n",
       "14                ADR Case Report   2020-01-24   \n",
       "15                ADR Case Report   2020-01-17   \n",
       "\n",
       "                                                Drugs  \\\n",
       "0   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "1   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "2   Atazanavir adverse reactions (Serious), Atazan...   \n",
       "3   Abacavir adverse reactions (Serious), Abacavir...   \n",
       "4   Abacavir adverse reactions (Serious), Abacavir...   \n",
       "5   Atazanavir adverse reactions, Cobicistat adver...   \n",
       "6   Atazanavir adverse reactions (Serious), Emtric...   \n",
       "7   Atazanavir adverse reactions, Cobicistat adver...   \n",
       "8   Abacavir adverse reactions (Serious), Atazanav...   \n",
       "9   Abacavir drug interactions (Serious), Atazanav...   \n",
       "10  Atazanavir adverse reactions, Atazanavir/riton...   \n",
       "11  Atazanavir adverse reactions (Serious), Ritona...   \n",
       "12             Atazanavir adverse reactions (Serious)   \n",
       "13  Atazanavir adverse reactions (Serious), Atazan...   \n",
       "14  Abacavir drug interactions (Serious), Atazanav...   \n",
       "15  Atazanavir drug interactions, Tacrolimus drug ...   \n",
       "\n",
       "                                       Adverse Events  Mechanism of Action  \\\n",
       "0   Chronic granulomatous disease drug-induced, In...                  NaN   \n",
       "1                                Anaemia drug-induced                  NaN   \n",
       "2                                                 NaN                  NaN   \n",
       "3   Dizziness drug-induced, Drowsiness drug-induce...                  NaN   \n",
       "4                            Weight gain drug-induced                  NaN   \n",
       "5   Anxiety drug-induced, Appetite disorders drug-...                  NaN   \n",
       "6   Hypertriglyceridaemia drug-induced, Pancreatit...                  NaN   \n",
       "7                                                 NaN                  NaN   \n",
       "8         Immune reconstitution syndrome drug-induced                  NaN   \n",
       "9   Abnormal laboratory parameters drug-induced, H...                  NaN   \n",
       "10        Abnormal laboratory parameters drug-induced                  NaN   \n",
       "11  Fanconi syndrome drug-induced, Rhabdomyolysis ...                  NaN   \n",
       "12                          Urolithiasis drug-induced                  NaN   \n",
       "13  Hepatic fibrosis drug-induced, Non-alcoholic f...                  NaN   \n",
       "14  Abnormal laboratory parameters drug-induced, D...                  NaN   \n",
       "15        Abnormal laboratory parameters drug-induced                  NaN   \n",
       "\n",
       "    Number of Cases Serious First Report  ... Reporter Country Source Country  \\\n",
       "0               1.0     Yes           No  ...              USA            NaN   \n",
       "1               2.0     Yes           No  ...            India            NaN   \n",
       "2               6.0     Yes           No  ...            India            NaN   \n",
       "3               4.0     Yes           No  ...        Singapore            NaN   \n",
       "4               1.0     Yes           No  ...           Israel            NaN   \n",
       "5               7.0      No           No  ...   United Kingdom            NaN   \n",
       "6               1.0     Yes           No  ...              USA            NaN   \n",
       "7               3.0      No           No  ...              USA            NaN   \n",
       "8              22.0     Yes           No  ...           France            NaN   \n",
       "9               1.0     Yes           No  ...           Canada            NaN   \n",
       "10              1.0      No           No  ...              USA            NaN   \n",
       "11              1.0     Yes           No  ...           France            NaN   \n",
       "12              1.0     Yes           No  ...           France            NaN   \n",
       "13              5.0     Yes           No  ...         Thailand            NaN   \n",
       "14              1.0     Yes           No  ...              USA            NaN   \n",
       "15              1.0      No           No  ...              USA            NaN   \n",
       "\n",
       "   Country of publication                                         Drug Class  \\\n",
       "0                     USA  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "1                     USA  Amides , Anti-infectives , Antiretrovirals , A...   \n",
       "2                     USA  3-ring heterocyclic compounds , Amides , Anti-...   \n",
       "3                 England  Alkynes , Antipsoriatics , Antiretrovirals , B...   \n",
       "4                     USA  Amides , Antiretrovirals , Antivirals , Carbam...   \n",
       "5                 England  Antiretrovirals , Carbamates , Furans , Morpho...   \n",
       "6                     USA  Antiretrovirals , Deoxyribonucleosides , Napht...   \n",
       "7                     USA  Amides , Antiretrovirals , Carbamates , Deoxyr...   \n",
       "8                     USA  3-ring heterocyclic compounds , Adenine nucleo...   \n",
       "9                  Turkey  Adenine nucleotides , Amides , Anti-inflammato...   \n",
       "10                England  Amides , Antiretrovirals , Carbamates , Oligop...   \n",
       "11                 France  Amides , Antiretrovirals , Antivirals , Carbam...   \n",
       "12                 France  Antiretrovirals , Oligopeptides , Pyridines , ...   \n",
       "13                    USA  3-ring heterocyclic compounds , Alkynes , Amid...   \n",
       "14                    USA  Acetanilides , Amides , Antiretrovirals , Carb...   \n",
       "15                    USA  Antiasthmatics , Antipsoriatics , Antiretrovir...   \n",
       "\n",
       "                Age Group Route Of Administration Treatment Special Situation  \\\n",
       "0                     NaN                     NaN       NaN               NaN   \n",
       "1                     NaN                     NaN       NaN               NaN   \n",
       "2                     NaN                     NaN       NaN               NaN   \n",
       "3                     NaN                     NaN       NaN               NaN   \n",
       "4                     NaN                    Oral       NaN               NaN   \n",
       "5                     NaN                     NaN       NaN               NaN   \n",
       "6                     NaN                     NaN       NaN               NaN   \n",
       "7                     NaN                     NaN       NaN               NaN   \n",
       "8                     NaN                     NaN       NaN               NaN   \n",
       "9                     NaN                    Oral       NaN               NaN   \n",
       "10                    NaN                     NaN       NaN               NaN   \n",
       "11                    NaN                     NaN       NaN               NaN   \n",
       "12                    NaN                     NaN       NaN               NaN   \n",
       "13  Adolescents, Children                     NaN       NaN               NaN   \n",
       "14                    NaN       Intravenous, Oral       NaN               NaN   \n",
       "15                    NaN                    Oral       NaN               NaN   \n",
       "\n",
       "                                           References  \\\n",
       "0   1. Varghese V, Rodriguez R, Self S, Velez JCQ....   \n",
       "1   1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...   \n",
       "2   1. Dravid AN, Gawali R, Betha TP, Sharma AK, M...   \n",
       "3   1. Ho S, Wong JG, Ng OT, Lee CC, Leo YS, Lye D...   \n",
       "4   1. Israel S, Elinav H, Elazary R, Porat D, Gib...   \n",
       "5   1. Tyler S, Sivaraj V, Kulasegaram R. Central ...   \n",
       "6   1. Joury A, Alshehri M, Mahendra A, Anteet M, ...   \n",
       "7   1. Badell ML, Sheth AN, Momplaisir F, Rahangda...   \n",
       "8   1. Melzani A, De Reynal De Saint Michel R, Nta...   \n",
       "9   1. Senechal I, Chateauvert N, Gervais P, Voisi...   \n",
       "10  1. Mandimika C, Ogbuagu O. Successful sofosbuv...   \n",
       "11  1. Favarel-Garrigues M, Hentzien M, Berger J-L...   \n",
       "12  1. Brunel V, Massy N, Malval B. Atazanavir uro...   \n",
       "13  1. Sudjaritruk T, Bunupuradah T, Aurpibul L, K...   \n",
       "14  1. Kramer ME, Holtan EE, Ives AL, Wall RT. Per...   \n",
       "15  1. Tsapepas DS, Webber AB, Aull MJ, Figueiro J...   \n",
       "\n",
       "                                                  URL  \n",
       "0   https://adisinsight.springer.com/drugsafety/80...  \n",
       "1   https://adisinsight.springer.com/drugsafety/80...  \n",
       "2   https://adisinsight.springer.com/drugsafety/80...  \n",
       "3   https://adisinsight.springer.com/drugsafety/80...  \n",
       "4   https://adisinsight.springer.com/drugsafety/80...  \n",
       "5   https://adisinsight.springer.com/drugsafety/80...  \n",
       "6   https://adisinsight.springer.com/drugsafety/80...  \n",
       "7   https://adisinsight.springer.com/drugsafety/80...  \n",
       "8   https://adisinsight.springer.com/drugsafety/80...  \n",
       "9   https://adisinsight.springer.com/drugsafety/80...  \n",
       "10  https://adisinsight.springer.com/drugsafety/80...  \n",
       "11  https://adisinsight.springer.com/drugsafety/80...  \n",
       "12  https://adisinsight.springer.com/drugsafety/80...  \n",
       "13  https://adisinsight.springer.com/drugsafety/80...  \n",
       "14  https://adisinsight.springer.com/drugsafety/80...  \n",
       "15  https://adisinsight.springer.com/drugsafety/80...  \n",
       "\n",
       "[16 rows x 23 columns]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atazanavir[(atazanavir[\"Release Date\"]<\"2020-10-30\") & (atazanavir[\"Release Date\"]>\"2020-01-01\")]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "atazanavir2020 = atazanavir[\n",
    "    (atazanavir['Release Date'] > '2020-01-01') & (atazanavir['Release Date'] < '2020-12-30')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "atazanavir2019 = atazanavir[(atazanavir['Release Date'] > '2019-01-1') & (atazanavir['Release Date'] < '2019-12-30')].head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "atazanavir2020.to_excel(\"Atazanavir ene-sept 2020.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "atazanavir2020.to_excel(\"2020/Atazanavir ene-sept 2020.xlsx\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Intento"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "amikacina2020 = pd.read_excel(\"2020/AMIKACINA_ene-sep2020.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "amikacina2019 = pd.read_excel(\"2019/AMIKACINA_ene-dic2019.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Report Id</th>\n",
       "      <th>Safety Report Name</th>\n",
       "      <th>Record Type</th>\n",
       "      <th>Release Date</th>\n",
       "      <th>Drugs</th>\n",
       "      <th>Adverse Events</th>\n",
       "      <th>Mechanism of Action</th>\n",
       "      <th>Number of Cases</th>\n",
       "      <th>Serious</th>\n",
       "      <th>First Report</th>\n",
       "      <th>...</th>\n",
       "      <th>Reporter Country</th>\n",
       "      <th>Source Country</th>\n",
       "      <th>Country of publication</th>\n",
       "      <th>Drug Class</th>\n",
       "      <th>Age Group</th>\n",
       "      <th>Route Of Administration</th>\n",
       "      <th>Treatment</th>\n",
       "      <th>Special Situation</th>\n",
       "      <th>References</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>803502438</td>\n",
       "      <td>Multiple drugs - Drug-drug interactions: 37 ca...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-09-18</td>\n",
       "      <td>Alprazolam drug interactions, Amikacin drug in...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>37.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Mexico</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Singapore</td>\n",
       "      <td>2 pyridinylmethylsulfinylbenzimidazoles , 2 ri...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Medina-Barajas F, Vazquez-Mendez E, Perez-G...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>803500198</td>\n",
       "      <td>Amikacin/vancomycin - Lack of efficacy during ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-09-02</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>Lack of efficacy in critical conditions drug-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Infants</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hadizadeh T, Uwaifo OO. Neonatal Acute Supp...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>803496420</td>\n",
       "      <td>Antibacterials/immunosuppressants - &lt;EM&gt;Tricho...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-08-11</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Aztreona...</td>\n",
       "      <td>Trichosporonosis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>China</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Singapore</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Anti-infla...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Zhang P, Yang Z, Li J, Li X. Trichosporon a...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>803495874</td>\n",
       "      <td>EMA releases highlights from the CHMP's July m...</td>\n",
       "      <td>News</td>\n",
       "      <td>2020-08-05</td>\n",
       "      <td>Abicipar pegol adverse reactions, Acalabrutini...</td>\n",
       "      <td>Various toxicities drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2 ring heterocyclic compounds , Acetanilides ,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. European Medicines Agency (EMA). Meeting hi...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>803494181</td>\n",
       "      <td>Antibacterials/anti-inflammatories/antitubercu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-31</td>\n",
       "      <td>Adalimumab adverse reactions (Serious), Amikac...</td>\n",
       "      <td>Hearing loss drug-induced, Nontuberculous myco...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Australia</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Stokes G, Overton K, Post JJ. Update on clu...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>803491817</td>\n",
       "      <td>Amikacin/cefoxitin/cotrimoxazole - Neutropenia...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-24</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Cefoxiti...</td>\n",
       "      <td>Kidney disorders drug-induced, Neutropenia dru...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Wang PP, Bray C-A, Lapierre SG, Soualhine H...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>803489055</td>\n",
       "      <td>Multiple drugs - Nontuberculous mycobacterial ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-14</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>Bacteraemia drug-induced, Nontuberculous mycob...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Amides , Aminoglycosides , Anti-infectives , A...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Nagata A, Sekiya N, Najima Y, Horiuchi M, F...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>803488430</td>\n",
       "      <td>Antibacterials/antituberculars - Paradoxical w...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-10</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Aminosal...</td>\n",
       "      <td>Tuberculosis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Desai L, Shah I, Shaan M. Retropharyngeal a...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>803486045</td>\n",
       "      <td>Amikacin/imipenem/cilastatin/levofloxacin - Na...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-01</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Cilastat...</td>\n",
       "      <td>Nausea drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Erber J, Weidlich S, Tschaikowsky T, Rothe ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>803485828</td>\n",
       "      <td>Multiple drugs - Various toxicities: 6 case re...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-01</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Busulfan...</td>\n",
       "      <td>Gastrointestinal disorders drug-induced, Hyper...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>China</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Abortifacients , Acyclic acids , Aminoglycosid...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Zeng Q-Z, Zhang Y-Y, Wu Y-J, Zhang Z-Y, Zha...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>803485905</td>\n",
       "      <td>Multiple drugs - Various toxicities: 15 case r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-07-01</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amoxicil...</td>\n",
       "      <td>Bradycardia drug-induced, Burning sensation dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>India</td>\n",
       "      <td>Acetanilides , Aminoglycosides , Aminophenols ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral, Topical</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bansod KA, Bashir MSM, Ingle SS. Adverse dr...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>803483785</td>\n",
       "      <td>Amikacin/amoxicillin/clavulanic-acid/clindamyc...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-22</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Belgium</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Preseau T, Deviendt J, Duttman R, Attou R, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>803481489</td>\n",
       "      <td>Antibacterials - Nausea, &lt;EM&gt;Clostridium diffi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Azithrom...</td>\n",
       "      <td>Barrett's oesophagus drug-induced, Clostridium...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Moral MZ, Desai K, Arain AR, O'Leary RE, Ha...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>803481467</td>\n",
       "      <td>Multiple drugs - Development of resistance: ca...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Amides , Aminoglycosides , Anti-infectives , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Khil PP, Dulanto Chiang A, Ho J, Youn JH, L...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>803481265</td>\n",
       "      <td>Multiple drugs - Invasive rhino-orbito-cerebra...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Fluconaz...</td>\n",
       "      <td>Zygomycosis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Slovakia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Czech Republic</td>\n",
       "      <td>Abortifacients , Aminoglycosides , Anti-infect...</td>\n",
       "      <td>Children</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bacova E, Chovanec F, Makohusova M, Hederov...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>803481413</td>\n",
       "      <td>Amikacin/polymyxin B - Lack of efficacy: case ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-11</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Nepal</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Nepal</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Keyal NK, Adhikari P, Baskota BD, Rai U, Th...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>803479521</td>\n",
       "      <td>Immunosuppressants and Antibacterials - Gastro...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-06-06</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Basilixi...</td>\n",
       "      <td>Lymphadenitis drug-induced, Pancreatitis drug-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Mexico</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hernandez-Robles CM, Velazquez-Cortes I, He...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>803478359</td>\n",
       "      <td>Antibiotics - Development of bacterial resista...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-05-29</td>\n",
       "      <td>Amikacin adverse reactions, Amikacin therapeut...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Flerlage T, Brazelton de Cardenas JN, Garne...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>803474575</td>\n",
       "      <td>Amikacin - Acute kidney injury, hypoacusia and...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-05-15</td>\n",
       "      <td>Amikacin adverse reactions (Serious)</td>\n",
       "      <td>Acute kidney injury drug-induced, Elevated cre...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Mexico</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cardenas-de la Garza JA, Welsh O, Cuellar-B...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>803475043</td>\n",
       "      <td>Antibiotics - Systemic candiasis, fungal sepsi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-05-15</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Cefotaxi...</td>\n",
       "      <td>Candidiasis drug-induced, Hyperpigmentation dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Prabhakar P, Batra P, Verma C, Harit D. Hyp...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>803474298</td>\n",
       "      <td>Amikacin - Ototoxicity: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-05-12</td>\n",
       "      <td>Amikacin adverse reactions (Serious)</td>\n",
       "      <td>Ear disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Thirion DJG, Pasche V, Matouk E, Marsot A. ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>803474121</td>\n",
       "      <td>Amikacin/cotrimoxazole/linezolid - Various tox...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-05-11</td>\n",
       "      <td>Amikacin adverse reactions, Cotrimoxazole adve...</td>\n",
       "      <td>Anaemia drug-induced, Exanthema drug-induced, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Spain</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Spain</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gimenez-Arufe V, Gutierrez-Urbon JM, Blanco...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>803473441</td>\n",
       "      <td>Antibacterials - Lack of efficacy and offlabel...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-05-08</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>2 ring heterocyclic compounds , Aminoglycoside...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Buonomo AR, Maraolo AE, Scotto R, Foggia M,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>803471726</td>\n",
       "      <td>Multiple drugs - Immune reconstitution inflamm...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-29</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Anakinra...</td>\n",
       "      <td>Immune reconstitution syndrome drug-induced, N...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Abortifacients , Acetamides , Aminoglycosides ...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Modi A, Bravo T. The Paradoxical Response i...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>803471694</td>\n",
       "      <td>Antituberculars - Paradoxical upgradation resp...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-29</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ethambut...</td>\n",
       "      <td>Tuberculosis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>India</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kabra MN, Kunapareddy T. Paradoxical upgrad...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>803471556</td>\n",
       "      <td>Antibacterials - Multifocal seizures: 2 case r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-28</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ceftazid...</td>\n",
       "      <td>Seizures drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Vietnam</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Infants</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Minh Nguyen K, Bustarret O, Jugie M, Nabbou...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>803470362</td>\n",
       "      <td>Antibacterials - Otoxicity and nephrotoxicity:...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Clarithr...</td>\n",
       "      <td>Ear disorders drug-induced, Kidney disorders d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Julian KG, Crook T, Curley E, Appenheimer A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>803469033</td>\n",
       "      <td>Amikacin/linezolid/meropenem - Lack of efficac...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-14</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. da Silva Campana P, Martinho LZM, Batista M...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>803465992</td>\n",
       "      <td>Multiple drugs - Various toxicities: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-04-03</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amphoter...</td>\n",
       "      <td>Candidiasis drug-induced, Cystitis drug-induce...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Russia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Russia</td>\n",
       "      <td>Acetamides , Amino acids , Aminoglycosides , A...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Dinikina YuV, Shadrivova OV, Belogurova MB,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>803466442</td>\n",
       "      <td>Amikacin - Lack of efficacy: case report</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-04-03</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Australia</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravitreal</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tran T, Symes R, Nolan T. Systemic nocardio...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>803464489</td>\n",
       "      <td>Amikacin/linezolid/tigecycline - Bone marrow s...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-03-27</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Linezoli...</td>\n",
       "      <td>Myelosuppression drug-induced, Pancreatitis dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Children</td>\n",
       "      <td>Intravenous, Intraventricular</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Lamb GS, Del Valle Mojica C, Srinivas N, St...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>803464327</td>\n",
       "      <td>Antibacterials - Various toxicities: 15 case r...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-03-24</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ampicill...</td>\n",
       "      <td>Anaphylaxis drug-induced, Angioedema drug-indu...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Chen XJC, Fong K, Altshuler D, Dubrovskaya ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>803463732</td>\n",
       "      <td>Antibacterials/norepinephrine - Lack of effica...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-03-20</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Tunisia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Aziz Daghmouri M, Affes FZ, Jebri A, Boussa...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>803463214</td>\n",
       "      <td>Amikacin/avibactam/ceftazidime - Treatment fai...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-03-16</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>Nosocomial pneumonia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>Amides , Aminoglycosides , Anti-infectives , A...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vena A, Giacobbe DR, Castaldo N, Cattelan A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>803462855</td>\n",
       "      <td>Antibacterials - Treatment failure: 2 case rep...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-03-16</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Saudi Arabia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>2 ring heterocyclic compounds , Aminoglycoside...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bosaeed M, Ahmad A, Alali A, Mahmoud E, Als...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>803460486</td>\n",
       "      <td>Amikacin - Acute kidney injury: 2 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-03-04</td>\n",
       "      <td>Amikacin adverse reactions (Serious)</td>\n",
       "      <td>Acute kidney injury drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>South Korea</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kim DJ, Lee J, Yu H, Lee DH, Kang T, Han YK...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>803458213</td>\n",
       "      <td>Amikacin/ceftriaxone/metronidazole - Diarrhoea...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-02-24</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ceftriax...</td>\n",
       "      <td>Colitis drug-induced, Diarrhoea drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Russia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Russia</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Children</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bekhtereva MK, Lobzin YuV, Ioffe MYa, Razdy...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>803453721</td>\n",
       "      <td>Antibacterials/glycosaminoglycans - Treatment ...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2020-02-07</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Intravesicular, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kuipers S, Ruth MM, Mientjes M, de Sevaux R...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>803452038</td>\n",
       "      <td>Antibacterials/ketoconazole - Various toxiciti...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-31</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Cefazoli...</td>\n",
       "      <td>Anaphylaxis drug-induced, Drug toxicity drug-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>China</td>\n",
       "      <td>NaN</td>\n",
       "      <td>China</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Pang X-Y, Cui M, Liu X-Y, Shen J-F. Relevan...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>803451036</td>\n",
       "      <td>Amikacin/linezolid - Ototoxicity and hearing l...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-27</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Linezoli...</td>\n",
       "      <td>Hearing loss drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Saudi Arabia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Infants</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Alshukairi AN, Moalim HM, Alsaedi A, Almans...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>803444980</td>\n",
       "      <td>Amikacin/cefepime - Drug rash: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-06</td>\n",
       "      <td>Amikacin adverse reactions, Cefepime adverse r...</td>\n",
       "      <td>Drug eruptions drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Hong Kong</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ling S-O, Yau P-YA, Kwan H-Y, Yim C-W, Poon...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>803444509</td>\n",
       "      <td>Multiple drugs - Posterior reversible leukoenc...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2020-01-03</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Antithym...</td>\n",
       "      <td>Reversible posterior leukoencephalopathy syndr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Turkey</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Turkey</td>\n",
       "      <td>Abortifacients , Amidohydrolases , Aminoglycos...</td>\n",
       "      <td>Children</td>\n",
       "      <td>Intrathecal, Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Malbora B, Avci Z, DoInmez F, AliogIlu B, B...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>42 rows  23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Report Id                                 Safety Report Name  \\\n",
       "0   803502438  Multiple drugs - Drug-drug interactions: 37 ca...   \n",
       "1   803500198  Amikacin/vancomycin - Lack of efficacy during ...   \n",
       "2   803496420  Antibacterials/immunosuppressants - <EM>Tricho...   \n",
       "3   803495874  EMA releases highlights from the CHMP's July m...   \n",
       "4   803494181  Antibacterials/anti-inflammatories/antitubercu...   \n",
       "5   803491817  Amikacin/cefoxitin/cotrimoxazole - Neutropenia...   \n",
       "6   803489055  Multiple drugs - Nontuberculous mycobacterial ...   \n",
       "7   803488430  Antibacterials/antituberculars - Paradoxical w...   \n",
       "8   803486045  Amikacin/imipenem/cilastatin/levofloxacin - Na...   \n",
       "9   803485828  Multiple drugs - Various toxicities: 6 case re...   \n",
       "10  803485905  Multiple drugs - Various toxicities: 15 case r...   \n",
       "11  803483785  Amikacin/amoxicillin/clavulanic-acid/clindamyc...   \n",
       "12  803481489  Antibacterials - Nausea, <EM>Clostridium diffi...   \n",
       "13  803481467  Multiple drugs - Development of resistance: ca...   \n",
       "14  803481265  Multiple drugs - Invasive rhino-orbito-cerebra...   \n",
       "15  803481413  Amikacin/polymyxin B - Lack of efficacy: case ...   \n",
       "16  803479521  Immunosuppressants and Antibacterials - Gastro...   \n",
       "17  803478359  Antibiotics - Development of bacterial resista...   \n",
       "18  803474575  Amikacin - Acute kidney injury, hypoacusia and...   \n",
       "19  803475043  Antibiotics - Systemic candiasis, fungal sepsi...   \n",
       "20  803474298                Amikacin - Ototoxicity: case report   \n",
       "21  803474121  Amikacin/cotrimoxazole/linezolid - Various tox...   \n",
       "22  803473441  Antibacterials - Lack of efficacy and offlabel...   \n",
       "23  803471726  Multiple drugs - Immune reconstitution inflamm...   \n",
       "24  803471694  Antituberculars - Paradoxical upgradation resp...   \n",
       "25  803471556  Antibacterials - Multifocal seizures: 2 case r...   \n",
       "26  803470362  Antibacterials - Otoxicity and nephrotoxicity:...   \n",
       "27  803469033  Amikacin/linezolid/meropenem - Lack of efficac...   \n",
       "28  803465992   Multiple drugs - Various toxicities: case report   \n",
       "29  803466442           Amikacin - Lack of efficacy: case report   \n",
       "30  803464489  Amikacin/linezolid/tigecycline - Bone marrow s...   \n",
       "31  803464327  Antibacterials - Various toxicities: 15 case r...   \n",
       "32  803463732  Antibacterials/norepinephrine - Lack of effica...   \n",
       "33  803463214  Amikacin/avibactam/ceftazidime - Treatment fai...   \n",
       "34  803462855  Antibacterials - Treatment failure: 2 case rep...   \n",
       "35  803460486     Amikacin - Acute kidney injury: 2 case reports   \n",
       "36  803458213  Amikacin/ceftriaxone/metronidazole - Diarrhoea...   \n",
       "37  803453721  Antibacterials/glycosaminoglycans - Treatment ...   \n",
       "38  803452038  Antibacterials/ketoconazole - Various toxiciti...   \n",
       "39  803451036  Amikacin/linezolid - Ototoxicity and hearing l...   \n",
       "40  803444980         Amikacin/cefepime - Drug rash: case report   \n",
       "41  803444509  Multiple drugs - Posterior reversible leukoenc...   \n",
       "\n",
       "                      Record Type Release Date  \\\n",
       "0   Special Situation Case Report   2020-09-18   \n",
       "1                 ADR Case Report   2020-09-02   \n",
       "2                 ADR Case Report   2020-08-11   \n",
       "3                            News   2020-08-05   \n",
       "4                 ADR Case Report   2020-07-31   \n",
       "5                 ADR Case Report   2020-07-24   \n",
       "6                 ADR Case Report   2020-07-14   \n",
       "7                 ADR Case Report   2020-07-10   \n",
       "8                 ADR Case Report   2020-07-01   \n",
       "9                 ADR Case Report   2020-07-01   \n",
       "10                ADR Case Report   2020-07-01   \n",
       "11                ADR Case Report   2020-06-22   \n",
       "12                ADR Case Report   2020-06-12   \n",
       "13                ADR Case Report   2020-06-12   \n",
       "14                ADR Case Report   2020-06-12   \n",
       "15                ADR Case Report   2020-06-11   \n",
       "16                ADR Case Report   2020-06-06   \n",
       "17                ADR Case Report   2020-05-29   \n",
       "18                ADR Case Report   2020-05-15   \n",
       "19                ADR Case Report   2020-05-15   \n",
       "20                ADR Case Report   2020-05-12   \n",
       "21                ADR Case Report   2020-05-11   \n",
       "22  Special Situation Case Report   2020-05-08   \n",
       "23                ADR Case Report   2020-04-29   \n",
       "24                ADR Case Report   2020-04-29   \n",
       "25                ADR Case Report   2020-04-28   \n",
       "26                ADR Case Report   2020-04-22   \n",
       "27                ADR Case Report   2020-04-14   \n",
       "28                ADR Case Report   2020-04-03   \n",
       "29  Special Situation Case Report   2020-04-03   \n",
       "30                ADR Case Report   2020-03-27   \n",
       "31                ADR Case Report   2020-03-24   \n",
       "32                ADR Case Report   2020-03-20   \n",
       "33                ADR Case Report   2020-03-16   \n",
       "34                ADR Case Report   2020-03-16   \n",
       "35                ADR Case Report   2020-03-04   \n",
       "36                ADR Case Report   2020-02-24   \n",
       "37  Special Situation Case Report   2020-02-07   \n",
       "38                ADR Case Report   2020-01-31   \n",
       "39                ADR Case Report   2020-01-27   \n",
       "40                ADR Case Report   2020-01-06   \n",
       "41                ADR Case Report   2020-01-03   \n",
       "\n",
       "                                                Drugs  \\\n",
       "0   Alprazolam drug interactions, Amikacin drug in...   \n",
       "1   Amikacin adverse reactions (Serious), Amikacin...   \n",
       "2   Amikacin adverse reactions (Serious), Aztreona...   \n",
       "3   Abicipar pegol adverse reactions, Acalabrutini...   \n",
       "4   Adalimumab adverse reactions (Serious), Amikac...   \n",
       "5   Amikacin adverse reactions (Serious), Cefoxiti...   \n",
       "6   Amikacin adverse reactions (Serious), Amikacin...   \n",
       "7   Amikacin adverse reactions (Serious), Aminosal...   \n",
       "8   Amikacin adverse reactions (Serious), Cilastat...   \n",
       "9   Amikacin adverse reactions (Serious), Busulfan...   \n",
       "10  Amikacin adverse reactions (Serious), Amoxicil...   \n",
       "11  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "12  Amikacin adverse reactions (Serious), Azithrom...   \n",
       "13  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "14  Amikacin adverse reactions (Serious), Fluconaz...   \n",
       "15  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "16  Amikacin adverse reactions (Serious), Basilixi...   \n",
       "17  Amikacin adverse reactions, Amikacin therapeut...   \n",
       "18               Amikacin adverse reactions (Serious)   \n",
       "19  Amikacin adverse reactions (Serious), Cefotaxi...   \n",
       "20               Amikacin adverse reactions (Serious)   \n",
       "21  Amikacin adverse reactions, Cotrimoxazole adve...   \n",
       "22  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "23  Amikacin adverse reactions (Serious), Anakinra...   \n",
       "24  Amikacin adverse reactions (Serious), Ethambut...   \n",
       "25  Amikacin adverse reactions (Serious), Ceftazid...   \n",
       "26  Amikacin adverse reactions (Serious), Clarithr...   \n",
       "27  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "28  Amikacin adverse reactions (Serious), Amphoter...   \n",
       "29  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "30  Amikacin adverse reactions (Serious), Linezoli...   \n",
       "31  Amikacin adverse reactions (Serious), Ampicill...   \n",
       "32  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "33  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "34  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "35               Amikacin adverse reactions (Serious)   \n",
       "36  Amikacin adverse reactions (Serious), Ceftriax...   \n",
       "37  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "38  Amikacin adverse reactions (Serious), Cefazoli...   \n",
       "39  Amikacin adverse reactions (Serious), Linezoli...   \n",
       "40  Amikacin adverse reactions, Cefepime adverse r...   \n",
       "41  Amikacin adverse reactions (Serious), Antithym...   \n",
       "\n",
       "                                       Adverse Events  Mechanism of Action  \\\n",
       "0                                                 NaN                  NaN   \n",
       "1   Lack of efficacy in critical conditions drug-i...                  NaN   \n",
       "2                       Trichosporonosis drug-induced                  NaN   \n",
       "3                     Various toxicities drug-induced                  NaN   \n",
       "4   Hearing loss drug-induced, Nontuberculous myco...                  NaN   \n",
       "5   Kidney disorders drug-induced, Neutropenia dru...                  NaN   \n",
       "6   Bacteraemia drug-induced, Nontuberculous mycob...                  NaN   \n",
       "7                           Tuberculosis drug-induced                  NaN   \n",
       "8                                 Nausea drug-induced                  NaN   \n",
       "9   Gastrointestinal disorders drug-induced, Hyper...                  NaN   \n",
       "10  Bradycardia drug-induced, Burning sensation dr...                  NaN   \n",
       "11                                                NaN                  NaN   \n",
       "12  Barrett's oesophagus drug-induced, Clostridium...                  NaN   \n",
       "13                                                NaN                  NaN   \n",
       "14                           Zygomycosis drug-induced                  NaN   \n",
       "15                                                NaN                  NaN   \n",
       "16  Lymphadenitis drug-induced, Pancreatitis drug-...                  NaN   \n",
       "17                                                NaN                  NaN   \n",
       "18  Acute kidney injury drug-induced, Elevated cre...                  NaN   \n",
       "19  Candidiasis drug-induced, Hyperpigmentation dr...                  NaN   \n",
       "20                         Ear disorders drug-induced                  NaN   \n",
       "21  Anaemia drug-induced, Exanthema drug-induced, ...                  NaN   \n",
       "22                                                NaN                  NaN   \n",
       "23  Immune reconstitution syndrome drug-induced, N...                  NaN   \n",
       "24                          Tuberculosis drug-induced                  NaN   \n",
       "25                              Seizures drug-induced                  NaN   \n",
       "26  Ear disorders drug-induced, Kidney disorders d...                  NaN   \n",
       "27                                                NaN                  NaN   \n",
       "28  Candidiasis drug-induced, Cystitis drug-induce...                  NaN   \n",
       "29                                                NaN                  NaN   \n",
       "30  Myelosuppression drug-induced, Pancreatitis dr...                  NaN   \n",
       "31  Anaphylaxis drug-induced, Angioedema drug-indu...                  NaN   \n",
       "32                                                NaN                  NaN   \n",
       "33                  Nosocomial pneumonia drug-induced                  NaN   \n",
       "34                                                NaN                  NaN   \n",
       "35                   Acute kidney injury drug-induced                  NaN   \n",
       "36       Colitis drug-induced, Diarrhoea drug-induced                  NaN   \n",
       "37                                                NaN                  NaN   \n",
       "38  Anaphylaxis drug-induced, Drug toxicity drug-i...                  NaN   \n",
       "39                          Hearing loss drug-induced                  NaN   \n",
       "40                        Drug eruptions drug-induced                  NaN   \n",
       "41  Reversible posterior leukoencephalopathy syndr...                  NaN   \n",
       "\n",
       "    Number of Cases Serious First Report  ... Reporter Country Source Country  \\\n",
       "0              37.0      No           No  ...           Mexico            NaN   \n",
       "1               1.0     Yes           No  ...        Australia            NaN   \n",
       "2               1.0     Yes           No  ...            China            NaN   \n",
       "3               NaN      No           No  ...              NaN    Netherlands   \n",
       "4               2.0     Yes           No  ...        Australia            NaN   \n",
       "5               1.0     Yes           No  ...           Canada            NaN   \n",
       "6               4.0     Yes           No  ...            Japan            NaN   \n",
       "7               1.0     Yes           No  ...            India            NaN   \n",
       "8               1.0     Yes           No  ...          Germany            NaN   \n",
       "9               6.0     Yes           No  ...            China            NaN   \n",
       "10             15.0     Yes           No  ...            India            NaN   \n",
       "11              1.0     Yes           No  ...          Belgium            NaN   \n",
       "12              1.0     Yes           No  ...              USA            NaN   \n",
       "13              1.0     Yes           No  ...              USA            NaN   \n",
       "14              1.0     Yes           No  ...         Slovakia            NaN   \n",
       "15              1.0     Yes           No  ...            Nepal            NaN   \n",
       "16              1.0     Yes           No  ...           Mexico            NaN   \n",
       "17              1.0     Yes           No  ...              USA            NaN   \n",
       "18              3.0     Yes           No  ...           Mexico            NaN   \n",
       "19              4.0     Yes           No  ...            India            NaN   \n",
       "20              1.0     Yes           No  ...           Canada            NaN   \n",
       "21              1.0     Yes           No  ...            Spain            NaN   \n",
       "22              4.0     Yes           No  ...            Italy            NaN   \n",
       "23              1.0     Yes           No  ...              USA            NaN   \n",
       "24              2.0     Yes           No  ...            India            NaN   \n",
       "25              2.0     Yes           No  ...          Vietnam            NaN   \n",
       "26              1.0     Yes           No  ...              USA            NaN   \n",
       "27              1.0     Yes           No  ...           Brazil            NaN   \n",
       "28              1.0     Yes           No  ...           Russia            NaN   \n",
       "29              1.0     Yes           No  ...        Australia            NaN   \n",
       "30              1.0     Yes           No  ...              USA            NaN   \n",
       "31             15.0     Yes           No  ...              USA            NaN   \n",
       "32              1.0     Yes           No  ...          Tunisia            NaN   \n",
       "33              1.0     Yes           No  ...            Italy            NaN   \n",
       "34              2.0     Yes           No  ...     Saudi Arabia            NaN   \n",
       "35              2.0     Yes           No  ...      South Korea            NaN   \n",
       "36              1.0     Yes           No  ...           Russia            NaN   \n",
       "37              1.0     Yes           No  ...      Netherlands            NaN   \n",
       "38             11.0     Yes           No  ...            China            NaN   \n",
       "39              3.0     Yes           No  ...     Saudi Arabia            NaN   \n",
       "40              1.0      No           No  ...        Hong Kong            NaN   \n",
       "41              6.0     Yes           No  ...           Turkey            NaN   \n",
       "\n",
       "   Country of publication                                         Drug Class  \\\n",
       "0               Singapore  2 pyridinylmethylsulfinylbenzimidazoles , 2 ri...   \n",
       "1                     USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "2               Singapore  Aminoglycosides , Anti-infectives , Anti-infla...   \n",
       "3                     NaN  2 ring heterocyclic compounds , Acetanilides ,...   \n",
       "4               Australia  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "5                  Canada  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "6                  Canada  Amides , Aminoglycosides , Anti-infectives , A...   \n",
       "7          United Kingdom  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "8                 England  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "9                     USA  Abortifacients , Acyclic acids , Aminoglycosid...   \n",
       "10                  India  Acetanilides , Aminoglycosides , Aminophenols ...   \n",
       "11                Germany  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "12                England  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "13                    USA  Amides , Aminoglycosides , Anti-infectives , A...   \n",
       "14         Czech Republic  Abortifacients , Aminoglycosides , Anti-infect...   \n",
       "15                  Nepal  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "16                    USA  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "17                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "18                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "19            Netherlands  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "20                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "21                  Spain  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "22                Germany  2 ring heterocyclic compounds , Aminoglycoside...   \n",
       "23                    USA  Abortifacients , Acetamides , Aminoglycosides ...   \n",
       "24                  India  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "25                 France  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "26                England  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "27            Netherlands  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "28                 Russia  Acetamides , Amino acids , Aminoglycosides , A...   \n",
       "29              Australia  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "30                    USA  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "31                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "32            Netherlands  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "33            Switzerland  Amides , Aminoglycosides , Anti-infectives , A...   \n",
       "34                    USA  2 ring heterocyclic compounds , Aminoglycoside...   \n",
       "35                Germany  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "36                 Russia  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "37                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "38                  China  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "39                England  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "40                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "41                 Turkey  Abortifacients , Amidohydrolases , Aminoglycos...   \n",
       "\n",
       "      Age Group            Route Of Administration Treatment  \\\n",
       "0           NaN                                NaN       NaN   \n",
       "1       Infants                        Intravenous       NaN   \n",
       "2           NaN                                NaN       NaN   \n",
       "3           NaN                                NaN       NaN   \n",
       "4       Elderly                        Intravenous       NaN   \n",
       "5           NaN                                NaN       NaN   \n",
       "6       Elderly                                NaN       NaN   \n",
       "7   Adolescents                                NaN       NaN   \n",
       "8           NaN                  Intravenous, Oral       NaN   \n",
       "9           NaN                  Intravenous, Oral       NaN   \n",
       "10          NaN                      Oral, Topical       NaN   \n",
       "11          NaN                        Intravenous       NaN   \n",
       "12      Elderly                                NaN       NaN   \n",
       "13          NaN                                NaN       NaN   \n",
       "14     Children                                NaN       NaN   \n",
       "15          NaN                                NaN       NaN   \n",
       "16          NaN                                NaN       NaN   \n",
       "17  Adolescents                                NaN       NaN   \n",
       "18          NaN                                NaN       NaN   \n",
       "19          NaN                        Intravenous       NaN   \n",
       "20          NaN                        Intravenous       NaN   \n",
       "21          NaN                               Oral       NaN   \n",
       "22      Elderly                        Intravenous       NaN   \n",
       "23      Elderly                  Intravenous, Oral       NaN   \n",
       "24          NaN                                NaN       NaN   \n",
       "25      Infants                                NaN       NaN   \n",
       "26          NaN                                NaN       NaN   \n",
       "27          NaN                        Intravenous       NaN   \n",
       "28  Adolescents                  Intravenous, Oral       NaN   \n",
       "29          NaN                       Intravitreal       NaN   \n",
       "30     Children      Intravenous, Intraventricular       NaN   \n",
       "31      Elderly                        Intravenous       NaN   \n",
       "32          NaN                                NaN       NaN   \n",
       "33      Elderly                        Intravenous       NaN   \n",
       "34      Elderly                                NaN       NaN   \n",
       "35          NaN                                NaN       NaN   \n",
       "36     Children                               Oral       NaN   \n",
       "37          NaN  Intravenous, Intravesicular, Oral       NaN   \n",
       "38          NaN                        Intravenous       NaN   \n",
       "39      Infants                                NaN       NaN   \n",
       "40          NaN                        Intravenous       NaN   \n",
       "41     Children     Intrathecal, Intravenous, Oral       NaN   \n",
       "\n",
       "   Special Situation                                         References  \\\n",
       "0                NaN  1. Medina-Barajas F, Vazquez-Mendez E, Perez-G...   \n",
       "1                NaN  1. Hadizadeh T, Uwaifo OO. Neonatal Acute Supp...   \n",
       "2                NaN  1. Zhang P, Yang Z, Li J, Li X. Trichosporon a...   \n",
       "3                NaN  1. European Medicines Agency (EMA). Meeting hi...   \n",
       "4                NaN  1. Stokes G, Overton K, Post JJ. Update on clu...   \n",
       "5                NaN  1. Wang PP, Bray C-A, Lapierre SG, Soualhine H...   \n",
       "6                NaN  1. Nagata A, Sekiya N, Najima Y, Horiuchi M, F...   \n",
       "7                NaN  1. Desai L, Shah I, Shaan M. Retropharyngeal a...   \n",
       "8                NaN  1. Erber J, Weidlich S, Tschaikowsky T, Rothe ...   \n",
       "9                NaN  1. Zeng Q-Z, Zhang Y-Y, Wu Y-J, Zhang Z-Y, Zha...   \n",
       "10               NaN  1. Bansod KA, Bashir MSM, Ingle SS. Adverse dr...   \n",
       "11               NaN  1. Preseau T, Deviendt J, Duttman R, Attou R, ...   \n",
       "12               NaN  1. Moral MZ, Desai K, Arain AR, O'Leary RE, Ha...   \n",
       "13               NaN  1. Khil PP, Dulanto Chiang A, Ho J, Youn JH, L...   \n",
       "14               NaN  1. Bacova E, Chovanec F, Makohusova M, Hederov...   \n",
       "15               NaN  1. Keyal NK, Adhikari P, Baskota BD, Rai U, Th...   \n",
       "16               NaN  1. Hernandez-Robles CM, Velazquez-Cortes I, He...   \n",
       "17               NaN  1. Flerlage T, Brazelton de Cardenas JN, Garne...   \n",
       "18               NaN  1. Cardenas-de la Garza JA, Welsh O, Cuellar-B...   \n",
       "19               NaN  1. Prabhakar P, Batra P, Verma C, Harit D. Hyp...   \n",
       "20               NaN  1. Thirion DJG, Pasche V, Matouk E, Marsot A. ...   \n",
       "21               NaN  1. Gimenez-Arufe V, Gutierrez-Urbon JM, Blanco...   \n",
       "22               NaN  1. Buonomo AR, Maraolo AE, Scotto R, Foggia M,...   \n",
       "23               NaN  1. Modi A, Bravo T. The Paradoxical Response i...   \n",
       "24               NaN  1. Kabra MN, Kunapareddy T. Paradoxical upgrad...   \n",
       "25               NaN  1. Minh Nguyen K, Bustarret O, Jugie M, Nabbou...   \n",
       "26               NaN  1. Julian KG, Crook T, Curley E, Appenheimer A...   \n",
       "27               NaN  1. da Silva Campana P, Martinho LZM, Batista M...   \n",
       "28               NaN  1. Dinikina YuV, Shadrivova OV, Belogurova MB,...   \n",
       "29               NaN  1. Tran T, Symes R, Nolan T. Systemic nocardio...   \n",
       "30               NaN  1. Lamb GS, Del Valle Mojica C, Srinivas N, St...   \n",
       "31               NaN  1. Chen XJC, Fong K, Altshuler D, Dubrovskaya ...   \n",
       "32               NaN  1. Aziz Daghmouri M, Affes FZ, Jebri A, Boussa...   \n",
       "33               NaN  1. Vena A, Giacobbe DR, Castaldo N, Cattelan A...   \n",
       "34               NaN  1. Bosaeed M, Ahmad A, Alali A, Mahmoud E, Als...   \n",
       "35               NaN  1. Kim DJ, Lee J, Yu H, Lee DH, Kang T, Han YK...   \n",
       "36               NaN  1. Bekhtereva MK, Lobzin YuV, Ioffe MYa, Razdy...   \n",
       "37               NaN  1. Kuipers S, Ruth MM, Mientjes M, de Sevaux R...   \n",
       "38               NaN  1. Pang X-Y, Cui M, Liu X-Y, Shen J-F. Relevan...   \n",
       "39               NaN  1. Alshukairi AN, Moalim HM, Alsaedi A, Almans...   \n",
       "40               NaN  1. Ling S-O, Yau P-YA, Kwan H-Y, Yim C-W, Poon...   \n",
       "41               NaN  1. Malbora B, Avci Z, DoInmez F, AliogIlu B, B...   \n",
       "\n",
       "                                                  URL  \n",
       "0   https://adisinsight.springer.com/drugsafety/80...  \n",
       "1   https://adisinsight.springer.com/drugsafety/80...  \n",
       "2   https://adisinsight.springer.com/drugsafety/80...  \n",
       "3   https://adisinsight.springer.com/drugsafety/80...  \n",
       "4   https://adisinsight.springer.com/drugsafety/80...  \n",
       "5   https://adisinsight.springer.com/drugsafety/80...  \n",
       "6   https://adisinsight.springer.com/drugsafety/80...  \n",
       "7   https://adisinsight.springer.com/drugsafety/80...  \n",
       "8   https://adisinsight.springer.com/drugsafety/80...  \n",
       "9   https://adisinsight.springer.com/drugsafety/80...  \n",
       "10  https://adisinsight.springer.com/drugsafety/80...  \n",
       "11  https://adisinsight.springer.com/drugsafety/80...  \n",
       "12  https://adisinsight.springer.com/drugsafety/80...  \n",
       "13  https://adisinsight.springer.com/drugsafety/80...  \n",
       "14  https://adisinsight.springer.com/drugsafety/80...  \n",
       "15  https://adisinsight.springer.com/drugsafety/80...  \n",
       "16  https://adisinsight.springer.com/drugsafety/80...  \n",
       "17  https://adisinsight.springer.com/drugsafety/80...  \n",
       "18  https://adisinsight.springer.com/drugsafety/80...  \n",
       "19  https://adisinsight.springer.com/drugsafety/80...  \n",
       "20  https://adisinsight.springer.com/drugsafety/80...  \n",
       "21  https://adisinsight.springer.com/drugsafety/80...  \n",
       "22  https://adisinsight.springer.com/drugsafety/80...  \n",
       "23  https://adisinsight.springer.com/drugsafety/80...  \n",
       "24  https://adisinsight.springer.com/drugsafety/80...  \n",
       "25  https://adisinsight.springer.com/drugsafety/80...  \n",
       "26  https://adisinsight.springer.com/drugsafety/80...  \n",
       "27  https://adisinsight.springer.com/drugsafety/80...  \n",
       "28  https://adisinsight.springer.com/drugsafety/80...  \n",
       "29  https://adisinsight.springer.com/drugsafety/80...  \n",
       "30  https://adisinsight.springer.com/drugsafety/80...  \n",
       "31  https://adisinsight.springer.com/drugsafety/80...  \n",
       "32  https://adisinsight.springer.com/drugsafety/80...  \n",
       "33  https://adisinsight.springer.com/drugsafety/80...  \n",
       "34  https://adisinsight.springer.com/drugsafety/80...  \n",
       "35  https://adisinsight.springer.com/drugsafety/80...  \n",
       "36  https://adisinsight.springer.com/drugsafety/80...  \n",
       "37  https://adisinsight.springer.com/drugsafety/80...  \n",
       "38  https://adisinsight.springer.com/drugsafety/80...  \n",
       "39  https://adisinsight.springer.com/drugsafety/80...  \n",
       "40  https://adisinsight.springer.com/drugsafety/80...  \n",
       "41  https://adisinsight.springer.com/drugsafety/80...  \n",
       "\n",
       "[42 rows x 23 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "amikacina2020"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Report Id</th>\n",
       "      <th>Safety Report Name</th>\n",
       "      <th>Record Type</th>\n",
       "      <th>Release Date</th>\n",
       "      <th>Drugs</th>\n",
       "      <th>Adverse Events</th>\n",
       "      <th>Mechanism of Action</th>\n",
       "      <th>Number of Cases</th>\n",
       "      <th>Serious</th>\n",
       "      <th>First Report</th>\n",
       "      <th>...</th>\n",
       "      <th>Reporter Country</th>\n",
       "      <th>Source Country</th>\n",
       "      <th>Country of publication</th>\n",
       "      <th>Drug Class</th>\n",
       "      <th>Age Group</th>\n",
       "      <th>Route Of Administration</th>\n",
       "      <th>Treatment</th>\n",
       "      <th>Special Situation</th>\n",
       "      <th>References</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>803443542</td>\n",
       "      <td>Antituberculars - Treatment failure: 13 case r...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-12-27</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Strydom N, Gupta SV, Fox WS, Via LE, Bang H...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>803442599</td>\n",
       "      <td>Antibacterials/Quetiapine - Various toxicities...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-12-24</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Clofazim...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, K...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Aminoglycosides , Analgesics , Anti-infectives...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Tiong CW, Nack T, Tai AYC, Friedman ND. Med...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>803442529</td>\n",
       "      <td>Antibacterials/immunosuppressants - Escherichi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-12-24</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Antithym...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Czech Republic</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Acyclic acids , Aminoglycosides , Anti-infecti...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kieslichova E, Protus M, Nemcova D, Uchytil...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>803443065</td>\n",
       "      <td>Multiple drugs - Treatment failure: 3 case rep...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-12-24</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Thailand</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Nookeu P, Angkasekwinai N, Foongladda S, Ph...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>803440393</td>\n",
       "      <td>Antituberculars/antibacterials - Drug-induced ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-12-13</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Aminosal...</td>\n",
       "      <td>Liver injury drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Musso M, Mosti S, Gualano G, Mencarini P, U...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>803438871</td>\n",
       "      <td>Antibacterials - Drug resistance and lack of e...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-12-06</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Saudi Arabia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Neonates</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Alsubaie S, Anwar Z, Alhadidi M, Alsaadi B,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>803438265</td>\n",
       "      <td>Antibacterials/antifungals/antineoplastics - &lt;...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-12-03</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amphoter...</td>\n",
       "      <td>Mycoses drug-induced, Pneumonia drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Czech Republic</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>Abortifacients , Acetamides , Aminoglycosides ...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intrathecal, Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Buchta V, Bolehovska R, Hovorkova E, Cornel...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>803437662</td>\n",
       "      <td>Amikacin/meropenem/rituximab - Sudden cardiac ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-11-29</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Meropene...</td>\n",
       "      <td>Heart arrest drug-induced, Ventricular fibrill...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Poland</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Poland</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sosnowska-Pasiarska B, Zgodka P, Steckiewic...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>803437099</td>\n",
       "      <td>Amikacin/clarithromycin - Development of bacte...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-11-26</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Clarithr...</td>\n",
       "      <td>Vertigo drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Australia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Xie O, Khan S, Globan M, Lea K, Bajel A, Sl...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>803434578</td>\n",
       "      <td>Multiple drugs - Acute petrified myocardium an...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>Myocardial disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Santos ACEZ, Luglio M, Delgado AF, Schuwart...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>803431689</td>\n",
       "      <td>Amikacin/gentamicin - Various toxicities: 13 c...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-30</td>\n",
       "      <td>Amikacin adverse reactions, Gentamicin adverse...</td>\n",
       "      <td>Anorexia drug-induced, Drowsiness drug-induced...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Indonesia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>India</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Adolescents, Children, Infants</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sari SP, Sartika SS, Rianti A. Side effects...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>803430743</td>\n",
       "      <td>Antibacterials - Development of bacterial resi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-23</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Bedaquil...</td>\n",
       "      <td>Hearing loss drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Germany</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>2 ring heterocyclic compounds , Aminoglycoside...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intrapulmonary</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Polsfuss S, Hofmann-Thiel S, Merker M, Krie...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>803429564</td>\n",
       "      <td>Global report on AEs in patients with drug-res...</td>\n",
       "      <td>News</td>\n",
       "      <td>2019-10-17</td>\n",
       "      <td>Amikacin adverse reactions, Bedaquiline advers...</td>\n",
       "      <td>Heart disorders drug-induced, QT interval prol...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Russia</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>2 ring heterocyclic compounds , Acetamides , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Borisov S, Danila E, Maryandyshev A, Dalcol...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>803428169</td>\n",
       "      <td>Antibacterials - Various toxicities: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-15</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ceftriax...</td>\n",
       "      <td>Ear disorders drug-induced, Fever drug-induced...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Saudi Arabia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Fatani DF, Alsanoosi WA, Badawi MA, Thabit ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>803427892</td>\n",
       "      <td>Multiple drugs - Various toxicities: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-15</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Aspirin ...</td>\n",
       "      <td>Agranulocytosis drug-induced, Drug toxicity dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>Aminoglycosides , Analgesics , Anti-infectives...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Skaistys A, Ratz Bravo AE, Leuppi-Taegtmeye...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>803427379</td>\n",
       "      <td>Amikacin/azithromycin/imipenem - Granulomatosi...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-14</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Azithrom...</td>\n",
       "      <td>Granulomatosis with polyangiitis drug-induced,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Almeida P, Diaz R, Hernandez F, Ferrer G. A...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>803427599</td>\n",
       "      <td>Antibacterials - Gastrointestinal toxicity and...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-10-13</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Azithrom...</td>\n",
       "      <td>Gastrointestinal disorders drug-induced, Neuro...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inhalation</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Roy SB, Abdelrazek H, Luzny T, Walia R, Pan...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>803424340</td>\n",
       "      <td>Antibacterials /posaconazole - Progressive ren...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-09-27</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Dapsone ...</td>\n",
       "      <td>Liver failure drug-induced, Renal failure drug...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Amides , Aminoglycosides , Anti-infectives , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inhalation</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Aslam S, Courtwright AM, Koval C, Lehman SM...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>803420428</td>\n",
       "      <td>Amikacin/clarithromycin/moxifloxacin - QT prol...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-09-09</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Clarithr...</td>\n",
       "      <td>QT interval prolongation drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Wallace J-A, Miskin H, Cannella A, Taha O. ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>803417978</td>\n",
       "      <td>Amikacin/cefoxitin - Acute kidney injury, drug...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-30</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>Acute kidney injury drug-induced, Ear disorder...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Hamad Y, Pilewski JM, Morrell M, D'Cunha J,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>803416596</td>\n",
       "      <td>Antibacterials - Treatment failure: 7 case rep...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-08-23</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Goldstein N, St Clair JB, Kasperbauer SH, D...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>803416574</td>\n",
       "      <td>Multiple drugs - Multisystem toxicities: 7 cas...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-23</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Azathiop...</td>\n",
       "      <td>Acute kidney injury drug-induced, Fever drug-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Abortifacients , Acyclic acids , Aminoglycosid...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Goldstein N, St Clair JB, Kasperbauer SH, D...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>803415958</td>\n",
       "      <td>Amikacin - Ototoxicity: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-20</td>\n",
       "      <td>Amikacin adverse reactions (Serious)</td>\n",
       "      <td>Ear disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Musharbash M, Para A, Choi J. Widespread cu...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>803415644</td>\n",
       "      <td>Amikacin/prednisone/vancomycin - Deafness and ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-19</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Predniso...</td>\n",
       "      <td>Cataracts drug-induced, Deafness drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Anti-infla...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Nisimoto MYSM, Rubinho R, Morales AG, Faria...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>803415012</td>\n",
       "      <td>Multiple drugs - BCGitis, elevated liver enzym...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-16</td>\n",
       "      <td>Amikacin adverse reactions, BCG vaccine advers...</td>\n",
       "      <td>Abnormal laboratory parameters drug-induced, E...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Saudi Arabia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Children, Infants</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Alsuhaibani M, Felimban G, Shoukri M, Alosa...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>803411789</td>\n",
       "      <td>Multiple drugs - Latent tuberculosis reactivat...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-02</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Cotrimox...</td>\n",
       "      <td>Tuberculosis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>South Korea</td>\n",
       "      <td>NaN</td>\n",
       "      <td>South Korea</td>\n",
       "      <td>Amides , Aminoglycosides , Anti-infectives , A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kim DJ, Jeong S, Kong SG, Lee HS. First cas...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>803411513</td>\n",
       "      <td>Antimicrobials - DRESS syndrome: 2 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-02</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Cotrimox...</td>\n",
       "      <td>DRESS syndrome drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kizilbash Q, Vasquez A, Seaworth B. Strateg...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>803411670</td>\n",
       "      <td>Amikacin/ciclosporin - &lt;EM&gt;Mycobacterium absce...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-08-02</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ciclospo...</td>\n",
       "      <td>Kidney disorders drug-induced, Lymphadenitis d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Pakistan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Pakistan</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Anti-infla...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Khalid M, Ali SA. Mycobacterium abscessus l...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>803409351</td>\n",
       "      <td>Antituberculars - Novel gene mutations leading...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-23</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Aminosal...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>China</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Anti-infla...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Sun L, Zhang L, Wang T, Jiao W, Li Q, Yin Q...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>803406889</td>\n",
       "      <td>Amikacin - Various toxicities: 4 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-12</td>\n",
       "      <td>Amikacin adverse reactions (Serious)</td>\n",
       "      <td>Acute kidney injury drug-induced, Ear disorder...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Aznar ML, Marras TK, Elshal AS, Mehrabi M, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>803406463</td>\n",
       "      <td>Antibacterials/antifungals - Lack of efficacy:...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-10</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Elderly</td>\n",
       "      <td>Ophthalmic, Oral, Topical</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Martinez JD, Arboleda A, Naranjo A, Aguilar...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>803405255</td>\n",
       "      <td>Multiple drugs - Oliguric acute kidney injury ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-05</td>\n",
       "      <td>Aciclovir adverse reactions (Serious), Amikaci...</td>\n",
       "      <td>Acute kidney injury drug-induced, Leucopenia d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Acyclic acids , Aminoglycosides , Anti-infecti...</td>\n",
       "      <td>Adolescents, Children</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Cocchi E, Chiale F, Gianoglio B, Deorsola L...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>803405526</td>\n",
       "      <td>Multiple drugs - Toxic agranulocytosis, aggrav...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-04</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>Agranulocytosis drug-induced, Sepsis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Amines , Aminoglycosides , Analgesics , Anti-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Contou D, Lecronier M, Bitot V, Hersant B, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>803404956</td>\n",
       "      <td>Antibacterials - Various toxicities: 6 case re...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-07-02</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Cefoxiti...</td>\n",
       "      <td>Ear disorders drug-induced, Kidney disorders d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>Adolescents</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Perez AA, Singer JP, Schwartz BS, Chin-Hong...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>803397216</td>\n",
       "      <td>Antibacterials/antineoplastics - &lt;EM&gt;Geotrichu...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-06-03</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Colistin...</td>\n",
       "      <td>Febrile neutropenia drug-induced, Fungaemia dr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Tunisia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Ben Neji H, Bchir M, Hamdoun M, Kallel A, K...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>803394020</td>\n",
       "      <td>Antibacterials - Acquired blood coagulation fa...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-05-17</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ceftazid...</td>\n",
       "      <td>Blood coagulation disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>China</td>\n",
       "      <td>NaN</td>\n",
       "      <td>China</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bi XJ, Jin XF, Zhang HF, Su ZX, Shen B. Acq...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>803392294</td>\n",
       "      <td>Multiple drugs - Various toxicites and off-lab...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-05-10</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Azithrom...</td>\n",
       "      <td>Hearing loss drug-induced, Liver injury drug-i...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Belgium</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Raats D, Lorent N, Saegeman V, Vos R, van I...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>803390581</td>\n",
       "      <td>Anti-tuberculosis regimen - Exposure during pr...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-05-03</td>\n",
       "      <td>Amikacin adverse reactions, Amoxicillin advers...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Peru</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Peru</td>\n",
       "      <td>Acetamides , Aminoglycosides , Anti-infectives...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Del Castillo H, Lopez AS, Temoche AP, Mosqu...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>803390441</td>\n",
       "      <td>Antibacterials - Lack of efficacy: case report</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-05-03</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>India</td>\n",
       "      <td>NaN</td>\n",
       "      <td>England</td>\n",
       "      <td>2 ring heterocyclic compounds , Aminoglycoside...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Vanukuru J, Bagga R, Muthyala T, Gautam V, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>803390349</td>\n",
       "      <td>Amikacin - Treatment failure in &lt;EM&gt;Klebsiella...</td>\n",
       "      <td>Special Situation Case Report</td>\n",
       "      <td>2019-04-30</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Freire MP, de Oliveira Garcia D, Cury AP, F...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>803389895</td>\n",
       "      <td>Amikacin - Graft loss due to nephrotoxicity: c...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-04-30</td>\n",
       "      <td>Amikacin adverse reactions (Serious)</td>\n",
       "      <td>Drug toxicity drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Germany</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Freire MP, de Oliveira Garcia D, Cury AP, F...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>803382262</td>\n",
       "      <td>Multiple drugs - Dress syndrome and Stevens-Jo...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-03-29</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Carbamaz...</td>\n",
       "      <td>DRESS syndrome drug-induced, Stevens-Johnson s...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>16.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>South Korea</td>\n",
       "      <td>NaN</td>\n",
       "      <td>South Korea</td>\n",
       "      <td>Abortifacients , Aminoglycosides , Anthracycli...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Kang MG, Sohn KH, Kang DY, Park HK, Yang MS...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>803381614</td>\n",
       "      <td>Amikacin/Azathioprine - Mycobacterium chimaera...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-03-25</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Azathiop...</td>\n",
       "      <td>Mycobacterial infections drug-induced, Renal f...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Haager PK, Hoffmann M, Hasse B, Maisano F, ...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>803381782</td>\n",
       "      <td>Antibiotics - Fever: 2 case reports</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-03-25</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amoxicil...</td>\n",
       "      <td>Fever drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>France</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Children, Infants</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Bernier M, Duquesne F, Zemouri N, Akhdar M,...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>803381116</td>\n",
       "      <td>Amikacin/tobramycin - Various toxicities: 4 ca...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-03-22</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Tobramyc...</td>\n",
       "      <td>Hearing loss drug-induced, Sensorineural heari...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intravenous</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Garinis AC, Keefe DH, Hunter LL, Fitzpatric...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>803379942</td>\n",
       "      <td>Amikacin overdose - Vomiting secondary to amik...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-03-14</td>\n",
       "      <td>Amikacin overdose (Serious)</td>\n",
       "      <td>Drug toxicity drug-induced, Vomiting drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Turkey</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Turkey</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Infants</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gucer E, Yalaki Z, Arikan FI, Dallar Y. Are...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>803377631</td>\n",
       "      <td>Itraconazole/salmeterol/fluticasone-propionate...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-03-01</td>\n",
       "      <td>Amikacin adverse reactions, Fluticasone propio...</td>\n",
       "      <td>Adrenal insufficiency drug-induced, Mycobacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>Aminoglycosides , Androstadienes , Anti-infect...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inhalation, Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Gynthersen R, Qvist T, Andersen AB, Katzens...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>803375918</td>\n",
       "      <td>Amikacin/ethambutol - Retinal and renal toxici...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-02-18</td>\n",
       "      <td>Amikacin adverse reactions, Ethambutol adverse...</td>\n",
       "      <td>Kidney disorders drug-induced, Retinal disorde...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>USA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Shah VN, Orlov OI, Sternlieb MP, Plestis KA...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>803375443</td>\n",
       "      <td>Amikacin/ceftazidime/oxacillin - Toxic epiderm...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-02-14</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Ceftazid...</td>\n",
       "      <td>Toxic epidermal necrolysis drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Brazil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Children</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Rocha AL, De Souza AF, Nunes LFM, Cunha NDS...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>803368528</td>\n",
       "      <td>Antibacterials/antifungals/BCG vaccine - Lack ...</td>\n",
       "      <td>ADR Case Report</td>\n",
       "      <td>2019-01-11</td>\n",
       "      <td>Amikacin adverse reactions (Serious), Amikacin...</td>\n",
       "      <td>Immunodeficiency disorders drug-induced</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>...</td>\n",
       "      <td>Ukraine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Hungary</td>\n",
       "      <td>Aminoglycosides , Anti-infectives , Antibacter...</td>\n",
       "      <td>Neonates</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1. Smiyan O, Lyndin M, Romaniuk O, Sikora V, P...</td>\n",
       "      <td>https://adisinsight.springer.com/drugsafety/80...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>50 rows  23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Report Id                                 Safety Report Name  \\\n",
       "0   803443542  Antituberculars - Treatment failure: 13 case r...   \n",
       "1   803442599  Antibacterials/Quetiapine - Various toxicities...   \n",
       "2   803442529  Antibacterials/immunosuppressants - Escherichi...   \n",
       "3   803443065  Multiple drugs - Treatment failure: 3 case rep...   \n",
       "4   803440393  Antituberculars/antibacterials - Drug-induced ...   \n",
       "5   803438871  Antibacterials - Drug resistance and lack of e...   \n",
       "6   803438265  Antibacterials/antifungals/antineoplastics - <...   \n",
       "7   803437662  Amikacin/meropenem/rituximab - Sudden cardiac ...   \n",
       "8   803437099  Amikacin/clarithromycin - Development of bacte...   \n",
       "9   803434578  Multiple drugs - Acute petrified myocardium an...   \n",
       "10  803431689  Amikacin/gentamicin - Various toxicities: 13 c...   \n",
       "11  803430743  Antibacterials - Development of bacterial resi...   \n",
       "12  803429564  Global report on AEs in patients with drug-res...   \n",
       "13  803428169   Antibacterials - Various toxicities: case report   \n",
       "14  803427892   Multiple drugs - Various toxicities: case report   \n",
       "15  803427379  Amikacin/azithromycin/imipenem - Granulomatosi...   \n",
       "16  803427599  Antibacterials - Gastrointestinal toxicity and...   \n",
       "17  803424340  Antibacterials /posaconazole - Progressive ren...   \n",
       "18  803420428  Amikacin/clarithromycin/moxifloxacin - QT prol...   \n",
       "19  803417978  Amikacin/cefoxitin - Acute kidney injury, drug...   \n",
       "20  803416596  Antibacterials - Treatment failure: 7 case rep...   \n",
       "21  803416574  Multiple drugs - Multisystem toxicities: 7 cas...   \n",
       "22  803415958                Amikacin - Ototoxicity: case report   \n",
       "23  803415644  Amikacin/prednisone/vancomycin - Deafness and ...   \n",
       "24  803415012  Multiple drugs - BCGitis, elevated liver enzym...   \n",
       "25  803411789  Multiple drugs - Latent tuberculosis reactivat...   \n",
       "26  803411513    Antimicrobials - DRESS syndrome: 2 case reports   \n",
       "27  803411670  Amikacin/ciclosporin - <EM>Mycobacterium absce...   \n",
       "28  803409351  Antituberculars - Novel gene mutations leading...   \n",
       "29  803406889      Amikacin - Various toxicities: 4 case reports   \n",
       "30  803406463  Antibacterials/antifungals - Lack of efficacy:...   \n",
       "31  803405255  Multiple drugs - Oliguric acute kidney injury ...   \n",
       "32  803405526  Multiple drugs - Toxic agranulocytosis, aggrav...   \n",
       "33  803404956  Antibacterials - Various toxicities: 6 case re...   \n",
       "34  803397216  Antibacterials/antineoplastics - <EM>Geotrichu...   \n",
       "35  803394020  Antibacterials - Acquired blood coagulation fa...   \n",
       "36  803392294  Multiple drugs - Various toxicites and off-lab...   \n",
       "37  803390581  Anti-tuberculosis regimen - Exposure during pr...   \n",
       "38  803390441     Antibacterials - Lack of efficacy: case report   \n",
       "39  803390349  Amikacin - Treatment failure in <EM>Klebsiella...   \n",
       "40  803389895  Amikacin - Graft loss due to nephrotoxicity: c...   \n",
       "41  803382262  Multiple drugs - Dress syndrome and Stevens-Jo...   \n",
       "42  803381614  Amikacin/Azathioprine - Mycobacterium chimaera...   \n",
       "43  803381782                Antibiotics - Fever: 2 case reports   \n",
       "44  803381116  Amikacin/tobramycin - Various toxicities: 4 ca...   \n",
       "45  803379942  Amikacin overdose - Vomiting secondary to amik...   \n",
       "46  803377631  Itraconazole/salmeterol/fluticasone-propionate...   \n",
       "47  803375918  Amikacin/ethambutol - Retinal and renal toxici...   \n",
       "48  803375443  Amikacin/ceftazidime/oxacillin - Toxic epiderm...   \n",
       "49  803368528  Antibacterials/antifungals/BCG vaccine - Lack ...   \n",
       "\n",
       "                      Record Type Release Date  \\\n",
       "0   Special Situation Case Report   2019-12-27   \n",
       "1                 ADR Case Report   2019-12-24   \n",
       "2                 ADR Case Report   2019-12-24   \n",
       "3   Special Situation Case Report   2019-12-24   \n",
       "4                 ADR Case Report   2019-12-13   \n",
       "5                 ADR Case Report   2019-12-06   \n",
       "6                 ADR Case Report   2019-12-03   \n",
       "7                 ADR Case Report   2019-11-29   \n",
       "8                 ADR Case Report   2019-11-26   \n",
       "9                 ADR Case Report   2019-11-15   \n",
       "10                ADR Case Report   2019-10-30   \n",
       "11                ADR Case Report   2019-10-23   \n",
       "12                           News   2019-10-17   \n",
       "13                ADR Case Report   2019-10-15   \n",
       "14                ADR Case Report   2019-10-15   \n",
       "15                ADR Case Report   2019-10-14   \n",
       "16                ADR Case Report   2019-10-13   \n",
       "17                ADR Case Report   2019-09-27   \n",
       "18                ADR Case Report   2019-09-09   \n",
       "19                ADR Case Report   2019-08-30   \n",
       "20  Special Situation Case Report   2019-08-23   \n",
       "21                ADR Case Report   2019-08-23   \n",
       "22                ADR Case Report   2019-08-20   \n",
       "23                ADR Case Report   2019-08-19   \n",
       "24                ADR Case Report   2019-08-16   \n",
       "25                ADR Case Report   2019-08-02   \n",
       "26                ADR Case Report   2019-08-02   \n",
       "27                ADR Case Report   2019-08-02   \n",
       "28                ADR Case Report   2019-07-23   \n",
       "29                ADR Case Report   2019-07-12   \n",
       "30                ADR Case Report   2019-07-10   \n",
       "31                ADR Case Report   2019-07-05   \n",
       "32                ADR Case Report   2019-07-04   \n",
       "33                ADR Case Report   2019-07-02   \n",
       "34                ADR Case Report   2019-06-03   \n",
       "35                ADR Case Report   2019-05-17   \n",
       "36                ADR Case Report   2019-05-10   \n",
       "37  Special Situation Case Report   2019-05-03   \n",
       "38                ADR Case Report   2019-05-03   \n",
       "39  Special Situation Case Report   2019-04-30   \n",
       "40                ADR Case Report   2019-04-30   \n",
       "41                ADR Case Report   2019-03-29   \n",
       "42                ADR Case Report   2019-03-25   \n",
       "43                ADR Case Report   2019-03-25   \n",
       "44                ADR Case Report   2019-03-22   \n",
       "45                ADR Case Report   2019-03-14   \n",
       "46                ADR Case Report   2019-03-01   \n",
       "47                ADR Case Report   2019-02-18   \n",
       "48                ADR Case Report   2019-02-14   \n",
       "49                ADR Case Report   2019-01-11   \n",
       "\n",
       "                                                Drugs  \\\n",
       "0   Amikacin adverse reactions (Serious), Amikacin...   \n",
       "1   Amikacin adverse reactions (Serious), Clofazim...   \n",
       "2   Amikacin adverse reactions (Serious), Antithym...   \n",
       "3   Amikacin adverse reactions (Serious), Amikacin...   \n",
       "4   Amikacin adverse reactions (Serious), Aminosal...   \n",
       "5   Amikacin adverse reactions (Serious), Amikacin...   \n",
       "6   Amikacin adverse reactions (Serious), Amphoter...   \n",
       "7   Amikacin adverse reactions (Serious), Meropene...   \n",
       "8   Amikacin adverse reactions (Serious), Clarithr...   \n",
       "9   Amikacin adverse reactions (Serious), Amikacin...   \n",
       "10  Amikacin adverse reactions, Gentamicin adverse...   \n",
       "11  Amikacin adverse reactions (Serious), Bedaquil...   \n",
       "12  Amikacin adverse reactions, Bedaquiline advers...   \n",
       "13  Amikacin adverse reactions (Serious), Ceftriax...   \n",
       "14  Amikacin adverse reactions (Serious), Aspirin ...   \n",
       "15  Amikacin adverse reactions (Serious), Azithrom...   \n",
       "16  Amikacin adverse reactions (Serious), Azithrom...   \n",
       "17  Amikacin adverse reactions (Serious), Dapsone ...   \n",
       "18  Amikacin adverse reactions (Serious), Clarithr...   \n",
       "19  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "20  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "21  Amikacin adverse reactions (Serious), Azathiop...   \n",
       "22               Amikacin adverse reactions (Serious)   \n",
       "23  Amikacin adverse reactions (Serious), Predniso...   \n",
       "24  Amikacin adverse reactions, BCG vaccine advers...   \n",
       "25  Amikacin adverse reactions (Serious), Cotrimox...   \n",
       "26  Amikacin adverse reactions (Serious), Cotrimox...   \n",
       "27  Amikacin adverse reactions (Serious), Ciclospo...   \n",
       "28  Amikacin adverse reactions (Serious), Aminosal...   \n",
       "29               Amikacin adverse reactions (Serious)   \n",
       "30  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "31  Aciclovir adverse reactions (Serious), Amikaci...   \n",
       "32  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "33  Amikacin adverse reactions (Serious), Cefoxiti...   \n",
       "34  Amikacin adverse reactions (Serious), Colistin...   \n",
       "35  Amikacin adverse reactions (Serious), Ceftazid...   \n",
       "36  Amikacin adverse reactions (Serious), Azithrom...   \n",
       "37  Amikacin adverse reactions, Amoxicillin advers...   \n",
       "38  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "39  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "40               Amikacin adverse reactions (Serious)   \n",
       "41  Amikacin adverse reactions (Serious), Carbamaz...   \n",
       "42  Amikacin adverse reactions (Serious), Azathiop...   \n",
       "43  Amikacin adverse reactions (Serious), Amoxicil...   \n",
       "44  Amikacin adverse reactions (Serious), Tobramyc...   \n",
       "45                        Amikacin overdose (Serious)   \n",
       "46  Amikacin adverse reactions, Fluticasone propio...   \n",
       "47  Amikacin adverse reactions, Ethambutol adverse...   \n",
       "48  Amikacin adverse reactions (Serious), Ceftazid...   \n",
       "49  Amikacin adverse reactions (Serious), Amikacin...   \n",
       "\n",
       "                                       Adverse Events  Mechanism of Action  \\\n",
       "0                                                 NaN                  NaN   \n",
       "1   Abnormal laboratory parameters drug-induced, K...                  NaN   \n",
       "2                                                 NaN                  NaN   \n",
       "3                                                 NaN                  NaN   \n",
       "4                           Liver injury drug-induced                  NaN   \n",
       "5                                                 NaN                  NaN   \n",
       "6        Mycoses drug-induced, Pneumonia drug-induced                  NaN   \n",
       "7   Heart arrest drug-induced, Ventricular fibrill...                  NaN   \n",
       "8                                Vertigo drug-induced                  NaN   \n",
       "9                   Myocardial disorders drug-induced                  NaN   \n",
       "10  Anorexia drug-induced, Drowsiness drug-induced...                  NaN   \n",
       "11                          Hearing loss drug-induced                  NaN   \n",
       "12  Heart disorders drug-induced, QT interval prol...                  NaN   \n",
       "13  Ear disorders drug-induced, Fever drug-induced...                  NaN   \n",
       "14  Agranulocytosis drug-induced, Drug toxicity dr...                  NaN   \n",
       "15  Granulomatosis with polyangiitis drug-induced,...                  NaN   \n",
       "16  Gastrointestinal disorders drug-induced, Neuro...                  NaN   \n",
       "17  Liver failure drug-induced, Renal failure drug...                  NaN   \n",
       "18              QT interval prolongation drug-induced                  NaN   \n",
       "19  Acute kidney injury drug-induced, Ear disorder...                  NaN   \n",
       "20                                                NaN                  NaN   \n",
       "21  Acute kidney injury drug-induced, Fever drug-i...                  NaN   \n",
       "22                         Ear disorders drug-induced                  NaN   \n",
       "23      Cataracts drug-induced, Deafness drug-induced                  NaN   \n",
       "24  Abnormal laboratory parameters drug-induced, E...                  NaN   \n",
       "25                          Tuberculosis drug-induced                  NaN   \n",
       "26                        DRESS syndrome drug-induced                  NaN   \n",
       "27  Kidney disorders drug-induced, Lymphadenitis d...                  NaN   \n",
       "28                                                NaN                  NaN   \n",
       "29  Acute kidney injury drug-induced, Ear disorder...                  NaN   \n",
       "30                                                NaN                  NaN   \n",
       "31  Acute kidney injury drug-induced, Leucopenia d...                  NaN   \n",
       "32  Agranulocytosis drug-induced, Sepsis drug-induced                  NaN   \n",
       "33  Ear disorders drug-induced, Kidney disorders d...                  NaN   \n",
       "34  Febrile neutropenia drug-induced, Fungaemia dr...                  NaN   \n",
       "35           Blood coagulation disorders drug-induced                  NaN   \n",
       "36  Hearing loss drug-induced, Liver injury drug-i...                  NaN   \n",
       "37                                                NaN                  NaN   \n",
       "38                                                NaN                  NaN   \n",
       "39                                                NaN                  NaN   \n",
       "40                         Drug toxicity drug-induced                  NaN   \n",
       "41  DRESS syndrome drug-induced, Stevens-Johnson s...                  NaN   \n",
       "42  Mycobacterial infections drug-induced, Renal f...                  NaN   \n",
       "43                                 Fever drug-induced                  NaN   \n",
       "44  Hearing loss drug-induced, Sensorineural heari...                  NaN   \n",
       "45  Drug toxicity drug-induced, Vomiting drug-induced                  NaN   \n",
       "46  Adrenal insufficiency drug-induced, Mycobacter...                  NaN   \n",
       "47  Kidney disorders drug-induced, Retinal disorde...                  NaN   \n",
       "48            Toxic epidermal necrolysis drug-induced                  NaN   \n",
       "49            Immunodeficiency disorders drug-induced                  NaN   \n",
       "\n",
       "    Number of Cases Serious First Report  ... Reporter Country Source Country  \\\n",
       "0              13.0     Yes           No  ...              USA            NaN   \n",
       "1               1.0     Yes           No  ...        Australia            NaN   \n",
       "2               4.0     Yes           No  ...   Czech Republic            NaN   \n",
       "3               3.0     Yes           No  ...         Thailand            NaN   \n",
       "4               2.0     Yes           No  ...            Italy            NaN   \n",
       "5               8.0     Yes           No  ...     Saudi Arabia            NaN   \n",
       "6               6.0     Yes           No  ...   Czech Republic            NaN   \n",
       "7               1.0     Yes           No  ...           Poland            NaN   \n",
       "8               1.0     Yes           No  ...        Australia            NaN   \n",
       "9               1.0     Yes           No  ...           Brazil            NaN   \n",
       "10             13.0      No           No  ...        Indonesia            NaN   \n",
       "11              1.0     Yes           No  ...          Germany            NaN   \n",
       "12              NaN      No           No  ...              NaN         Russia   \n",
       "13              1.0     Yes           No  ...     Saudi Arabia            NaN   \n",
       "14              1.0     Yes           No  ...      Switzerland            NaN   \n",
       "15              1.0     Yes           No  ...              USA            NaN   \n",
       "16              1.0     Yes           No  ...          Unknown            NaN   \n",
       "17              2.0     Yes           No  ...              USA            NaN   \n",
       "18              1.0     Yes           No  ...              USA            NaN   \n",
       "19              2.0     Yes           No  ...              USA            NaN   \n",
       "20              7.0     Yes           No  ...              USA            NaN   \n",
       "21              7.0     Yes           No  ...              USA            NaN   \n",
       "22              1.0     Yes           No  ...              USA            NaN   \n",
       "23              1.0     Yes           No  ...           Brazil            NaN   \n",
       "24             10.0     Yes           No  ...     Saudi Arabia            NaN   \n",
       "25              1.0     Yes           No  ...      South Korea            NaN   \n",
       "26              2.0     Yes           No  ...              USA            NaN   \n",
       "27              1.0     Yes           No  ...         Pakistan            NaN   \n",
       "28              1.0     Yes           No  ...            China            NaN   \n",
       "29              4.0     Yes           No  ...           Canada            NaN   \n",
       "30              3.0     Yes           No  ...              USA            NaN   \n",
       "31              2.0     Yes           No  ...            Italy            NaN   \n",
       "32              1.0     Yes           No  ...           France            NaN   \n",
       "33              6.0     Yes           No  ...              USA            NaN   \n",
       "34              4.0     Yes           No  ...          Tunisia            NaN   \n",
       "35              1.0     Yes           No  ...            China            NaN   \n",
       "36              4.0     Yes           No  ...          Belgium            NaN   \n",
       "37              1.0      No           No  ...             Peru            NaN   \n",
       "38              1.0     Yes           No  ...            India            NaN   \n",
       "39              4.0     Yes           No  ...           Brazil            NaN   \n",
       "40              1.0     Yes           No  ...           Brazil            NaN   \n",
       "41             16.0     Yes           No  ...      South Korea            NaN   \n",
       "42              1.0     Yes           No  ...      Switzerland            NaN   \n",
       "43              2.0     Yes           No  ...           France            NaN   \n",
       "44              4.0     Yes           No  ...              USA            NaN   \n",
       "45              1.0     Yes           No  ...           Turkey            NaN   \n",
       "46              1.0     Yes           No  ...          Denmark            NaN   \n",
       "47              1.0     Yes           No  ...              USA            NaN   \n",
       "48              1.0     Yes           No  ...           Brazil            NaN   \n",
       "49              1.0     Yes           No  ...          Ukraine            NaN   \n",
       "\n",
       "   Country of publication                                         Drug Class  \\\n",
       "0                     USA  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "1                 England  Aminoglycosides , Analgesics , Anti-infectives...   \n",
       "2                 England  Acyclic acids , Aminoglycosides , Anti-infecti...   \n",
       "3                     USA  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "4                 England  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "5                     USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "6             Switzerland  Abortifacients , Acetamides , Aminoglycosides ...   \n",
       "7                  Poland  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "8                 Denmark  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "9                  Brazil  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "10                  India  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "11                    USA  2 ring heterocyclic compounds , Aminoglycoside...   \n",
       "12                Denmark  2 ring heterocyclic compounds , Acetamides , A...   \n",
       "13            Netherlands  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "14            Switzerland  Aminoglycosides , Analgesics , Anti-infectives...   \n",
       "15                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "16                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "17                England  Amides , Aminoglycosides , Anti-infectives , A...   \n",
       "18                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "19                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "20                    USA  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "21                    USA  Abortifacients , Acyclic acids , Aminoglycosid...   \n",
       "22                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "23                    USA  Aminoglycosides , Anti-infectives , Anti-infla...   \n",
       "24            Netherlands  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "25            South Korea  Amides , Aminoglycosides , Anti-infectives , A...   \n",
       "26                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "27               Pakistan  Aminoglycosides , Anti-infectives , Anti-infla...   \n",
       "28            Netherlands  Aminoglycosides , Anti-infectives , Anti-infla...   \n",
       "29                England  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "30                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "31                    USA  Acyclic acids , Aminoglycosides , Anti-infecti...   \n",
       "32                 France  Amines , Aminoglycosides , Analgesics , Anti-i...   \n",
       "33                Denmark  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "34                 France  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "35                  China  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "36                Denmark  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "37                   Peru  Acetamides , Aminoglycosides , Anti-infectives...   \n",
       "38                England  2 ring heterocyclic compounds , Aminoglycoside...   \n",
       "39                Germany  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "40                Germany  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "41            South Korea  Abortifacients , Aminoglycosides , Anthracycli...   \n",
       "42            Switzerland  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "43                 France  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "44                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "45                 Turkey  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "46                Denmark  Aminoglycosides , Androstadienes , Anti-infect...   \n",
       "47            Netherlands  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "48                    USA  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "49                Hungary  Aminoglycosides , Anti-infectives , Antibacter...   \n",
       "\n",
       "                         Age Group         Route Of Administration Treatment  \\\n",
       "0                              NaN                             NaN       NaN   \n",
       "1                              NaN               Intravenous, Oral       NaN   \n",
       "2                              NaN                     Intravenous       NaN   \n",
       "3                          Elderly                             NaN       NaN   \n",
       "4                          Elderly                             NaN       NaN   \n",
       "5                         Neonates                             NaN       NaN   \n",
       "6                          Elderly  Intrathecal, Intravenous, Oral       NaN   \n",
       "7                              NaN                     Intravenous       NaN   \n",
       "8                              NaN                             NaN       NaN   \n",
       "9                      Adolescents                             NaN       NaN   \n",
       "10  Adolescents, Children, Infants                             NaN       NaN   \n",
       "11                             NaN                  Intrapulmonary       NaN   \n",
       "12                             NaN                             NaN       NaN   \n",
       "13                             NaN               Intravenous, Oral       NaN   \n",
       "14                         Elderly                            Oral       NaN   \n",
       "15                             NaN                             NaN       NaN   \n",
       "16                             NaN                      Inhalation       NaN   \n",
       "17                             NaN                      Inhalation       NaN   \n",
       "18                             NaN                             NaN       NaN   \n",
       "19                             NaN                     Intravenous       NaN   \n",
       "20                         Elderly               Intravenous, Oral       NaN   \n",
       "21                         Elderly               Intravenous, Oral       NaN   \n",
       "22                         Elderly                     Intravenous       NaN   \n",
       "23                             NaN                             NaN       NaN   \n",
       "24               Children, Infants                            Oral       NaN   \n",
       "25                             NaN                            Oral       NaN   \n",
       "26                             NaN                             NaN       NaN   \n",
       "27                     Adolescents                     Intravenous       NaN   \n",
       "28                             NaN                             NaN       NaN   \n",
       "29                             NaN                     Intravenous       NaN   \n",
       "30                         Elderly       Ophthalmic, Oral, Topical       NaN   \n",
       "31           Adolescents, Children                             NaN       NaN   \n",
       "32                             NaN               Intravenous, Oral       NaN   \n",
       "33                     Adolescents               Intravenous, Oral       NaN   \n",
       "34                             NaN                             NaN       NaN   \n",
       "35                             NaN                             NaN       NaN   \n",
       "36                             NaN               Intravenous, Oral       NaN   \n",
       "37                             NaN                             NaN       NaN   \n",
       "38                             NaN                             NaN       NaN   \n",
       "39                             NaN                             NaN       NaN   \n",
       "40                             NaN                             NaN       NaN   \n",
       "41                             NaN                             NaN       NaN   \n",
       "42                             NaN                             NaN       NaN   \n",
       "43               Children, Infants                     Intravenous       NaN   \n",
       "44                             NaN                     Intravenous       NaN   \n",
       "45                         Infants                             NaN       NaN   \n",
       "46                             NaN                Inhalation, Oral       NaN   \n",
       "47                             NaN                             NaN       NaN   \n",
       "48                        Children                             NaN       NaN   \n",
       "49                        Neonates                             NaN       NaN   \n",
       "\n",
       "   Special Situation                                         References  \\\n",
       "0                NaN  1. Strydom N, Gupta SV, Fox WS, Via LE, Bang H...   \n",
       "1                NaN  1. Tiong CW, Nack T, Tai AYC, Friedman ND. Med...   \n",
       "2                NaN  1. Kieslichova E, Protus M, Nemcova D, Uchytil...   \n",
       "3                NaN  1. Nookeu P, Angkasekwinai N, Foongladda S, Ph...   \n",
       "4                NaN  1. Musso M, Mosti S, Gualano G, Mencarini P, U...   \n",
       "5                NaN  1. Alsubaie S, Anwar Z, Alhadidi M, Alsaadi B,...   \n",
       "6                NaN  1. Buchta V, Bolehovska R, Hovorkova E, Cornel...   \n",
       "7                NaN  1. Sosnowska-Pasiarska B, Zgodka P, Steckiewic...   \n",
       "8                NaN  1. Xie O, Khan S, Globan M, Lea K, Bajel A, Sl...   \n",
       "9                NaN  1. Santos ACEZ, Luglio M, Delgado AF, Schuwart...   \n",
       "10               NaN  1. Sari SP, Sartika SS, Rianti A. Side effects...   \n",
       "11               NaN  1. Polsfuss S, Hofmann-Thiel S, Merker M, Krie...   \n",
       "12               NaN  1. Borisov S, Danila E, Maryandyshev A, Dalcol...   \n",
       "13               NaN  1. Fatani DF, Alsanoosi WA, Badawi MA, Thabit ...   \n",
       "14               NaN  1. Skaistys A, Ratz Bravo AE, Leuppi-Taegtmeye...   \n",
       "15               NaN  1. Almeida P, Diaz R, Hernandez F, Ferrer G. A...   \n",
       "16               NaN  1. Roy SB, Abdelrazek H, Luzny T, Walia R, Pan...   \n",
       "17               NaN  1. Aslam S, Courtwright AM, Koval C, Lehman SM...   \n",
       "18               NaN  1. Wallace J-A, Miskin H, Cannella A, Taha O. ...   \n",
       "19               NaN  1. Hamad Y, Pilewski JM, Morrell M, D'Cunha J,...   \n",
       "20               NaN  1. Goldstein N, St Clair JB, Kasperbauer SH, D...   \n",
       "21               NaN  1. Goldstein N, St Clair JB, Kasperbauer SH, D...   \n",
       "22               NaN  1. Musharbash M, Para A, Choi J. Widespread cu...   \n",
       "23               NaN  1. Nisimoto MYSM, Rubinho R, Morales AG, Faria...   \n",
       "24               NaN  1. Alsuhaibani M, Felimban G, Shoukri M, Alosa...   \n",
       "25               NaN  1. Kim DJ, Jeong S, Kong SG, Lee HS. First cas...   \n",
       "26               NaN  1. Kizilbash Q, Vasquez A, Seaworth B. Strateg...   \n",
       "27               NaN  1. Khalid M, Ali SA. Mycobacterium abscessus l...   \n",
       "28               NaN  1. Sun L, Zhang L, Wang T, Jiao W, Li Q, Yin Q...   \n",
       "29               NaN  1. Aznar ML, Marras TK, Elshal AS, Mehrabi M, ...   \n",
       "30               NaN  1. Martinez JD, Arboleda A, Naranjo A, Aguilar...   \n",
       "31               NaN  1. Cocchi E, Chiale F, Gianoglio B, Deorsola L...   \n",
       "32               NaN  1. Contou D, Lecronier M, Bitot V, Hersant B, ...   \n",
       "33               NaN  1. Perez AA, Singer JP, Schwartz BS, Chin-Hong...   \n",
       "34               NaN  1. Ben Neji H, Bchir M, Hamdoun M, Kallel A, K...   \n",
       "35               NaN  1. Bi XJ, Jin XF, Zhang HF, Su ZX, Shen B. Acq...   \n",
       "36               NaN  1. Raats D, Lorent N, Saegeman V, Vos R, van I...   \n",
       "37               NaN  1. Del Castillo H, Lopez AS, Temoche AP, Mosqu...   \n",
       "38               NaN  1. Vanukuru J, Bagga R, Muthyala T, Gautam V, ...   \n",
       "39               NaN  1. Freire MP, de Oliveira Garcia D, Cury AP, F...   \n",
       "40               NaN  1. Freire MP, de Oliveira Garcia D, Cury AP, F...   \n",
       "41               NaN  1. Kang MG, Sohn KH, Kang DY, Park HK, Yang MS...   \n",
       "42               NaN  1. Haager PK, Hoffmann M, Hasse B, Maisano F, ...   \n",
       "43               NaN  1. Bernier M, Duquesne F, Zemouri N, Akhdar M,...   \n",
       "44               NaN  1. Garinis AC, Keefe DH, Hunter LL, Fitzpatric...   \n",
       "45               NaN  1. Gucer E, Yalaki Z, Arikan FI, Dallar Y. Are...   \n",
       "46               NaN  1. Gynthersen R, Qvist T, Andersen AB, Katzens...   \n",
       "47               NaN  1. Shah VN, Orlov OI, Sternlieb MP, Plestis KA...   \n",
       "48               NaN  1. Rocha AL, De Souza AF, Nunes LFM, Cunha NDS...   \n",
       "49               NaN  1. Smiyan O, Lyndin M, Romaniuk O, Sikora V, P...   \n",
       "\n",
       "                                                  URL  \n",
       "0   https://adisinsight.springer.com/drugsafety/80...  \n",
       "1   https://adisinsight.springer.com/drugsafety/80...  \n",
       "2   https://adisinsight.springer.com/drugsafety/80...  \n",
       "3   https://adisinsight.springer.com/drugsafety/80...  \n",
       "4   https://adisinsight.springer.com/drugsafety/80...  \n",
       "5   https://adisinsight.springer.com/drugsafety/80...  \n",
       "6   https://adisinsight.springer.com/drugsafety/80...  \n",
       "7   https://adisinsight.springer.com/drugsafety/80...  \n",
       "8   https://adisinsight.springer.com/drugsafety/80...  \n",
       "9   https://adisinsight.springer.com/drugsafety/80...  \n",
       "10  https://adisinsight.springer.com/drugsafety/80...  \n",
       "11  https://adisinsight.springer.com/drugsafety/80...  \n",
       "12  https://adisinsight.springer.com/drugsafety/80...  \n",
       "13  https://adisinsight.springer.com/drugsafety/80...  \n",
       "14  https://adisinsight.springer.com/drugsafety/80...  \n",
       "15  https://adisinsight.springer.com/drugsafety/80...  \n",
       "16  https://adisinsight.springer.com/drugsafety/80...  \n",
       "17  https://adisinsight.springer.com/drugsafety/80...  \n",
       "18  https://adisinsight.springer.com/drugsafety/80...  \n",
       "19  https://adisinsight.springer.com/drugsafety/80...  \n",
       "20  https://adisinsight.springer.com/drugsafety/80...  \n",
       "21  https://adisinsight.springer.com/drugsafety/80...  \n",
       "22  https://adisinsight.springer.com/drugsafety/80...  \n",
       "23  https://adisinsight.springer.com/drugsafety/80...  \n",
       "24  https://adisinsight.springer.com/drugsafety/80...  \n",
       "25  https://adisinsight.springer.com/drugsafety/80...  \n",
       "26  https://adisinsight.springer.com/drugsafety/80...  \n",
       "27  https://adisinsight.springer.com/drugsafety/80...  \n",
       "28  https://adisinsight.springer.com/drugsafety/80...  \n",
       "29  https://adisinsight.springer.com/drugsafety/80...  \n",
       "30  https://adisinsight.springer.com/drugsafety/80...  \n",
       "31  https://adisinsight.springer.com/drugsafety/80...  \n",
       "32  https://adisinsight.springer.com/drugsafety/80...  \n",
       "33  https://adisinsight.springer.com/drugsafety/80...  \n",
       "34  https://adisinsight.springer.com/drugsafety/80...  \n",
       "35  https://adisinsight.springer.com/drugsafety/80...  \n",
       "36  https://adisinsight.springer.com/drugsafety/80...  \n",
       "37  https://adisinsight.springer.com/drugsafety/80...  \n",
       "38  https://adisinsight.springer.com/drugsafety/80...  \n",
       "39  https://adisinsight.springer.com/drugsafety/80...  \n",
       "40  https://adisinsight.springer.com/drugsafety/80...  \n",
       "41  https://adisinsight.springer.com/drugsafety/80...  \n",
       "42  https://adisinsight.springer.com/drugsafety/80...  \n",
       "43  https://adisinsight.springer.com/drugsafety/80...  \n",
       "44  https://adisinsight.springer.com/drugsafety/80...  \n",
       "45  https://adisinsight.springer.com/drugsafety/80...  \n",
       "46  https://adisinsight.springer.com/drugsafety/80...  \n",
       "47  https://adisinsight.springer.com/drugsafety/80...  \n",
       "48  https://adisinsight.springer.com/drugsafety/80...  \n",
       "49  https://adisinsight.springer.com/drugsafety/80...  \n",
       "\n",
       "[50 rows x 23 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "amikacina2019"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Report Id                   0\n",
       "Safety Report Name          0\n",
       "Record Type                 0\n",
       "Release Date                0\n",
       "Drugs                       0\n",
       "Adverse Events             10\n",
       "Mechanism of Action        50\n",
       "Number of Cases             1\n",
       "Serious                     0\n",
       "First Report                0\n",
       "Overdose                    0\n",
       "Drug Interaction            0\n",
       "Narrative and comments      0\n",
       "Reporter Country            1\n",
       "Source Country             49\n",
       "Country of publication      0\n",
       "Drug Class                  0\n",
       "Age Group                  31\n",
       "Route Of Administration    26\n",
       "Treatment                  50\n",
       "Special Situation          50\n",
       "References                  0\n",
       "URL                         0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# este comando te da el numero de valores no reportados\n",
    "amikacina2019.isna().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "numero_de_casos = amikacina2019[\"Number of Cases\"].fillna(1).sum()\n",
    "numero_de_reportes = amikacina2019.shape[0]\n",
    "numero_de_offlabel = amikacina2019[amikacina2019[\"Record Type\"] == \"Special Situation Case Report\"].shape[0]\n",
    "pais_con_mas_reportes = amikacina2019[\"Reporter Country\"].value_counts().index[0]\n",
    "top_age_group = amikacina2019[\"Age Group\"].value_counts().index[0]\n",
    "numero_de_serios = amikacina2019[amikacina2019[\"Serious\"] == \"Yes\"].shape[0]\n",
    "numero_de_no_serios = amikacina2019[amikacina2019[\"Serious\"] == \"No\"].shape[0]\n",
    "numero_de_first_reports = amikacina2019[amikacina2019[\"First Report\"] == \"Yes\"].shape[0]\n",
    "numero_de_no_first_reports = amikacina2019[amikacina2019[\"First Report\"] == \"No\"].shape[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "nombres = [\"Casos\", \"Reportes\", \"Off Label\", \"Pais con mas Reportes\", \n",
    "           \"Top Age Group\", \"Casos Serios\", \"Casos No Serios\", \"First Reports\", \n",
    "           \"No First Reports\"]\n",
    "\n",
    "valores = [numero_de_casos, numero_de_reportes, numero_de_offlabel, pais_con_mas_reportes, top_age_group,\n",
    "           numero_de_serios, numero_de_no_serios, numero_de_first_reports, numero_de_no_first_reports]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Descripcion</th>\n",
       "      <th>Valores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Casos</td>\n",
       "      <td>155</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Reportes</td>\n",
       "      <td>50</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Off Label</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Pais con mas Reportes</td>\n",
       "      <td>USA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Top Age Group</td>\n",
       "      <td>Elderly</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Casos Serios</td>\n",
       "      <td>47</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Casos No Serios</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>First Reports</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>No First Reports</td>\n",
       "      <td>50</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             Descripcion  Valores\n",
       "0                  Casos      155\n",
       "1               Reportes       50\n",
       "2              Off Label        5\n",
       "3  Pais con mas Reportes      USA\n",
       "4          Top Age Group  Elderly\n",
       "5           Casos Serios       47\n",
       "6        Casos No Serios        3\n",
       "7          First Reports        0\n",
       "8       No First Reports       50"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_table = pd.DataFrame({\n",
    "    \"Descripcion\": nombres,\n",
    "    \"Valores\": valores\n",
    "})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_data(data):\n",
    "    numero_de_casos = data[\"Number of Cases\"].fillna(1).sum()\n",
    "    numero_de_reportes = data.shape[0]\n",
    "    numero_de_offlabel = data[data[\"Record Type\"] == \"Special Situation Case Report\"].shape[0]\n",
    "    pais_con_mas_reportes = data[\"Reporter Country\"].value_counts().index[0]\n",
    "    top_age_group = data[\"Age Group\"].fillna(\"Desconocido\").value_counts().index[0]\n",
    "    numero_de_serios = data[data[\"Serious\"] == \"Yes\"].shape[0]\n",
    "    numero_de_no_serios = data[data[\"Serious\"] == \"No\"].shape[0]\n",
    "    numero_de_first_reports = data[data[\"First Report\"] == \"Yes\"].shape[0]\n",
    "    numero_de_no_first_reports = data[data[\"First Report\"] == \"No\"].shape[0]\n",
    "    \n",
    "    nombres = [\"Casos\", \"Reportes\", \"Off Label\", \"Pais con mas Reportes\", \n",
    "           \"Top Age Group\", \"Casos Serios\", \"Casos No Serios\", \"First Reports\", \n",
    "           \"No First Reports\"]\n",
    "\n",
    "    valores = [numero_de_casos, numero_de_reportes, numero_de_offlabel, pais_con_mas_reportes, top_age_group,\n",
    "               numero_de_serios, numero_de_no_serios, numero_de_first_reports, numero_de_no_first_reports]\n",
    "    \n",
    "    final_table = pd.DataFrame({\n",
    "        \"Descripcion\": nombres,\n",
    "        \"Valores\": valores\n",
    "    })\n",
    "    \n",
    "    return final_table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "original_directory2019 = \"2019/\"\n",
    "original_files2019 = os.listdir(original_directory2019)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [],
   "source": [
    "original_directory2020 = \"2020/\"\n",
    "original_files2020 = os.listdir(original_directory2020)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "directory_2019 = \"2019_resumen/\"\n",
    "directory_2020 = \"2020_resumen/\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "BETAMETHASONE_ene-dic2019.xlsx\n",
      "FLUCONAZOL_ene-dic2019.xlsx\n",
      "CHLOROQUINE_ene-dic2019.xlsx\n",
      "CIPROFIBRATO_ene-dic2019.xlsx\n",
      "SUCCINILCOLINA_ene-dic2019.xlsx\n",
      "METOCLOPRAMIDA_ene-dic2019.xlsx\n",
      "INSULINAHUMANA_ene-dic2019.xlsx\n",
      "RIBAVIRIN_ene-dic2019.xlsx\n",
      "FUROSEMIDA_ene-dic2019.xlsx\n",
      ".DS_Store\n",
      "FENTANILO_ene-dic2019.xlsx\n",
      "TOCILIZUMAB_ene-dic2019.xlsx\n",
      "MELATONIN_ene-dic2019.xlsx\n",
      "LOPINAVIR_ene-dic2019.xlsx\n",
      "FAVIPIRAVIR_ene-dic2019.xlsx\n",
      "VITAMIN_ene-dic2019.xlsx\n",
      "CEFTRIAXONE_ene-dic2019.xlsx\n",
      "OSELTAMIVIR_ene-dic2019.xlsx\n",
      "ATRACURIO_ene-dic2019.xlsx\n",
      "IVERMECTIN_ene-dic2019.xlsx\n",
      "HYDROXYCHLOROQUINE_ene-dic2019.xlsx\n",
      "SALBUTAMOL_ene-dic2019.xlsx\n",
      "CEFTAZIDIMA_ene-dic2019.xlsx\n",
      "RANITIDINA_ene-dic2019.xlsx\n",
      "METILPREDNISOLONA_ene-dic2019.xlsx\n",
      "ENOXAPARINA_ene-dic2019.xlsx\n",
      "DEXAMETHASONE_ene-dic2019.xlsx\n",
      "ANFOTERICINA_ene-dic2019.xlsx\n",
      "RITONAVIR_ene-dic2019.xlsx\n",
      "KETOCONAZOL_ene-dic2019.xlsx\n",
      "BROMURO_ene-dic2019.xlsx\n",
      "FONDAPARINUX_ene-dic2019.xlsx\n",
      "MIDAZOLAM_ene-dic2019.xlsx\n",
      "INSULINA_ene-dic2019.xlsx\n",
      "ATAZANAVIR_ene-dic2019.xlsx\n",
      "TRIMETOPRIM_ene-dic2019.xlsx\n",
      "CEFTAROLINA_ene-dic2019.xlsx\n",
      "AZITHROMYCIN_ene-dic2019.xlsx\n",
      "INMUNOGLOBULINA_ene-dic2019.xlsx\n",
      "HALOPERIDOL_ene-dic2019.xlsx\n",
      "HIDROCORTISONA_ene-dic2019.xlsx\n",
      "NITAZOXANIDA_ene-dic2019.xlsx\n",
      "DOBUTAMINA_ene-dic2019.xlsx\n",
      "NISTATINA_ene-dic2019.xlsx\n",
      "AMONNIA_ene-dic2019.xlsx\n",
      "NOREPINEFRINA_ene-dic2019.xlsx\n",
      "MORFINA_ene-dic2019.xlsx\n",
      "PROPOFOL_ene-dic2019.xlsx\n",
      "PIPERACILINA-TAZOBACTAM_ene-dic2019.xlsx\n",
      "HEPARINA_ene-dic2019.xlsx\n",
      "ONDANSETRON_ene-dic2019.xlsx\n",
      "ANIDULAFUNGINA_ene-dic2019.xlsx\n",
      "AMBROXOL_ene-dic2019.xlsx\n",
      "LOPINAVIR-RITONAVIR_ene-dic2019.xlsx\n",
      "INSULINAGLARGINA_ene-dic2019.xlsx\n",
      "ATROPINA_ene-dic2019.xlsx\n",
      "LORAZEPAM_ene-dic2019.xlsx\n",
      "FORMOTEROL_ene-dic2019.xlsx\n",
      "RIVAROXABAN_ene-dic2019.xlsx\n",
      "PEG_ene-dic2019.xlsx\n",
      "AMOXICILINA-AC_ene-dic2019.xlsx\n",
      "ATORVASTATINA_ene-dic2019.xlsx\n",
      "REMDESIVIR_ene-dic2019.xlsx\n",
      "INSULINAHUMANA-NPH_ene-dic2019.xlsx\n",
      "PARACETAMOL_ene-dic2019.xlsx\n",
      "OMEPRAZOL_ene-dic2019.xlsx\n",
      "MEROPENEM_ene-dic2019.xlsx\n",
      "LINEZOLID_ene-dic2019.xlsx\n",
      "VANCOMICINA_ene-dic2019.xlsx\n",
      "INSULINALISPRO_ene-dic2019.xlsx\n",
      "GAMMAGLOBULINA_ene-dic2019.xlsx\n",
      "EPINEFRINA_ene-dic2019.xlsx\n",
      "TEDIZOLID_ene-dic2019.xlsx\n",
      "AMIKACINA_ene-dic2019.xlsx\n",
      "TIGECICLINA_ene-dic2019.xlsx\n"
     ]
    }
   ],
   "source": [
    "for i in original_files2019:\n",
    "    print(i)\n",
    "    if i == \".DS_Store\" or i.startswith(\"~\"):\n",
    "        continue\n",
    "        \n",
    "    data = pd.read_excel( os.path.join(original_directory2019, i) )\n",
    "    \n",
    "    if data.shape[0] == 0:\n",
    "        continue\n",
    "    \n",
    "    final_data2019 = get_data(data)\n",
    "    final_data2019.to_excel(os.path.join(directory_2019, i.split(\"_\")[0] + \"_resumen2019.xlsx\"), index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEXAMETHASONE_ene-sep2020.xlsx\n",
      "ANFOTERICINA_ene-sep2020.xlsx\n",
      "ENOXAPARINA_ene-sep2020.xlsx\n",
      "BROMURO_ene-sep2020.xlsx\n",
      "RITONAVIR_ene-sep2020.xlsx\n",
      "KETOCONAZOL_ene-sep2020.xlsx\n",
      ".DS_Store\n",
      "RANITIDINA_ene-sep2020.xlsx\n",
      "METILPREDNISOLONA_ene-sep2020.xlsx\n",
      "HYDROXYCHLOROQUINE_ene-sep2020.xlsx\n",
      "SALBUTAMOL_ene-sep2020.xlsx\n",
      "CEFTAZIDIMA_ene-sep2020.xlsx\n",
      "FENTANILO_ene-sep2020.xlsx\n",
      "MELATONIN_ene-sep2020.xlsx\n",
      "TOCILIZUMAB_ene-sep2020.xlsx\n",
      "LOPINAVIR_ene-sep2020.xlsx\n",
      "FAVIPIRAVIR_ene-sep2020.xlsx\n",
      "FUROSEMIDA_ene-sep2020.xlsx\n",
      "ATRACURIO_ene-sep2020.xlsx\n",
      "OSELTAMIVIR_ene-sep2020.xlsx\n",
      "CEFTRIAXONE_ene-sep2020.xlsx\n",
      "IVERMECTIN_ene-sep2020.xlsx\n",
      "VITAMIN_ene-sep2020.xlsx\n",
      "CHLOROQUINE_ene-sep2020.xlsx\n",
      "BETAMETHASONE_ene-sep2020.xlsx\n",
      "FLUCONAZOL_ene-sep2020.xlsx\n",
      "INSULINAHUMANA_ene-sep2020.xlsx\n",
      "RIBAVIRIN_ene-sep2020.xlsx\n",
      "CIPROFIBRATO_ene-sep2020.xlsx\n",
      "SUCCINILCOLINA_ene-sep2020.xlsx\n",
      "METOCLOPRAMIDA_ene-sep2020.xlsx\n",
      "GAMMAGLOBULINA_ene-sep2020.xlsx\n",
      "EPINEFRINA_ene-sep2020.xlsx\n",
      "TEDIZOLID_ene-sep2020.xlsx\n",
      "AMIKACINA_ene-sep2020.xlsx\n",
      "LINEZOLID_ene-sep2020.xlsx\n",
      "VANCOMICINA_ene-sep2020.xlsx\n",
      "INSULINALISPRO_ene-sep2020.xlsx\n",
      "TIGECICLINA_ene-sep2020.xlsx\n",
      "RIVAROXABAN_ene-sep2020.xlsx\n",
      "FORMOTEROL_ene-sep2020.xlsx\n",
      "PEG_ene-sep2020.xlsx\n",
      "AMOXICILINA-AC_ene-sep2020.xlsx\n",
      "ATROPINA_ene-sep2020.xlsx\n",
      "INSULINAGLARGINA_ene-sep2020.xlsx\n",
      "LORAZEPAM_ene-sep2020.xlsx\n",
      "OMEPRAZOL_ene-sep2020.xlsx\n",
      "MEROPENEM_ene-sep2020.xlsx\n",
      "ATORVASTATINA_ene-sep2020.xlsx\n",
      "REMDESIVIR_ene-sep2020.xlsx\n",
      "INSULINAHUMANA-NPH_ene-sep2020.xlsx\n",
      "PARACETAMOL_ene-sep2020.xlsx\n",
      "NOREPINEFRINA_ene-sep2020.xlsx\n",
      "NISTATINA_ene-sep2020.xlsx\n",
      "AMONNIA_ene-sep2020.xlsx\n",
      "ONDANSETRON_ene-sep2020.xlsx\n",
      "ANIDULAFUNGINA_ene-sep2020.xlsx\n",
      "HEPARINA_ene-sep2020.xlsx\n",
      "AMBROXOL_ene-sep2020.xlsx\n",
      "LOPINAVIR-RITONAVIR_ene-sep2020.xlsx\n",
      "MORFINA_ene-sep2020.xlsx\n",
      "PROPOFOL_ene-sep2020.xlsx\n",
      "PIPERACILINA-TAZOBACTAM_ene-sep2020.xlsx\n",
      "INSULINA_ene-sep2020.xlsx\n",
      "ATAZANAVIR_ene-sep2020.xlsx\n",
      "CEFTAROLINA_ene-sep2020.xlsx\n",
      "TRIMETOPRIM_ene-sep2020.xlsx\n",
      "INMUNOGLOBULINA_ene-sep2020.xlsx\n",
      "AZITHROMYCIN_ene-sep2020.xlsx\n",
      "FONDAPARINUX_ene-sep2020.xlsx\n",
      "MIDAZOLAM_ene-sep2020.xlsx\n",
      "DOBUTAMINA_ene-sep2020.xlsx\n",
      "HALOPERIDOL_ene-sep2020.xlsx\n",
      "HIDROCORTISONA_ene-sep2020.xlsx\n",
      "NITAZOXANIDA_ene-sep2020.xlsx\n"
     ]
    }
   ],
   "source": [
    "for i in original_files2020:\n",
    "    print(i)\n",
    "    if i == \".DS_Store\" or i.startswith(\"~\"):\n",
    "        continue\n",
    "        \n",
    "    data = pd.read_excel( os.path.join(original_directory2020, i) )\n",
    "    \n",
    "    if data.shape[0] == 0:\n",
    "        continue\n",
    "    \n",
    "    final_data2020 = get_data(data)\n",
    "    final_data2020.to_excel(os.path.join(directory_2020, i.split(\"_\")[0] + \"_resumen2020.xlsx\"), index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Nuevo"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "from shutil import copyfile"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "original_directory2020 = \"2020/\"\n",
    "original_files2020 = os.listdir(original_directory2020)\n",
    "\n",
    "covid_2020_directory = \"2020_covid/\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "keywords = [\"coronavirus\", \"covid\", \"sars-cov2\", \"off label\", \"covid-19\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEXAMETHASONE_ene-sep2020.xlsx\n",
      "ENOXAPARINA_ene-sep2020.xlsx\n",
      "RITONAVIR_ene-sep2020.xlsx\n",
      "RANITIDINA_ene-sep2020.xlsx\n",
      "METILPREDNISOLONA_ene-sep2020.xlsx\n",
      "HYDROXYCHLOROQUINE_ene-sep2020.xlsx\n",
      "SALBUTAMOL_ene-sep2020.xlsx\n",
      "CEFTAZIDIMA_ene-sep2020.xlsx\n",
      "FENTANILO_ene-sep2020.xlsx\n",
      "MELATONIN_ene-sep2020.xlsx\n",
      "TOCILIZUMAB_ene-sep2020.xlsx\n",
      "LOPINAVIR_ene-sep2020.xlsx\n",
      "FAVIPIRAVIR_ene-sep2020.xlsx\n",
      "FUROSEMIDA_ene-sep2020.xlsx\n",
      "OSELTAMIVIR_ene-sep2020.xlsx\n",
      "CEFTRIAXONE_ene-sep2020.xlsx\n",
      "VITAMIN_ene-sep2020.xlsx\n",
      "CHLOROQUINE_ene-sep2020.xlsx\n",
      "BETAMETHASONE_ene-sep2020.xlsx\n",
      "FLUCONAZOL_ene-sep2020.xlsx\n",
      "INSULINAHUMANA_ene-sep2020.xlsx\n",
      "RIBAVIRIN_ene-sep2020.xlsx\n",
      "SUCCINILCOLINA_ene-sep2020.xlsx\n",
      "GAMMAGLOBULINA_ene-sep2020.xlsx\n",
      "EPINEFRINA_ene-sep2020.xlsx\n",
      "AMIKACINA_ene-sep2020.xlsx\n",
      "LINEZOLID_ene-sep2020.xlsx\n",
      "VANCOMICINA_ene-sep2020.xlsx\n",
      "TIGECICLINA_ene-sep2020.xlsx\n",
      "RIVAROXABAN_ene-sep2020.xlsx\n",
      "FORMOTEROL_ene-sep2020.xlsx\n",
      "AMOXICILINA-AC_ene-sep2020.xlsx\n",
      "ATROPINA_ene-sep2020.xlsx\n",
      "LORAZEPAM_ene-sep2020.xlsx\n",
      "MEROPENEM_ene-sep2020.xlsx\n",
      "REMDESIVIR_ene-sep2020.xlsx\n",
      "PARACETAMOL_ene-sep2020.xlsx\n",
      "NOREPINEFRINA_ene-sep2020.xlsx\n",
      "HEPARINA_ene-sep2020.xlsx\n",
      "AMBROXOL_ene-sep2020.xlsx\n",
      "LOPINAVIR-RITONAVIR_ene-sep2020.xlsx\n",
      "MORFINA_ene-sep2020.xlsx\n",
      "PROPOFOL_ene-sep2020.xlsx\n",
      "PIPERACILINA-TAZOBACTAM_ene-sep2020.xlsx\n",
      "INSULINA_ene-sep2020.xlsx\n",
      "CEFTAROLINA_ene-sep2020.xlsx\n",
      "TRIMETOPRIM_ene-sep2020.xlsx\n",
      "AZITHROMYCIN_ene-sep2020.xlsx\n",
      "MIDAZOLAM_ene-sep2020.xlsx\n",
      "HALOPERIDOL_ene-sep2020.xlsx\n",
      "HIDROCORTISONA_ene-sep2020.xlsx\n",
      "NITAZOXANIDA_ene-sep2020.xlsx\n"
     ]
    }
   ],
   "source": [
    "for i in original_files2020:\n",
    "    if i == \".DS_Store\" or i.startswith(\"~\"):\n",
    "        continue\n",
    "        \n",
    "    data = pd.read_excel( os.path.join(original_directory2020, i) )\n",
    "    \n",
    "    if data.shape[0] == 0:\n",
    "        continue\n",
    "    \n",
    "    for word in keywords:\n",
    "        data[word] = data.apply(lambda row: row.astype(str).str.contains(word.lower(), case=False).any(), axis=1)\n",
    "        \n",
    "        \n",
    "    if data.iloc[:, -len(keywords):].sum().values.sum() > 0:\n",
    "        print(i)\n",
    "        copyfile(os.path.join(original_directory2020, i), os.path.join(covid_2020_directory, i))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
